[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$ffWom9JfbkoQTKBrWXjggQAeHZIDjR9GWUhzXWeo36Ao":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":35,"phaseBuckets":84,"rows":91},"Medical University of South Carolina",[4],848,false,179,36,179506,62,560,[14,17,20,23,25,27,30,33],{"name":15,"count":16},"Stroke",43,{"name":18,"count":19},"Depression",30,{"name":21,"count":22},"Smoking Cessation",20,{"name":24,"count":22},"Nicotine Dependence",{"name":26,"count":22},"Smoking",{"name":28,"count":29},"Alcohol Use Disorder",19,{"name":31,"count":32},"Prostate Cancer",18,{"name":34,"count":32},"Alcohol Dependence",[36,41,46,51,55,60,65,69,74,79],{"nctId":37,"briefTitle":38,"date":39,"intervention":40},"NCT04482673","Vitamin D Supplementation in the Prevention and Mitigation of COVID-19 Infection","2022-12-31","Daily Vitamin D3",{"nctId":42,"briefTitle":43,"date":44,"intervention":45},"NCT05870111","Citicoline in Youth Alcohol Use Disorder","2026-04-29","Citicoline",{"nctId":47,"briefTitle":48,"date":49,"intervention":50},"NCT04523922","Oxytocin to Enhance Integrated Treatment for AUD and PTSD","2026-06-01","40 IU Intranasal Oxytocin",{"nctId":52,"briefTitle":53,"date":49,"intervention":54},"NCT06688539","E-cigarette Cessation in Adults Who Co-use Cannabis","Varenicline Pill",{"nctId":56,"briefTitle":57,"date":58,"intervention":59},"NCT06144177","Induction in the Dark","2026-06-15","Preoperative midazolam",{"nctId":61,"briefTitle":62,"date":63,"intervention":64},"NCT06634823","Efficacy of Intramuscular Steroid Injection for Chronic Cough.","2026-06-30","Triamcinolone Acetonide Injectable Suspension",{"nctId":66,"briefTitle":67,"date":63,"intervention":68},"NCT05064319","Gabapentin for Restoring GABA\u002FGlutamate Homeostasis in Co-occurring Bipolar and Cannabis Use Disorders","Gabapentin",{"nctId":70,"briefTitle":71,"date":72,"intervention":73},"NCT05702853","Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed\u002FRefractory NHL, CLL\u002FSLL","2026-11-06","Cyclophosphamide",{"nctId":75,"briefTitle":76,"date":77,"intervention":78},"NCT06039566","NAC vs Placebo on Opioid Use for Hysterectomy","2026-11-25","IV N-acetylcysteine",{"nctId":80,"briefTitle":81,"date":82,"intervention":83},"NCT07022418","Formoterol in Diabetes","2026-12","Formoterol furmarate",[85,86,87,88,89,90],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[92,123,151,169,187,205,227,254,276,301,334,362,380,406,431,453,471,571,629,682,719,758,780,810,842,867,885,903,929,947,965,983,1001,1022,1046,1068,1091,1115,1139,1169,1187,1205,1223,1248,1274,1299,1317,1335,1359,1427,1464,1490,1525,1547,1572,1645,1680,1698,1716,1740,1758,1781,1808,1892,1946,1988,2028,2069,2108,2141,2178,2212,2235,2260,2289,2307,2334,2352,2380,2398,2416,2441,2459,2477,2495,2520,2538,2564,2582,2606,2631,2649,2673,2699,2717,2735,2762,2784,2808,2832,2854,2881,2899,2923,3054,3088,3111,3136,3161,3179,3197,3221,3245,3263,3287,3311,3336,3359,3381,3404,3445,3477,3525,3569,3591,3622,3655,3689,3721,3757,3785,3816,3849,3880,3898,3922,3947,3965,3987,4009,4031,4049,4067,4085,4112,4130,4148,4169,4187,4212,4230,4248,4266,4288,4315,4333,4357,4380,4401,4425,4446,4472,4501,4519,4537,4555,4573,4591,4616,4634,4657,4683,4708,4726,4744,4767,4785,4809,4827,4852,4873,4897,4921,4939,4957,4983,5005,5029,5047,5071,5095,5119,5143,5167,5185,5211,5229,5253,5276,5298,5322,5347,5365,5383,5406,5424,5451,5474,5497,5515,5533,5557,5581,5604,5628,5653,5675,5698,5722,5740,5766,5784,5807,5825,5843,5866,5884,5902,5920,5938,5959,5977,6003,6030,6053,6071,6095,6113,6135,6153,6177,6199,6223,6248,6266,6291,6317,6335,6363,6386,6409,6432,6450,6476,6494,6520,6538,6625,6684,6725,6750,6778,6800,6827,6854,6878,6901,6926,6944,6966,6991,7009,7027,7049,7076,7099,7117,7142,7160,7183,7206,7224,7248,7266,7290,7318,7336,7359,7385,7403,7421,7446,7470,7499,7517,7535,7553,7571,7594,7620,7638,7656,7680,7706,7730,7748,7766,7789,7807,7830,7853,7871,7893,7916,7934,7952,7974],{"intervention":93,"totalTrials":94,"cells":95},"Remimazolam besylate",1,{"EARLY_PHASE1":96,"PHASE1":99,"PHASE2":101,"PHASE3":103,"PHASE4":105,"NA":121},{"trials":97,"activeCount":98},[],0,{"trials":100,"activeCount":98},[],{"trials":102,"activeCount":98},[],{"trials":104,"activeCount":98},[],{"trials":106,"activeCount":94,"soonestReadout":112},[107],{"nctId":108,"briefTitle":109,"status":110,"phases":111,"primaryCompletion":112,"completion":112,"start":113,"enrollment":114,"conditions":115,"interventions":119},"NCT07213544","Remimazolam vs Propofol in Laser Burn Cases","RECRUITING",[89],"2027-01-01","2025-11-12",136,[116,117,118],"Burn Scar","Hypertrophic Scarring","Procedural Sedation",[93,120],"Propofol",{"trials":122,"activeCount":98},[],{"intervention":40,"totalTrials":94,"cells":124},{"EARLY_PHASE1":125,"PHASE1":127,"PHASE2":129,"PHASE3":131,"PHASE4":133,"NA":149},{"trials":126,"activeCount":98},[],{"trials":128,"activeCount":98},[],{"trials":130,"activeCount":98},[],{"trials":132,"activeCount":98},[],{"trials":134,"activeCount":94,"soonestReadout":39},[135],{"nctId":37,"briefTitle":38,"status":136,"phases":137,"primaryCompletion":39,"completion":138,"start":139,"enrollment":140,"conditions":141,"interventions":145},"ACTIVE_NOT_RECRUITING",[89],"2023-12-31","2020-07-31",95,[142,143,144],"COVID-19","Vitamin D Deficiency","Respiratory Viral Infection",[40,146,147,148],"Daily placebo","Bolus vitamin D3","Bolus placebo",{"trials":150,"activeCount":98},[],{"intervention":146,"totalTrials":94,"cells":152},{"EARLY_PHASE1":153,"PHASE1":155,"PHASE2":157,"PHASE3":159,"PHASE4":161,"NA":167},{"trials":154,"activeCount":98},[],{"trials":156,"activeCount":98},[],{"trials":158,"activeCount":98},[],{"trials":160,"activeCount":98},[],{"trials":162,"activeCount":94,"soonestReadout":39},[163],{"nctId":37,"briefTitle":38,"status":136,"phases":164,"primaryCompletion":39,"completion":138,"start":139,"enrollment":140,"conditions":165,"interventions":166},[89],[142,143,144],[40,146,147,148],{"trials":168,"activeCount":98},[],{"intervention":147,"totalTrials":94,"cells":170},{"EARLY_PHASE1":171,"PHASE1":173,"PHASE2":175,"PHASE3":177,"PHASE4":179,"NA":185},{"trials":172,"activeCount":98},[],{"trials":174,"activeCount":98},[],{"trials":176,"activeCount":98},[],{"trials":178,"activeCount":98},[],{"trials":180,"activeCount":94,"soonestReadout":39},[181],{"nctId":37,"briefTitle":38,"status":136,"phases":182,"primaryCompletion":39,"completion":138,"start":139,"enrollment":140,"conditions":183,"interventions":184},[89],[142,143,144],[40,146,147,148],{"trials":186,"activeCount":98},[],{"intervention":148,"totalTrials":94,"cells":188},{"EARLY_PHASE1":189,"PHASE1":191,"PHASE2":193,"PHASE3":195,"PHASE4":197,"NA":203},{"trials":190,"activeCount":98},[],{"trials":192,"activeCount":98},[],{"trials":194,"activeCount":98},[],{"trials":196,"activeCount":98},[],{"trials":198,"activeCount":94,"soonestReadout":39},[199],{"nctId":37,"briefTitle":38,"status":136,"phases":200,"primaryCompletion":39,"completion":138,"start":139,"enrollment":140,"conditions":201,"interventions":202},[89],[142,143,144],[40,146,147,148],{"trials":204,"activeCount":98},[],{"intervention":59,"totalTrials":94,"cells":206},{"EARLY_PHASE1":207,"PHASE1":209,"PHASE2":211,"PHASE3":213,"PHASE4":215,"NA":225},{"trials":208,"activeCount":98},[],{"trials":210,"activeCount":98},[],{"trials":212,"activeCount":98},[],{"trials":214,"activeCount":98},[],{"trials":216,"activeCount":94,"soonestReadout":58},[217],{"nctId":56,"briefTitle":57,"status":110,"phases":218,"primaryCompletion":58,"completion":219,"start":220,"enrollment":221,"conditions":222,"interventions":224},[89],"2026-06-22","2024-04-16",240,[223],"Anesthesia Induction",[59],{"trials":226,"activeCount":98},[],{"intervention":228,"totalTrials":94,"cells":229},"Progesterone supplementation",{"EARLY_PHASE1":230,"PHASE1":232,"PHASE2":234,"PHASE3":236,"PHASE4":238,"NA":252},{"trials":231,"activeCount":98},[],{"trials":233,"activeCount":98},[],{"trials":235,"activeCount":98},[],{"trials":237,"activeCount":98},[],{"trials":239,"activeCount":94,"soonestReadout":245},[240],{"nctId":241,"briefTitle":242,"status":243,"phases":244,"primaryCompletion":245,"completion":245,"start":246,"enrollment":247,"conditions":248,"interventions":251},"NCT07448597","Progesterone Preeclampsia","NOT_YET_RECRUITING",[89],"2028-05-01","2026-08-01",642,[249,250],"Preeclampsia","Hypertensive Disorder of Pregnancy",[228],{"trials":253,"activeCount":98},[],{"intervention":54,"totalTrials":94,"cells":255},{"EARLY_PHASE1":256,"PHASE1":258,"PHASE2":260,"PHASE3":262,"PHASE4":264,"NA":274},{"trials":257,"activeCount":98},[],{"trials":259,"activeCount":98},[],{"trials":261,"activeCount":98},[],{"trials":263,"activeCount":98},[],{"trials":265,"activeCount":94,"soonestReadout":49},[266],{"nctId":52,"briefTitle":53,"status":110,"phases":267,"primaryCompletion":49,"completion":268,"start":269,"enrollment":270,"conditions":271,"interventions":273},[89],"2026-09-01","2025-02-19",105,[24,272],"Tobacco Use Disorder",[54],{"trials":275,"activeCount":98},[],{"intervention":277,"totalTrials":94,"cells":278},"Biologic Agents",{"EARLY_PHASE1":279,"PHASE1":281,"PHASE2":283,"PHASE3":285,"PHASE4":287,"NA":299},{"trials":280,"activeCount":98},[],{"trials":282,"activeCount":98},[],{"trials":284,"activeCount":98},[],{"trials":286,"activeCount":98},[],{"trials":288,"activeCount":94,"soonestReadout":293},[289],{"nctId":290,"briefTitle":291,"status":243,"phases":292,"primaryCompletion":293,"completion":293,"start":63,"enrollment":294,"conditions":295,"interventions":298},"NCT06824649","Biologics in Chronic Rhinosinusitis With Nasal Polyposis",[89],"2030-02",504,[296,297],"Chronic Sinusitis","Nasal Polyps",[277],{"trials":300,"activeCount":98},[],{"intervention":120,"totalTrials":302,"cells":303},2,{"EARLY_PHASE1":304,"PHASE1":306,"PHASE2":308,"PHASE3":310,"PHASE4":312,"NA":318},{"trials":305,"activeCount":98},[],{"trials":307,"activeCount":98},[],{"trials":309,"activeCount":98},[],{"trials":311,"activeCount":98},[],{"trials":313,"activeCount":94,"soonestReadout":112},[314],{"nctId":108,"briefTitle":109,"status":110,"phases":315,"primaryCompletion":112,"completion":112,"start":113,"enrollment":114,"conditions":316,"interventions":317},[89],[116,117,118],[93,120],{"trials":319,"activeCount":98},[320],{"nctId":321,"briefTitle":322,"status":323,"phases":324,"primaryCompletion":325,"completion":326,"start":327,"enrollment":328,"conditions":329,"interventions":331},"NCT02697448","Comparison of Propofol and Sevoflurane as a Primary Anesthetic for Cardiac Ablation of Atrial Fibrillation.","COMPLETED",[90],"2023-06-30","2024-02-28","2016-06-08",135,[330],"Atrial Fibrillation",[332,333],"propofol","sevoflurane",{"intervention":335,"totalTrials":94,"cells":336},"NAC and taVNS",{"EARLY_PHASE1":337,"PHASE1":339,"PHASE2":341,"PHASE3":343,"PHASE4":358,"NA":360},{"trials":338,"activeCount":98},[],{"trials":340,"activeCount":98},[],{"trials":342,"activeCount":98},[],{"trials":344,"activeCount":94,"soonestReadout":349},[345],{"nctId":346,"briefTitle":347,"status":110,"phases":348,"primaryCompletion":349,"completion":350,"start":351,"enrollment":352,"conditions":353,"interventions":356},"NCT07049952","BabySTrong II taVNS Feeding Trial",[87,88],"2027-04-01","2027-12-30","2025-11-16",88,[354,355],"Feeding Delays","Neonates and Term Infants",[335,357],"sterile water and inactive taVNS",{"trials":359,"activeCount":98},[],{"trials":361,"activeCount":98},[],{"intervention":357,"totalTrials":94,"cells":363},{"EARLY_PHASE1":364,"PHASE1":366,"PHASE2":368,"PHASE3":370,"PHASE4":376,"NA":378},{"trials":365,"activeCount":98},[],{"trials":367,"activeCount":98},[],{"trials":369,"activeCount":98},[],{"trials":371,"activeCount":94,"soonestReadout":349},[372],{"nctId":346,"briefTitle":347,"status":110,"phases":373,"primaryCompletion":349,"completion":350,"start":351,"enrollment":352,"conditions":374,"interventions":375},[87,88],[354,355],[335,357],{"trials":377,"activeCount":98},[],{"trials":379,"activeCount":98},[],{"intervention":381,"totalTrials":94,"cells":382},"Methadone Hydrochloride",{"EARLY_PHASE1":383,"PHASE1":385,"PHASE2":387,"PHASE3":389,"PHASE4":402,"NA":404},{"trials":384,"activeCount":98},[],{"trials":386,"activeCount":98},[],{"trials":388,"activeCount":98},[],{"trials":390,"activeCount":94,"soonestReadout":395},[391],{"nctId":392,"briefTitle":393,"status":110,"phases":394,"primaryCompletion":395,"completion":396,"start":397,"enrollment":398,"conditions":399,"interventions":401},"NCT07226076","Methadone in TKA for Post-op Pain and Opioid Reduction",[88],"2026-12-28","2027-01-15","2026-01-08",162,[400],"Post Operative Pain",[381],{"trials":403,"activeCount":98},[],{"trials":405,"activeCount":98},[],{"intervention":407,"totalTrials":94,"cells":408},"Methadone",{"EARLY_PHASE1":409,"PHASE1":411,"PHASE2":413,"PHASE3":415,"PHASE4":427,"NA":429},{"trials":410,"activeCount":98},[],{"trials":412,"activeCount":98},[],{"trials":414,"activeCount":98},[],{"trials":416,"activeCount":94,"soonestReadout":421},[417],{"nctId":418,"briefTitle":419,"status":110,"phases":420,"primaryCompletion":421,"completion":422,"start":423,"enrollment":398,"conditions":424,"interventions":426},"NCT07227064","Methadone in THA for Post-op Pain and Opioid Reduction",[88],"2026-12-31","2027-01-31","2026-01-12",[400,425],"Total Hip Arthroplasty",[407],{"trials":428,"activeCount":98},[],{"trials":430,"activeCount":98},[],{"intervention":78,"totalTrials":94,"cells":432},{"EARLY_PHASE1":433,"PHASE1":435,"PHASE2":437,"PHASE3":439,"PHASE4":449,"NA":451},{"trials":434,"activeCount":98},[],{"trials":436,"activeCount":98},[],{"trials":438,"activeCount":98},[],{"trials":440,"activeCount":94,"soonestReadout":77},[441],{"nctId":75,"briefTitle":76,"status":110,"phases":442,"primaryCompletion":77,"completion":443,"start":444,"enrollment":221,"conditions":445,"interventions":447},[88],"2026-12-09","2023-11-30",[446],"Hysterectomy",[78,448],"IV Placebo",{"trials":450,"activeCount":98},[],{"trials":452,"activeCount":98},[],{"intervention":448,"totalTrials":94,"cells":454},{"EARLY_PHASE1":455,"PHASE1":457,"PHASE2":459,"PHASE3":461,"PHASE4":467,"NA":469},{"trials":456,"activeCount":98},[],{"trials":458,"activeCount":98},[],{"trials":460,"activeCount":98},[],{"trials":462,"activeCount":94,"soonestReadout":77},[463],{"nctId":75,"briefTitle":76,"status":110,"phases":464,"primaryCompletion":77,"completion":443,"start":444,"enrollment":221,"conditions":465,"interventions":466},[88],[446],[78,448],{"trials":468,"activeCount":98},[],{"trials":470,"activeCount":98},[],{"intervention":472,"totalTrials":473,"cells":474},"Varenicline",8,{"EARLY_PHASE1":475,"PHASE1":477,"PHASE2":479,"PHASE3":524,"PHASE4":548,"NA":560},{"trials":476,"activeCount":98},[],{"trials":478,"activeCount":98},[],{"trials":480,"activeCount":98},[481,491,502,513],{"nctId":482,"briefTitle":483,"status":323,"phases":484,"primaryCompletion":485,"completion":485,"start":486,"enrollment":487,"conditions":488,"interventions":489},"NCT00664755","Menstrual Cycle Effects on Smoking Cessation and Cue Reactivity",[87],"2013-12","2007-07",140,[24],[490],"varenicline",{"nctId":492,"briefTitle":493,"status":323,"phases":494,"primaryCompletion":495,"completion":496,"start":497,"enrollment":498,"conditions":499,"interventions":501},"NCT03980561","UH3 Varenicline for Cannabis Use Disorder",[87],"2023-02-09","2023-12-01","2020-01-31",174,[500],"Cannabis Use Disorder",[472],{"nctId":503,"briefTitle":504,"status":323,"phases":505,"primaryCompletion":506,"completion":507,"start":508,"enrollment":509,"conditions":510,"interventions":512},"NCT02892110","Varenicline Treatment for Cannabis Use Disorder",[87],"2018-11-08","2018-11-27","2017-02-13",72,[511],"Substance Use Disorder",[472],{"nctId":514,"briefTitle":515,"status":323,"phases":516,"primaryCompletion":517,"completion":517,"start":518,"enrollment":519,"conditions":520,"interventions":522},"NCT02723162","Translational Neuropsychopharmacology Research of Nicotine Addiction",[87],"2020-03-09","2016-05-04",67,[521],"Nicotine Dependence, Cigarettes",[472,523],"N-Acetylcysteine",{"trials":525,"activeCount":94,"soonestReadout":539},[526,535],{"nctId":527,"briefTitle":528,"status":323,"phases":529,"primaryCompletion":530,"completion":530,"start":531,"enrollment":532,"conditions":533,"interventions":534},"NCT01509547","Varenicline for Adolescent Smoking Cessation",[88],"2018-01-26","2012-08",157,[24],[472],{"nctId":536,"briefTitle":537,"status":110,"phases":538,"primaryCompletion":539,"completion":540,"start":541,"enrollment":542,"conditions":543,"interventions":547},"NCT06883162","Cannabis-Tobacco Co-Use Treatment Study",[88],"2028-09-01","2029-01-01","2025-05-06",200,[272,544,545,500,546],"Tobacco Use Cessation","Cannabis Use","Marijuana Use",[472],{"trials":549,"activeCount":98},[550],{"nctId":551,"briefTitle":552,"status":323,"phases":553,"primaryCompletion":554,"completion":555,"start":556,"enrollment":557,"conditions":558,"interventions":559},"NCT04228965","Cannabis and Tobacco Co-use Study",[89],"2024-06-12","2024-09-13","2020-01-28",181,[272],[472],{"trials":561,"activeCount":98},[562],{"nctId":563,"briefTitle":564,"status":323,"phases":565,"primaryCompletion":566,"completion":566,"start":567,"enrollment":568,"conditions":569,"interventions":570},"NCT00934024","Impact of Varenicline on Blood-Oxygen-Level Dependent (BOLD) Functional Magnetic Resonance Imaging (fMRI) Activation on Smokers",[90],"2012-01","2009-04",21,[24],[490],{"intervention":572,"totalTrials":573,"cells":574},"oxaliplatin",3,{"EARLY_PHASE1":575,"PHASE1":577,"PHASE2":579,"PHASE3":623,"PHASE4":625,"NA":627},{"trials":576,"activeCount":98},[],{"trials":578,"activeCount":98},[],{"trials":580,"activeCount":94,"soonestReadout":609},[581,594,605],{"nctId":582,"briefTitle":583,"status":323,"phases":584,"primaryCompletion":585,"completion":585,"start":586,"enrollment":587,"conditions":588,"interventions":590},"NCT00408564","Cetuximab, Gemcitabine, and Oxaliplatin Followed By Surgery or External-Beam Radiation Therapy and Capecitabine in Treating Patients With Locally Advanced, Nonmetastatic Pancreatic Cancer That Cannot Be Removed By Surgery",[87],"2013-04","2006-01",39,[589],"Pancreatic Cancer",[591,592,572,593],"cetuximab","capecitabine","Gemcitabine",{"nctId":595,"briefTitle":596,"status":597,"phases":598,"primaryCompletion":599,"completion":599,"start":600,"enrollment":601,"conditions":602,"interventions":604},"NCT00354224","Capecitabine and Oxaliplatin in Treating Patients With Locally Advanced, Unresectable, or Metastatic Stomach Cancer","TERMINATED",[87],"2008-08","2005-01",10,[603],"Gastric Cancer",[592,572],{"nctId":606,"briefTitle":607,"status":110,"phases":608,"primaryCompletion":609,"completion":610,"start":611,"enrollment":612,"conditions":613,"interventions":616},"NCT07076212","Evaluating NALIRIFOX vs Modified Gemcitabine, Nab-Paclitaxel and Cisplatin in Patients With Locally Advanced and Metastatic Pancreatic Adenocarcinoma",[87],"2028-05","2029-11","2026-04-02",52,[614,615],"Metastatic Pancreatic Adenocarcinoma","Locally Advanced Pancreatic Adenocarcinoma",[617,618,619,620,593,621,622],"Liposomal Irinotecan","Oxaliplatin","5-Fluorouracil","Leucovorin","Nab-paclitaxel","Cisplatin",{"trials":624,"activeCount":98},[],{"trials":626,"activeCount":98},[],{"trials":628,"activeCount":98},[],{"intervention":630,"totalTrials":573,"cells":631},"bevacizumab",{"EARLY_PHASE1":632,"PHASE1":634,"PHASE2":636,"PHASE3":676,"PHASE4":678,"NA":680},{"trials":633,"activeCount":98},[],{"trials":635,"activeCount":98},[],{"trials":637,"activeCount":94,"soonestReadout":666},[638,650,662],{"nctId":639,"briefTitle":640,"status":323,"phases":641,"primaryCompletion":642,"completion":643,"start":644,"enrollment":140,"conditions":645,"interventions":647},"NCT00881751","Bevacizumab and Erlotinib or Sorafenib as First-Line Therapy in Treating Patients With Advanced Liver Cancer",[87],"2016-05","2017-02","2009-03",[646],"Liver Cancer",[630,648,649],"erlotinib hydrochloride","sorafenib tosylate",{"nctId":651,"briefTitle":652,"status":597,"phases":653,"primaryCompletion":654,"completion":654,"start":655,"enrollment":568,"conditions":656,"interventions":658},"NCT00268450","Cisplatin, Bevacizumab, and Gemcitabine Followed by Surgery, Bevacizumab, and Paclitaxel in Treating Patients With Locally Advanced Nonmetastatic Bladder Cancer That Can Be Removed By Surgery",[87],"2012-04","2005-09-21",[657],"Bladder Cancer",[630,659,660,661],"cisplatin","gemcitabine hydrochloride","paclitaxel",{"nctId":663,"briefTitle":664,"status":110,"phases":665,"primaryCompletion":666,"completion":667,"start":668,"enrollment":669,"conditions":670,"interventions":672},"NCT06971744","Autophagy Maintenance (AUTOMAIN)",[87],"2028-06-18","2029-06-18","2025-12-18",38,[671],"Ovarian Cancer",[673,674,675],"Hydroxychloroquine","Nelfinavir","Bevacizumab",{"trials":677,"activeCount":98},[],{"trials":679,"activeCount":98},[],{"trials":681,"activeCount":98},[],{"intervention":683,"totalTrials":302,"cells":684},"Sirolimus",{"EARLY_PHASE1":685,"PHASE1":687,"PHASE2":689,"PHASE3":713,"PHASE4":715,"NA":717},{"trials":686,"activeCount":98},[],{"trials":688,"activeCount":98},[],{"trials":690,"activeCount":94,"soonestReadout":695},[691,702],{"nctId":692,"briefTitle":693,"status":110,"phases":694,"primaryCompletion":695,"completion":695,"start":696,"enrollment":697,"conditions":698,"interventions":701},"NCT04861064","Weekly Sirolimus Therapy",[87],"2027-12","2022-01-18",24,[699,700],"Venous Malformation","Lymphatic Malformation",[683],{"nctId":703,"briefTitle":704,"status":323,"phases":705,"primaryCompletion":706,"completion":706,"start":707,"enrollment":708,"conditions":709,"interventions":711},"NCT04161144","Enhancing Self Regulation Among Smokers",[87],"2019-12-20","2018-10-01",22,[21,710,24],"Smoking, Cigarette",[712],"sirolimus",{"trials":714,"activeCount":98},[],{"trials":716,"activeCount":98},[],{"trials":718,"activeCount":98},[],{"intervention":720,"totalTrials":302,"cells":721},"Pembrolizumab",{"EARLY_PHASE1":722,"PHASE1":724,"PHASE2":738,"PHASE3":752,"PHASE4":754,"NA":756},{"trials":723,"activeCount":98},[],{"trials":725,"activeCount":98},[726],{"nctId":727,"briefTitle":728,"status":323,"phases":729,"primaryCompletion":730,"completion":731,"start":732,"enrollment":22,"conditions":733,"interventions":735},"NCT03245489","Anti-platelet + Pembro for H&N Tumors",[86],"2023-11-20","2024-11-20","2018-03-06",[734],"Head and Neck Cancer",[720,736,737],"Clopidogrel","acetylsalicylic acid",{"trials":739,"activeCount":94,"soonestReadout":744},[740],{"nctId":741,"briefTitle":742,"status":110,"phases":743,"primaryCompletion":744,"completion":745,"start":746,"enrollment":16,"conditions":747,"interventions":749},"NCT06845319","NeoCARD: Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Triple-Negative Breast Cancer Patients",[87],"2027-10-20","2028-10-20","2025-10-20",[748],"Triple Negative Breast Cancer",[750,751,720],"Carboplatin","Paclitaxel",{"trials":753,"activeCount":98},[],{"trials":755,"activeCount":98},[],{"trials":757,"activeCount":98},[],{"intervention":661,"totalTrials":302,"cells":759},{"EARLY_PHASE1":760,"PHASE1":762,"PHASE2":764,"PHASE3":774,"PHASE4":776,"NA":778},{"trials":761,"activeCount":98},[],{"trials":763,"activeCount":98},[],{"trials":765,"activeCount":94,"soonestReadout":744},[766,770],{"nctId":651,"briefTitle":652,"status":597,"phases":767,"primaryCompletion":654,"completion":654,"start":655,"enrollment":568,"conditions":768,"interventions":769},[87],[657],[630,659,660,661],{"nctId":741,"briefTitle":742,"status":110,"phases":771,"primaryCompletion":744,"completion":745,"start":746,"enrollment":16,"conditions":772,"interventions":773},[87],[748],[750,751,720],{"trials":775,"activeCount":98},[],{"trials":777,"activeCount":98},[],{"trials":779,"activeCount":98},[],{"intervention":750,"totalTrials":302,"cells":781},{"EARLY_PHASE1":782,"PHASE1":784,"PHASE2":798,"PHASE3":804,"PHASE4":806,"NA":808},{"trials":783,"activeCount":98},[],{"trials":785,"activeCount":98},[786],{"nctId":787,"briefTitle":788,"status":597,"phases":789,"primaryCompletion":790,"completion":790,"start":791,"enrollment":792,"conditions":793,"interventions":796},"NCT01373463","Cisplatin and Pemetrexed With Radiation Followed by Lobectomy",[86],"2012-06","2011-05",48,[794,795],"Nonsquamous Nonsmall Cell Neoplasm of Lung","Nonsmall Cell Lung Cancer Stage III",[797,750,797,622],"Pemetrexed",{"trials":799,"activeCount":94,"soonestReadout":744},[800],{"nctId":741,"briefTitle":742,"status":110,"phases":801,"primaryCompletion":744,"completion":745,"start":746,"enrollment":16,"conditions":802,"interventions":803},[87],[748],[750,751,720],{"trials":805,"activeCount":98},[],{"trials":807,"activeCount":98},[],{"trials":809,"activeCount":98},[],{"intervention":811,"totalTrials":302,"cells":812},"Rapamycin",{"EARLY_PHASE1":813,"PHASE1":815,"PHASE2":825,"PHASE3":836,"PHASE4":838,"NA":840},{"trials":814,"activeCount":98},[],{"trials":816,"activeCount":98},[817],{"nctId":818,"briefTitle":819,"status":323,"phases":820,"primaryCompletion":706,"completion":821,"start":822,"enrollment":568,"conditions":823,"interventions":824},"NCT03732248","Altering Memories That Increase Risk of Relapse in Alcohol Use Disorders",[86],"2020-01-20","2018-07-12",[28,34],[811],{"trials":826,"activeCount":94,"soonestReadout":831},[827],{"nctId":828,"briefTitle":829,"status":136,"phases":830,"primaryCompletion":831,"completion":831,"start":832,"enrollment":22,"conditions":833,"interventions":835},"NCT05342519","Daily Topical Rapamycin for Vitiligo",[87],"2027-12-01","2022-07-28",[834],"Vitiligo",[811,811],{"trials":837,"activeCount":98},[],{"trials":839,"activeCount":98},[],{"trials":841,"activeCount":98},[],{"intervention":73,"totalTrials":94,"cells":843},{"EARLY_PHASE1":844,"PHASE1":846,"PHASE2":848,"PHASE3":861,"PHASE4":863,"NA":865},{"trials":845,"activeCount":98},[],{"trials":847,"activeCount":98},[],{"trials":849,"activeCount":94,"soonestReadout":72},[850],{"nctId":70,"briefTitle":71,"status":110,"phases":851,"primaryCompletion":72,"completion":852,"start":853,"enrollment":854,"conditions":855,"interventions":858},[86,87],"2026-12-30","2023-11-06",27,[856,857],"B-cell Non Hodgkin Lymphoma","Chronic Lymphocytic Leukemia",[73,859,860],"Fludarabine","CD19-CD34t metabolically programmed CAR transduced T-cells",{"trials":862,"activeCount":98},[],{"trials":864,"activeCount":98},[],{"trials":866,"activeCount":98},[],{"intervention":859,"totalTrials":94,"cells":868},{"EARLY_PHASE1":869,"PHASE1":871,"PHASE2":873,"PHASE3":879,"PHASE4":881,"NA":883},{"trials":870,"activeCount":98},[],{"trials":872,"activeCount":98},[],{"trials":874,"activeCount":94,"soonestReadout":72},[875],{"nctId":70,"briefTitle":71,"status":110,"phases":876,"primaryCompletion":72,"completion":852,"start":853,"enrollment":854,"conditions":877,"interventions":878},[86,87],[856,857],[73,859,860],{"trials":880,"activeCount":98},[],{"trials":882,"activeCount":98},[],{"trials":884,"activeCount":98},[],{"intervention":860,"totalTrials":94,"cells":886},{"EARLY_PHASE1":887,"PHASE1":889,"PHASE2":891,"PHASE3":897,"PHASE4":899,"NA":901},{"trials":888,"activeCount":98},[],{"trials":890,"activeCount":98},[],{"trials":892,"activeCount":94,"soonestReadout":72},[893],{"nctId":70,"briefTitle":71,"status":110,"phases":894,"primaryCompletion":72,"completion":852,"start":853,"enrollment":854,"conditions":895,"interventions":896},[86,87],[856,857],[73,859,860],{"trials":898,"activeCount":98},[],{"trials":900,"activeCount":98},[],{"trials":902,"activeCount":98},[],{"intervention":904,"totalTrials":94,"cells":905},"Indocyanine Green",{"EARLY_PHASE1":906,"PHASE1":908,"PHASE2":910,"PHASE3":923,"PHASE4":925,"NA":927},{"trials":907,"activeCount":98},[],{"trials":909,"activeCount":98},[],{"trials":911,"activeCount":94,"soonestReadout":916},[912],{"nctId":913,"briefTitle":914,"status":110,"phases":915,"primaryCompletion":916,"completion":917,"start":918,"enrollment":19,"conditions":919,"interventions":922},"NCT07149207","Intraoperative Molecular Imaging Using ICG for Head and Neck Tumors",[87],"2028-04-07","2029-04-07","2026-05-04",[920,921],"Squamous Cell Carcinoma Head and Neck Cancer (HNSCC)","Margin Assessment",[904],{"trials":924,"activeCount":98},[],{"trials":926,"activeCount":98},[],{"trials":928,"activeCount":98},[],{"intervention":617,"totalTrials":94,"cells":930},{"EARLY_PHASE1":931,"PHASE1":933,"PHASE2":935,"PHASE3":941,"PHASE4":943,"NA":945},{"trials":932,"activeCount":98},[],{"trials":934,"activeCount":98},[],{"trials":936,"activeCount":94,"soonestReadout":609},[937],{"nctId":606,"briefTitle":607,"status":110,"phases":938,"primaryCompletion":609,"completion":610,"start":611,"enrollment":612,"conditions":939,"interventions":940},[87],[614,615],[617,618,619,620,593,621,622],{"trials":942,"activeCount":98},[],{"trials":944,"activeCount":98},[],{"trials":946,"activeCount":98},[],{"intervention":619,"totalTrials":94,"cells":948},{"EARLY_PHASE1":949,"PHASE1":951,"PHASE2":953,"PHASE3":959,"PHASE4":961,"NA":963},{"trials":950,"activeCount":98},[],{"trials":952,"activeCount":98},[],{"trials":954,"activeCount":94,"soonestReadout":609},[955],{"nctId":606,"briefTitle":607,"status":110,"phases":956,"primaryCompletion":609,"completion":610,"start":611,"enrollment":612,"conditions":957,"interventions":958},[87],[614,615],[617,618,619,620,593,621,622],{"trials":960,"activeCount":98},[],{"trials":962,"activeCount":98},[],{"trials":964,"activeCount":98},[],{"intervention":620,"totalTrials":94,"cells":966},{"EARLY_PHASE1":967,"PHASE1":969,"PHASE2":971,"PHASE3":977,"PHASE4":979,"NA":981},{"trials":968,"activeCount":98},[],{"trials":970,"activeCount":98},[],{"trials":972,"activeCount":94,"soonestReadout":609},[973],{"nctId":606,"briefTitle":607,"status":110,"phases":974,"primaryCompletion":609,"completion":610,"start":611,"enrollment":612,"conditions":975,"interventions":976},[87],[614,615],[617,618,619,620,593,621,622],{"trials":978,"activeCount":98},[],{"trials":980,"activeCount":98},[],{"trials":982,"activeCount":98},[],{"intervention":621,"totalTrials":94,"cells":984},{"EARLY_PHASE1":985,"PHASE1":987,"PHASE2":989,"PHASE3":995,"PHASE4":997,"NA":999},{"trials":986,"activeCount":98},[],{"trials":988,"activeCount":98},[],{"trials":990,"activeCount":94,"soonestReadout":609},[991],{"nctId":606,"briefTitle":607,"status":110,"phases":992,"primaryCompletion":609,"completion":610,"start":611,"enrollment":612,"conditions":993,"interventions":994},[87],[614,615],[617,618,619,620,593,621,622],{"trials":996,"activeCount":98},[],{"trials":998,"activeCount":98},[],{"trials":1000,"activeCount":98},[],{"intervention":45,"totalTrials":94,"cells":1002},{"EARLY_PHASE1":1003,"PHASE1":1005,"PHASE2":1007,"PHASE3":1016,"PHASE4":1018,"NA":1020},{"trials":1004,"activeCount":98},[],{"trials":1006,"activeCount":98},[],{"trials":1008,"activeCount":94,"soonestReadout":44},[1009],{"nctId":42,"briefTitle":43,"status":136,"phases":1010,"primaryCompletion":44,"completion":1011,"start":1012,"enrollment":1013,"conditions":1014,"interventions":1015},[87],"2029-02","2024-10-01",56,[28],[45],{"trials":1017,"activeCount":98},[],{"trials":1019,"activeCount":98},[],{"trials":1021,"activeCount":98},[],{"intervention":1023,"totalTrials":94,"cells":1024},"Simvastatin 40mg",{"EARLY_PHASE1":1025,"PHASE1":1027,"PHASE2":1029,"PHASE3":1040,"PHASE4":1042,"NA":1044},{"trials":1026,"activeCount":98},[],{"trials":1028,"activeCount":98},[],{"trials":1030,"activeCount":94,"soonestReadout":1035},[1031],{"nctId":1032,"briefTitle":1033,"status":110,"phases":1034,"primaryCompletion":1035,"completion":1036,"start":1037,"enrollment":9,"conditions":1038,"interventions":1039},"NCT05586360","T-reg Function Changes: a Novel Immune Regulatory Effect Underlying Benefit of Statin Use on Lethal Prostate Cancer",[87],"2027-03-01","2027-08-01","2024-03-11",[31],[1023],{"trials":1041,"activeCount":98},[],{"trials":1043,"activeCount":98},[],{"trials":1045,"activeCount":98},[],{"intervention":50,"totalTrials":94,"cells":1047},{"EARLY_PHASE1":1048,"PHASE1":1050,"PHASE2":1052,"PHASE3":1062,"PHASE4":1064,"NA":1066},{"trials":1049,"activeCount":98},[],{"trials":1051,"activeCount":98},[],{"trials":1053,"activeCount":94,"soonestReadout":49},[1054],{"nctId":47,"briefTitle":48,"status":136,"phases":1055,"primaryCompletion":49,"completion":1056,"start":1057,"enrollment":1058,"conditions":1059,"interventions":1061},[87],"2026-12-01","2021-03-29",175,[1060,28],"PTSD",[50],{"trials":1063,"activeCount":98},[],{"trials":1065,"activeCount":98},[],{"trials":1067,"activeCount":98},[],{"intervention":83,"totalTrials":94,"cells":1069},{"EARLY_PHASE1":1070,"PHASE1":1072,"PHASE2":1074,"PHASE3":1085,"PHASE4":1087,"NA":1089},{"trials":1071,"activeCount":98},[],{"trials":1073,"activeCount":98},[],{"trials":1075,"activeCount":94,"soonestReadout":82},[1076],{"nctId":80,"briefTitle":81,"status":110,"phases":1077,"primaryCompletion":82,"completion":1078,"start":1079,"enrollment":1080,"conditions":1081,"interventions":1084},[87],"2027-11","2025-12-01",120,[1082,1083],"Diabetic Nephropathies","Diabetic Kidney Disease",[83],{"trials":1086,"activeCount":98},[],{"trials":1088,"activeCount":98},[],{"trials":1090,"activeCount":98},[],{"intervention":1092,"totalTrials":94,"cells":1093},"Cannabidiol oral solution",{"EARLY_PHASE1":1094,"PHASE1":1096,"PHASE2":1098,"PHASE3":1109,"PHASE4":1111,"NA":1113},{"trials":1095,"activeCount":98},[],{"trials":1097,"activeCount":98},[],{"trials":1099,"activeCount":94,"soonestReadout":1104},[1100],{"nctId":1101,"briefTitle":1102,"status":110,"phases":1103,"primaryCompletion":1104,"completion":1104,"start":1105,"enrollment":1106,"conditions":1107,"interventions":1108},"NCT05885542","SCORE Emerging Adult Cannabis Use & Stress",[86,87],"2028-07-31","2023-11-01",148,[500],[1092],{"trials":1110,"activeCount":98},[],{"trials":1112,"activeCount":98},[],{"trials":1114,"activeCount":98},[],{"intervention":1116,"totalTrials":94,"cells":1117},"oleoylethanolamide",{"EARLY_PHASE1":1118,"PHASE1":1120,"PHASE2":1122,"PHASE3":1133,"PHASE4":1135,"NA":1137},{"trials":1119,"activeCount":98},[],{"trials":1121,"activeCount":98},[],{"trials":1123,"activeCount":94,"soonestReadout":1128},[1124],{"nctId":1125,"briefTitle":1126,"status":243,"phases":1127,"primaryCompletion":1128,"completion":1128,"start":49,"enrollment":1129,"conditions":1130,"interventions":1132},"NCT07503782","OEA for Young Adults With Alcohol Use Disorder",[87],"2031-03-31",42,[1131],"Alcohol Use Disorder (AUD)",[1116],{"trials":1134,"activeCount":98},[],{"trials":1136,"activeCount":98},[],{"trials":1138,"activeCount":98},[],{"intervention":1140,"totalTrials":94,"cells":1141},"Hydroxychloroquine, Metformin, Sirolimus",{"EARLY_PHASE1":1142,"PHASE1":1144,"PHASE2":1146,"PHASE3":1163,"PHASE4":1165,"NA":1167},{"trials":1143,"activeCount":98},[],{"trials":1145,"activeCount":98},[],{"trials":1147,"activeCount":94,"soonestReadout":1152},[1148],{"nctId":1149,"briefTitle":1150,"status":110,"phases":1151,"primaryCompletion":1152,"completion":1153,"start":1154,"enrollment":1155,"conditions":1156,"interventions":1159},"NCT05036226","COAST Therapy in Advanced Solid Tumors and Prostate Cancer",[86,87],"2027-05-21","2028-05-21","2022-03-03",76,[1157,1158],"Prostate Cancer Recurrent","Solid Tumor, Adult",[1140,1160,1161,1162,1161,1162],"Hydroxychloroquine, Metformin, Sirolimus, Dasatanib","Hydroxychloroquine, Metformin, Sirolimus, Nelfinavir","Hydroxychloroquine, Metformin, Sirolimus, Nelfinavir, Dasatinib",{"trials":1164,"activeCount":98},[],{"trials":1166,"activeCount":98},[],{"trials":1168,"activeCount":98},[],{"intervention":1160,"totalTrials":94,"cells":1170},{"EARLY_PHASE1":1171,"PHASE1":1173,"PHASE2":1175,"PHASE3":1181,"PHASE4":1183,"NA":1185},{"trials":1172,"activeCount":98},[],{"trials":1174,"activeCount":98},[],{"trials":1176,"activeCount":94,"soonestReadout":1152},[1177],{"nctId":1149,"briefTitle":1150,"status":110,"phases":1178,"primaryCompletion":1152,"completion":1153,"start":1154,"enrollment":1155,"conditions":1179,"interventions":1180},[86,87],[1157,1158],[1140,1160,1161,1162,1161,1162],{"trials":1182,"activeCount":98},[],{"trials":1184,"activeCount":98},[],{"trials":1186,"activeCount":98},[],{"intervention":1161,"totalTrials":94,"cells":1188},{"EARLY_PHASE1":1189,"PHASE1":1191,"PHASE2":1193,"PHASE3":1199,"PHASE4":1201,"NA":1203},{"trials":1190,"activeCount":98},[],{"trials":1192,"activeCount":98},[],{"trials":1194,"activeCount":94,"soonestReadout":1152},[1195],{"nctId":1149,"briefTitle":1150,"status":110,"phases":1196,"primaryCompletion":1152,"completion":1153,"start":1154,"enrollment":1155,"conditions":1197,"interventions":1198},[86,87],[1157,1158],[1140,1160,1161,1162,1161,1162],{"trials":1200,"activeCount":98},[],{"trials":1202,"activeCount":98},[],{"trials":1204,"activeCount":98},[],{"intervention":1162,"totalTrials":94,"cells":1206},{"EARLY_PHASE1":1207,"PHASE1":1209,"PHASE2":1211,"PHASE3":1217,"PHASE4":1219,"NA":1221},{"trials":1208,"activeCount":98},[],{"trials":1210,"activeCount":98},[],{"trials":1212,"activeCount":94,"soonestReadout":1152},[1213],{"nctId":1149,"briefTitle":1150,"status":110,"phases":1214,"primaryCompletion":1152,"completion":1153,"start":1154,"enrollment":1155,"conditions":1215,"interventions":1216},[86,87],[1157,1158],[1140,1160,1161,1162,1161,1162],{"trials":1218,"activeCount":98},[],{"trials":1220,"activeCount":98},[],{"trials":1222,"activeCount":98},[],{"intervention":1224,"totalTrials":94,"cells":1225},"Fingolimod 0.5 milligram (mg) [Gilenya]",{"EARLY_PHASE1":1226,"PHASE1":1228,"PHASE2":1230,"PHASE3":1242,"PHASE4":1244,"NA":1246},{"trials":1227,"activeCount":98},[],{"trials":1229,"activeCount":98},[],{"trials":1231,"activeCount":94,"soonestReadout":1236},[1232],{"nctId":1233,"briefTitle":1234,"status":110,"phases":1235,"primaryCompletion":1236,"completion":245,"start":1237,"enrollment":669,"conditions":1238,"interventions":1241},"NCT06424067","Phase 2 Study of Fingolimod in Lung Cancers",[87],"2027-05-01","2025-05-01",[1239,1240],"Non Small Cell Lung Cancer","Small-cell Lung Cancer",[1224],{"trials":1243,"activeCount":98},[],{"trials":1245,"activeCount":98},[],{"trials":1247,"activeCount":98},[],{"intervention":1249,"totalTrials":94,"cells":1250},"Buprenorphine Patch",{"EARLY_PHASE1":1251,"PHASE1":1253,"PHASE2":1255,"PHASE3":1268,"PHASE4":1270,"NA":1272},{"trials":1252,"activeCount":98},[],{"trials":1254,"activeCount":98},[],{"trials":1256,"activeCount":94,"soonestReadout":1261},[1257],{"nctId":1258,"briefTitle":1259,"status":110,"phases":1260,"primaryCompletion":1261,"completion":1262,"start":1263,"enrollment":221,"conditions":1264,"interventions":1267},"NCT06442566","ACTION: Trial of Adding Buprenorphine, CBT, and TMS to Improve Outcomes of Long-Term Opioid Therapy for Chronic Pain",[86,87],"2028-03-31","2029-03-31","2024-08-12",[1265,1266],"Opioid Withdrawal","Chronic Pain",[1249],{"trials":1269,"activeCount":98},[],{"trials":1271,"activeCount":98},[],{"trials":1273,"activeCount":98},[],{"intervention":1275,"totalTrials":94,"cells":1276},"8mg dexamethasone",{"EARLY_PHASE1":1277,"PHASE1":1279,"PHASE2":1281,"PHASE3":1293,"PHASE4":1295,"NA":1297},{"trials":1278,"activeCount":98},[],{"trials":1280,"activeCount":98},[],{"trials":1282,"activeCount":94,"soonestReadout":1287},[1283],{"nctId":1284,"briefTitle":1285,"status":243,"phases":1286,"primaryCompletion":1287,"completion":1288,"start":1289,"enrollment":1080,"conditions":1290,"interventions":1292},"NCT06818981","Post-Operative Steroids After Sleep Surgery",[87],"2027-06-30","2028-06-30","2026-07-01",[1291],"Obstructive Sleep Apnea",[1275],{"trials":1294,"activeCount":98},[],{"trials":1296,"activeCount":98},[],{"trials":1298,"activeCount":98},[],{"intervention":673,"totalTrials":94,"cells":1300},{"EARLY_PHASE1":1301,"PHASE1":1303,"PHASE2":1305,"PHASE3":1311,"PHASE4":1313,"NA":1315},{"trials":1302,"activeCount":98},[],{"trials":1304,"activeCount":98},[],{"trials":1306,"activeCount":94,"soonestReadout":666},[1307],{"nctId":663,"briefTitle":664,"status":110,"phases":1308,"primaryCompletion":666,"completion":667,"start":668,"enrollment":669,"conditions":1309,"interventions":1310},[87],[671],[673,674,675],{"trials":1312,"activeCount":98},[],{"trials":1314,"activeCount":98},[],{"trials":1316,"activeCount":98},[],{"intervention":674,"totalTrials":94,"cells":1318},{"EARLY_PHASE1":1319,"PHASE1":1321,"PHASE2":1323,"PHASE3":1329,"PHASE4":1331,"NA":1333},{"trials":1320,"activeCount":98},[],{"trials":1322,"activeCount":98},[],{"trials":1324,"activeCount":94,"soonestReadout":666},[1325],{"nctId":663,"briefTitle":664,"status":110,"phases":1326,"primaryCompletion":666,"completion":667,"start":668,"enrollment":669,"conditions":1327,"interventions":1328},[87],[671],[673,674,675],{"trials":1330,"activeCount":98},[],{"trials":1332,"activeCount":98},[],{"trials":1334,"activeCount":98},[],{"intervention":1336,"totalTrials":94,"cells":1337},"Dronabinol",{"EARLY_PHASE1":1338,"PHASE1":1340,"PHASE2":1342,"PHASE3":1353,"PHASE4":1355,"NA":1357},{"trials":1339,"activeCount":98},[],{"trials":1341,"activeCount":98},[],{"trials":1343,"activeCount":94,"soonestReadout":1348},[1344],{"nctId":1345,"briefTitle":1346,"status":110,"phases":1347,"primaryCompletion":1348,"completion":1348,"start":1349,"enrollment":1350,"conditions":1351,"interventions":1352},"NCT07225777","Sex Differences in Neurobehavioral Response to THC",[87],"2027-12-31","2026-04-27",40,[500],[1336],{"trials":1354,"activeCount":98},[],{"trials":1356,"activeCount":98},[],{"trials":1358,"activeCount":98},[],{"intervention":68,"totalTrials":1360,"cells":1361},5,{"EARLY_PHASE1":1362,"PHASE1":1364,"PHASE2":1366,"PHASE3":1410,"PHASE4":1412,"NA":1414},{"trials":1363,"activeCount":98},[],{"trials":1365,"activeCount":98},[],{"trials":1367,"activeCount":94,"soonestReadout":63},[1368,1378,1391,1401],{"nctId":1369,"briefTitle":1370,"status":323,"phases":1371,"primaryCompletion":1372,"completion":1372,"start":1373,"enrollment":1374,"conditions":1375,"interventions":1377},"NCT02349477","Gabapentin for Alcohol Relapse Prevention",[87],"2018-08-27","2014-11",96,[28,1376],"Alcohol Withdrawal",[68],{"nctId":66,"briefTitle":67,"status":110,"phases":1379,"primaryCompletion":63,"completion":63,"start":1380,"enrollment":1381,"conditions":1382,"interventions":1390},[87],"2022-02-24",68,[1383,545,1384,1385,1386,1387,1388,1389],"Bipolar Disorder","Schizoaffective Disorder, Bipolar Type","Bipolar I Disorder","Bipolar II Disorder","Cannabis Use Disorder, Mild","Cannabis Use Disorder, Moderate","Cannabis Use Disorder, Severe",[68],{"nctId":1392,"briefTitle":1393,"status":323,"phases":1394,"primaryCompletion":1395,"completion":1395,"start":1396,"enrollment":1397,"conditions":1398,"interventions":1400},"NCT03334721","Gabapentin for Bipolar & Cannabis Use Disorders",[87],"2019-07-01","2017-10-01",23,[1385,1386,500,1399],"Substance Use Disorders",[68],{"nctId":1402,"briefTitle":1403,"status":323,"phases":1404,"primaryCompletion":1405,"completion":1405,"start":1406,"enrollment":1407,"conditions":1408,"interventions":1409},"NCT03220776","Imaging GABAergic\u002FGlutamatergic Drugs in Bipolar Alcoholics Alcoholics",[87],"2022-11-21","2017-08-07",54,[28,1383],[523,68],{"trials":1411,"activeCount":98},[],{"trials":1413,"activeCount":98},[],{"trials":1415,"activeCount":98},[1416],{"nctId":1417,"briefTitle":1418,"status":323,"phases":1419,"primaryCompletion":1420,"completion":1420,"start":1421,"enrollment":11,"conditions":1422,"interventions":1426},"NCT00886236","Study of the Effect of the Drug Gabapentin on Postoperative Pain and Incidence of Postoperative Nausea and Vomiting",[90],"2011-01","2008-02",[1423,1424,1425],"Obesity, Morbid","Postoperative Pain","Postoperative Nausea and Vomiting",[68,68],{"intervention":622,"totalTrials":1428,"cells":1429},4,{"EARLY_PHASE1":1430,"PHASE1":1432,"PHASE2":1438,"PHASE3":1448,"PHASE4":1450,"NA":1452},{"trials":1431,"activeCount":98},[],{"trials":1433,"activeCount":98},[1434],{"nctId":787,"briefTitle":788,"status":597,"phases":1435,"primaryCompletion":790,"completion":790,"start":791,"enrollment":792,"conditions":1436,"interventions":1437},[86],[794,795],[797,750,797,622],{"trials":1439,"activeCount":94,"soonestReadout":609},[1440,1444],{"nctId":606,"briefTitle":607,"status":110,"phases":1441,"primaryCompletion":609,"completion":610,"start":611,"enrollment":612,"conditions":1442,"interventions":1443},[87],[614,615],[617,618,619,620,593,621,622],{"nctId":651,"briefTitle":652,"status":597,"phases":1445,"primaryCompletion":654,"completion":654,"start":655,"enrollment":568,"conditions":1446,"interventions":1447},[87],[657],[630,659,660,661],{"trials":1449,"activeCount":98},[],{"trials":1451,"activeCount":98},[],{"trials":1453,"activeCount":98},[1454],{"nctId":1455,"briefTitle":1456,"status":597,"phases":1457,"primaryCompletion":1458,"completion":1458,"start":1459,"enrollment":1460,"conditions":1461,"interventions":1463},"NCT02512692","Gemcitabine-Cisplatin-90Y TARE for Unresectable Intrahepatic Cholangiocarcinoma",[90],"2021-03-19","2015-07-21",6,[1462],"Intrahepatic Cholangiocarcinoma",[593,622],{"intervention":593,"totalTrials":573,"cells":1465},{"EARLY_PHASE1":1466,"PHASE1":1468,"PHASE2":1470,"PHASE3":1480,"PHASE4":1482,"NA":1484},{"trials":1467,"activeCount":98},[],{"trials":1469,"activeCount":98},[],{"trials":1471,"activeCount":94,"soonestReadout":609},[1472,1476],{"nctId":582,"briefTitle":583,"status":323,"phases":1473,"primaryCompletion":585,"completion":585,"start":586,"enrollment":587,"conditions":1474,"interventions":1475},[87],[589],[591,592,572,593],{"nctId":606,"briefTitle":607,"status":110,"phases":1477,"primaryCompletion":609,"completion":610,"start":611,"enrollment":612,"conditions":1478,"interventions":1479},[87],[614,615],[617,618,619,620,593,621,622],{"trials":1481,"activeCount":98},[],{"trials":1483,"activeCount":98},[],{"trials":1485,"activeCount":98},[1486],{"nctId":1455,"briefTitle":1456,"status":597,"phases":1487,"primaryCompletion":1458,"completion":1458,"start":1459,"enrollment":1460,"conditions":1488,"interventions":1489},[90],[1462],[593,622],{"intervention":1491,"totalTrials":302,"cells":1492},"Mesenchymal Stem Cells",{"EARLY_PHASE1":1493,"PHASE1":1505,"PHASE2":1517,"PHASE3":1519,"PHASE4":1521,"NA":1523},{"trials":1494,"activeCount":94,"soonestReadout":1499},[1495],{"nctId":1496,"briefTitle":1497,"status":110,"phases":1498,"primaryCompletion":1499,"completion":1500,"start":1501,"enrollment":792,"conditions":1502,"interventions":1504},"NCT06205342","Safety and Efficacy of Mesenchymal Stem Cells Associated With Chronic Pancreatitis Pain",[85],"2027-06-01","2028-06-01","2024-07-17",[1503,1266],"Chronic Pancreatitis",[1491],{"trials":1506,"activeCount":94,"soonestReadout":1511},[1507],{"nctId":1508,"briefTitle":1509,"status":136,"phases":1510,"primaryCompletion":1511,"completion":1511,"start":1512,"enrollment":1513,"conditions":1514,"interventions":1516},"NCT04061746","Cellular Therapy for Type 1 Diabetes Using Mesenchymal Stem Cells",[86],"2027-05-30","2020-02-27",60,[1515],"Diabetes Mellitus, Type 1",[1491],{"trials":1518,"activeCount":98},[],{"trials":1520,"activeCount":98},[],{"trials":1522,"activeCount":98},[],{"trials":1524,"activeCount":98},[],{"intervention":1526,"totalTrials":94,"cells":1527},"Bone marrow-derived mesenchymal stem cells",{"EARLY_PHASE1":1528,"PHASE1":1530,"PHASE2":1539,"PHASE3":1541,"PHASE4":1543,"NA":1545},{"trials":1529,"activeCount":98},[],{"trials":1531,"activeCount":94,"soonestReadout":1287},[1532],{"nctId":1533,"briefTitle":1534,"status":110,"phases":1535,"primaryCompletion":1287,"completion":1287,"start":1536,"enrollment":1129,"conditions":1537,"interventions":1538},"NCT05095532","Autologous Mesenchymal Stromal Cells and Islet Co-transplantation in TP-IAT",[86],"2021-12-01",[1503,1491],[1526],{"trials":1540,"activeCount":98},[],{"trials":1542,"activeCount":98},[],{"trials":1544,"activeCount":98},[],{"trials":1546,"activeCount":98},[],{"intervention":1548,"totalTrials":94,"cells":1549},"CBD",{"EARLY_PHASE1":1550,"PHASE1":1552,"PHASE2":1564,"PHASE3":1566,"PHASE4":1568,"NA":1570},{"trials":1551,"activeCount":98},[],{"trials":1553,"activeCount":94,"soonestReadout":1558},[1554],{"nctId":1555,"briefTitle":1556,"status":110,"phases":1557,"primaryCompletion":1558,"completion":1559,"start":58,"enrollment":1560,"conditions":1561,"interventions":1563},"NCT06148038","CBD for Breast Cancer Primary Tumors",[86],"2028-03-25","2029-03-25",84,[1562],"Breast Cancer",[1548],{"trials":1565,"activeCount":98},[],{"trials":1567,"activeCount":98},[],{"trials":1569,"activeCount":98},[],{"trials":1571,"activeCount":98},[],{"intervention":1573,"totalTrials":1460,"cells":1574},"Saline",{"EARLY_PHASE1":1575,"PHASE1":1595,"PHASE2":1597,"PHASE3":1611,"PHASE4":1613,"NA":1615},{"trials":1576,"activeCount":302,"soonestReadout":63},[1577,1585],{"nctId":61,"briefTitle":62,"status":110,"phases":1578,"primaryCompletion":63,"completion":63,"start":1579,"enrollment":1350,"conditions":1580,"interventions":1584},[85],"2024-12-02",[1581,1582,1583],"Chronic Cough (CC)","Laryngeal Disease","Coughing",[64,1573],{"nctId":1586,"briefTitle":1587,"status":110,"phases":1588,"primaryCompletion":112,"completion":1589,"start":1590,"enrollment":114,"conditions":1591,"interventions":1593},"NCT05490134","RM1 Project 1 - tAN Naloxone",[85],"2027-10-01","2023-03-22",[1592],"Analgesia",[1594,1573],"Naloxone",{"trials":1596,"activeCount":98},[],{"trials":1598,"activeCount":98},[1599],{"nctId":1600,"briefTitle":1601,"status":323,"phases":1602,"primaryCompletion":1603,"completion":1603,"start":1604,"enrollment":1605,"conditions":1606,"interventions":1608},"NCT01963091","Effect of Oxytocin on Stress Response in Cocaine-dependent Individuals",[87],"2012-10","2011-07",33,[1607],"Cocaine Dependence",[1609,1610],"oxytocin","saline",{"trials":1612,"activeCount":98},[],{"trials":1614,"activeCount":98},[],{"trials":1616,"activeCount":98},[1617,1626,1636],{"nctId":1618,"briefTitle":1619,"status":323,"phases":1620,"primaryCompletion":1621,"completion":1621,"start":1603,"enrollment":1622,"conditions":1623,"interventions":1624},"NCT01573273","Oxytocin in Cocaine Dependence",[90],"2017-12-19",112,[1607],[1625,1573],"Oxytocin",{"nctId":1627,"briefTitle":1628,"status":323,"phases":1629,"primaryCompletion":1630,"completion":1630,"start":1631,"enrollment":1632,"conditions":1633,"interventions":1635},"NCT01335789","Effect of Oxytocin on Stress in Marijuana Users",[90],"2012-07","2011-03",16,[1634],"Marijuana Dependence",[1625,1573],{"nctId":1637,"briefTitle":1638,"status":323,"phases":1639,"primaryCompletion":1640,"completion":1641,"start":1642,"enrollment":1632,"conditions":1643,"interventions":1644},"NCT01827332","Effect of Oxytocin on Craving and Therapy Response",[90],"2015-06","2016-07","2013-03",[1634],[1625,1573],{"intervention":1646,"totalTrials":302,"cells":1647},"Isotretinoin",{"EARLY_PHASE1":1648,"PHASE1":1662,"PHASE2":1664,"PHASE3":1674,"PHASE4":1676,"NA":1678},{"trials":1649,"activeCount":94,"soonestReadout":1654},[1650],{"nctId":1651,"briefTitle":1652,"status":110,"phases":1653,"primaryCompletion":1654,"completion":1655,"start":1656,"enrollment":1657,"conditions":1658,"interventions":1660},"NCT06225570","Weekly Isotretinoin vs Tetracycline for Moderate Acne",[85],"2027-03","2027-05","2025-02-01",50,[1659],"Acne Vulgaris",[1646,1661],"Tetracycline",{"trials":1663,"activeCount":98},[],{"trials":1665,"activeCount":98},[1666],{"nctId":1667,"briefTitle":1668,"status":323,"phases":1669,"primaryCompletion":1670,"completion":1670,"start":1671,"enrollment":708,"conditions":1672,"interventions":1673},"NCT04594759","Weekly Isotretinoin Therapy Study",[86,87],"2021-12-21","2020-11-11",[1659],[1646],{"trials":1675,"activeCount":98},[],{"trials":1677,"activeCount":98},[],{"trials":1679,"activeCount":98},[],{"intervention":64,"totalTrials":94,"cells":1681},{"EARLY_PHASE1":1682,"PHASE1":1688,"PHASE2":1690,"PHASE3":1692,"PHASE4":1694,"NA":1696},{"trials":1683,"activeCount":94,"soonestReadout":63},[1684],{"nctId":61,"briefTitle":62,"status":110,"phases":1685,"primaryCompletion":63,"completion":63,"start":1579,"enrollment":1350,"conditions":1686,"interventions":1687},[85],[1581,1582,1583],[64,1573],{"trials":1689,"activeCount":98},[],{"trials":1691,"activeCount":98},[],{"trials":1693,"activeCount":98},[],{"trials":1695,"activeCount":98},[],{"trials":1697,"activeCount":98},[],{"intervention":1661,"totalTrials":94,"cells":1699},{"EARLY_PHASE1":1700,"PHASE1":1706,"PHASE2":1708,"PHASE3":1710,"PHASE4":1712,"NA":1714},{"trials":1701,"activeCount":94,"soonestReadout":1654},[1702],{"nctId":1651,"briefTitle":1652,"status":110,"phases":1703,"primaryCompletion":1654,"completion":1655,"start":1656,"enrollment":1657,"conditions":1704,"interventions":1705},[85],[1659],[1646,1661],{"trials":1707,"activeCount":98},[],{"trials":1709,"activeCount":98},[],{"trials":1711,"activeCount":98},[],{"trials":1713,"activeCount":98},[],{"trials":1715,"activeCount":98},[],{"intervention":1717,"totalTrials":94,"cells":1718},"Topical Minocycline Foam FXFM244",{"EARLY_PHASE1":1719,"PHASE1":1730,"PHASE2":1732,"PHASE3":1734,"PHASE4":1736,"NA":1738},{"trials":1720,"activeCount":94,"soonestReadout":1725},[1721],{"nctId":1722,"briefTitle":1723,"status":243,"phases":1724,"primaryCompletion":1725,"completion":695,"start":49,"enrollment":1726,"conditions":1727,"interventions":1729},"NCT07462702","Topical Minocycline for CARP",[85],"2027-06",35,[1728],"Confluent and Reticulated Papillomatosis (CARP)",[1717],{"trials":1731,"activeCount":98},[],{"trials":1733,"activeCount":98},[],{"trials":1735,"activeCount":98},[],{"trials":1737,"activeCount":98},[],{"trials":1739,"activeCount":98},[],{"intervention":1594,"totalTrials":94,"cells":1741},{"EARLY_PHASE1":1742,"PHASE1":1748,"PHASE2":1750,"PHASE3":1752,"PHASE4":1754,"NA":1756},{"trials":1743,"activeCount":94,"soonestReadout":112},[1744],{"nctId":1586,"briefTitle":1587,"status":110,"phases":1745,"primaryCompletion":112,"completion":1589,"start":1590,"enrollment":114,"conditions":1746,"interventions":1747},[85],[1592],[1594,1573],{"trials":1749,"activeCount":98},[],{"trials":1751,"activeCount":98},[],{"trials":1753,"activeCount":98},[],{"trials":1755,"activeCount":98},[],{"trials":1757,"activeCount":98},[],{"intervention":1759,"totalTrials":94,"cells":1760},"Quitting using Medication",{"EARLY_PHASE1":1761,"PHASE1":1763,"PHASE2":1765,"PHASE3":1767,"PHASE4":1769,"NA":1771},{"trials":1762,"activeCount":98},[],{"trials":1764,"activeCount":98},[],{"trials":1766,"activeCount":98},[],{"trials":1768,"activeCount":98},[],{"trials":1770,"activeCount":98},[],{"trials":1772,"activeCount":94,"soonestReadout":539},[1773],{"nctId":1774,"briefTitle":1775,"status":110,"phases":1776,"primaryCompletion":539,"completion":539,"start":1777,"enrollment":221,"conditions":1778,"interventions":1780},"NCT06922617","STEPS: Substance Use Trial of E-cigarettes or Pharmacotherapy for Smoking",[90],"2025-10-17",[1779,1399],"Tobacco Use",[1759],{"intervention":1782,"totalTrials":94,"cells":1783},"Qutenza® 8% Capsaicin Topical System",{"EARLY_PHASE1":1784,"PHASE1":1786,"PHASE2":1788,"PHASE3":1790,"PHASE4":1792,"NA":1794},{"trials":1785,"activeCount":98},[],{"trials":1787,"activeCount":98},[],{"trials":1789,"activeCount":98},[],{"trials":1791,"activeCount":98},[],{"trials":1793,"activeCount":98},[],{"trials":1795,"activeCount":94,"soonestReadout":1801},[1796],{"nctId":1797,"briefTitle":1798,"status":1799,"phases":1800,"primaryCompletion":1801,"completion":1802,"start":1803,"enrollment":1657,"conditions":1804,"interventions":1807},"NCT06540456","Qutenza 8% Capsaicin Topical System for the Treatment of Neuropathic Axial Lower Back Pain and Lumbosacral Radiculopathy","ENROLLING_BY_INVITATION",[],"2027-07-03","2028-07-03","2025-03-13",[1805,1806],"Lower Back Pain","Lumbosacral Radiculopathy",[1782],{"intervention":1809,"totalTrials":1810,"cells":1811},"cholecalciferol",7,{"EARLY_PHASE1":1812,"PHASE1":1814,"PHASE2":1826,"PHASE3":1856,"PHASE4":1877,"NA":1890},{"trials":1813,"activeCount":98},[],{"trials":1815,"activeCount":98},[1816],{"nctId":1817,"briefTitle":1818,"status":323,"phases":1819,"primaryCompletion":599,"completion":1820,"start":1821,"enrollment":32,"conditions":1822,"interventions":1824},"NCT00418587","Vitamin D Therapy in Patients With Systemic Lupus Erythematosus (SLE)",[86],"2014-08","2006-12",[1823],"Systemic Lupus Erythematosus",[1825,1825,1825],"Cholecalciferol",{"trials":1827,"activeCount":98},[1828,1837,1846],{"nctId":1829,"briefTitle":1830,"status":323,"phases":1831,"primaryCompletion":1832,"completion":1833,"start":1834,"enrollment":1657,"conditions":1835,"interventions":1836},"NCT02726113","Vitamin D and Prostate Cancer: A Clinical Study Enrolling Subjects Undergoing Prostatectomy",[87],"2015-03","2015-12","2011-10",[31],[1809],{"nctId":1838,"briefTitle":1839,"status":323,"phases":1840,"primaryCompletion":1841,"completion":1841,"start":1842,"enrollment":1513,"conditions":1843,"interventions":1845},"NCT04621500","Vitamin D Supplementation in RNA-seq Profiles of Single-core Prostate Samples, Among Veterans",[87],"2022-02-04","2019-06-04",[31,143,1844],"Stress Reaction",[1809],{"nctId":1847,"briefTitle":1848,"status":323,"phases":1849,"primaryCompletion":1850,"completion":1850,"start":1851,"enrollment":1852,"conditions":1853,"interventions":1855},"NCT01911169","Vitamin D to Improve Endothelial Function in SLE",[87],"2014-01","2011-06",9,[1854,1823],"Atherosclerosis",[1825],{"trials":1857,"activeCount":98},[1858,1868],{"nctId":1859,"briefTitle":1860,"status":323,"phases":1861,"primaryCompletion":1862,"completion":1862,"start":1863,"enrollment":1864,"conditions":1865,"interventions":1867},"NCT00412087","Vitamin D Status of Pregnant Women and Their Children in Eau Claire, South Carolina",[88],"2009-07","2007-01",564,[143,1866],"Pregnancy",[1809,1809,1809],{"nctId":1869,"briefTitle":1870,"status":323,"phases":1871,"primaryCompletion":1872,"completion":1872,"start":1873,"enrollment":1874,"conditions":1875,"interventions":1876},"NCT00292591","Evaluation of Vitamin D Requirements During Pregnancy",[88],"2010-01","2004-01",501,[143],[1809,1809],{"trials":1878,"activeCount":98},[1879],{"nctId":1880,"briefTitle":1881,"status":597,"phases":1882,"primaryCompletion":1883,"completion":1884,"start":1885,"enrollment":473,"conditions":1886,"interventions":1888},"NCT04629534","Mothers' Own Milk Optimization for Preterm Infants Project (MoMO PIP) Pilot Study",[89],"2021-12-31","2022-04-01","2021-05-06",[143,1887],"Nutritional Deficiency",[1889,1825],"High dose Cholecalciferol",{"trials":1891,"activeCount":98},[],{"intervention":1893,"totalTrials":1428,"cells":1894},"Naltrexone",{"EARLY_PHASE1":1895,"PHASE1":1897,"PHASE2":1899,"PHASE3":1910,"PHASE4":1923,"NA":1944},{"trials":1896,"activeCount":98},[],{"trials":1898,"activeCount":98},[],{"trials":1900,"activeCount":98},[1901],{"nctId":1902,"briefTitle":1903,"status":323,"phases":1904,"primaryCompletion":791,"completion":791,"start":1905,"enrollment":1906,"conditions":1907,"interventions":1908},"NCT00667875","An Exploratory Study of Naltrexone Plus Aripiprazole for Alcohol Dependence",[87],"2008-04",65,[34],[1893,1909],"Naltrexone + Aripiprazole",{"trials":1911,"activeCount":98},[1912],{"nctId":1913,"briefTitle":1914,"status":323,"phases":1915,"primaryCompletion":1916,"completion":1917,"start":1918,"enrollment":1919,"conditions":1920,"interventions":1921},"NCT00183196","Effectiveness of Gabapentin When Used With Naltrexone to Treat Alcohol Dependence Compared to Placebo and Naltrexone Alone",[88],"2008-12","2009-06","2003-01",150,[34],[1893,1922],"Naltrexone plus Gabapentin",{"trials":1924,"activeCount":98},[1925,1933],{"nctId":1926,"briefTitle":1927,"status":323,"phases":1928,"primaryCompletion":1872,"completion":1872,"start":1929,"enrollment":1930,"conditions":1931,"interventions":1932},"NCT00366626","Effectiveness of Naltrexone Versus Placebo to Reduce Craving for Alcohol With Evaluation of Genetic Variability.",[89],"2006-04",83,[34],[1893],{"nctId":1934,"briefTitle":1935,"status":323,"phases":1936,"primaryCompletion":1937,"completion":1937,"start":1938,"enrollment":1939,"conditions":1940,"interventions":1942},"NCT00000456","Behavioral Therapy Plus Naltrexone for Alcoholism",[89],"2002-08","1992-09",160,[1941,34],"Alcoholism",[1943],"naltrexone",{"trials":1945,"activeCount":98},[],{"intervention":1947,"totalTrials":573,"cells":1948},"Modafinil",{"EARLY_PHASE1":1949,"PHASE1":1951,"PHASE2":1953,"PHASE3":1974,"PHASE4":1976,"NA":1986},{"trials":1950,"activeCount":98},[],{"trials":1952,"activeCount":98},[],{"trials":1954,"activeCount":98},[1955,1964],{"nctId":1956,"briefTitle":1957,"status":323,"phases":1958,"primaryCompletion":1959,"completion":1959,"start":1960,"enrollment":1961,"conditions":1962,"interventions":1963},"NCT00218387","Modafinil Combined With Cognitive Behavior Therapy to Treat Cocaine Addiction - 1",[87],"2010-07","2004-04",123,[1607],[1947,1947],{"nctId":1965,"briefTitle":1966,"status":323,"phases":1967,"primaryCompletion":1630,"completion":1630,"start":1968,"enrollment":1969,"conditions":1970,"interventions":1972},"NCT00613015","Stress and Medication Effects on Cocaine Cue Reactivity",[87],"2008-05",109,[1971],"Cocaine Related Disorders",[1973,1947],"Guanfacine",{"trials":1975,"activeCount":98},[],{"trials":1977,"activeCount":98},[1978],{"nctId":1979,"briefTitle":1980,"status":323,"phases":1981,"primaryCompletion":1959,"completion":1959,"start":1982,"enrollment":1350,"conditions":1983,"interventions":1985},"NCT00751023","Effects of Modafinil in Methamphetamine Dependence",[89],"2009-02",[1984],"Methamphetamine Dependence",[1947],{"trials":1987,"activeCount":98},[],{"intervention":1989,"totalTrials":573,"cells":1990},"Buspirone",{"EARLY_PHASE1":1991,"PHASE1":1993,"PHASE2":1995,"PHASE3":2013,"PHASE4":2015,"NA":2026},{"trials":1992,"activeCount":98},[],{"trials":1994,"activeCount":98},[],{"trials":1996,"activeCount":98},[1997,2007],{"nctId":1998,"briefTitle":1999,"status":323,"phases":2000,"completion":2001,"start":1960,"enrollment":2002,"conditions":2003,"interventions":2006},"NCT00149617","Effectiveness of Buspirone and Motivational Enhancement Therapy for the Treatment of Marijuana Dependence - 1",[87],"2007-12",81,[2004,2005],"Marijuana Abuse","Mood Disorders",[1989],{"nctId":2008,"briefTitle":2009,"status":323,"phases":2010,"completion":2001,"start":1960,"enrollment":2002,"conditions":2011,"interventions":2012},"NCT00360191","A Placebo-Controlled Trial of Buspirone for Treatment of Marijuana Dependence",[87],[2004],[1989],{"trials":2014,"activeCount":98},[],{"trials":2016,"activeCount":98},[2017],{"nctId":2018,"briefTitle":2019,"status":323,"phases":2020,"primaryCompletion":2021,"completion":2022,"start":2023,"enrollment":1058,"conditions":2024,"interventions":2025},"NCT00875836","Buspirone Treatment for Marijuana Dependence",[89],"2014-06","2016-03","2009-09",[1634],[1989],{"trials":2027,"activeCount":98},[],{"intervention":2029,"totalTrials":573,"cells":2030},"Acamprosate",{"EARLY_PHASE1":2031,"PHASE1":2033,"PHASE2":2035,"PHASE3":2044,"PHASE4":2046,"NA":2067},{"trials":2032,"activeCount":98},[],{"trials":2034,"activeCount":98},[],{"trials":2036,"activeCount":98},[2037],{"nctId":2038,"briefTitle":2039,"status":323,"phases":2040,"primaryCompletion":2041,"completion":2041,"start":1929,"enrollment":1852,"conditions":2042,"interventions":2043},"NCT00330486","Open Label Trial of Acamprosate in Bipolar Alcoholics",[86,87],"2007-06",[34,1383],[2029],{"trials":2045,"activeCount":98},[],{"trials":2047,"activeCount":98},[2048,2059],{"nctId":2049,"briefTitle":2050,"status":323,"phases":2051,"primaryCompletion":2052,"completion":2052,"start":1929,"enrollment":2053,"conditions":2054,"interventions":2058},"NCT00330174","Acamprosate in Alcoholics With Comorbid Anxiety or Depression",[89],"2010-09",90,[34,2055,2056,2057],"Major Depression","Social Anxiety Disorder","Generalized Anxiety Disorder",[2029],{"nctId":2060,"briefTitle":2061,"status":323,"phases":2062,"primaryCompletion":2063,"completion":2063,"start":2064,"enrollment":1605,"conditions":2065,"interventions":2066},"NCT00466661","Acamprosate vs. Placebo in Bipolar Alcoholics",[89],"2010-02","2007-04",[34,1383],[2029],{"trials":2068,"activeCount":98},[],{"intervention":2070,"totalTrials":302,"cells":2071},"Spironolactone 100Mg",{"EARLY_PHASE1":2072,"PHASE1":2074,"PHASE2":2088,"PHASE3":2090,"PHASE4":2092,"NA":2106},{"trials":2073,"activeCount":98},[],{"trials":2075,"activeCount":98},[2076],{"nctId":2077,"briefTitle":2078,"status":2079,"phases":2080,"primaryCompletion":2081,"completion":2081,"start":2082,"enrollment":98,"conditions":2083,"interventions":2085},"NCT03953209","Spironolactone for the Treatment of Melasma","WITHDRAWN",[86],"2021-01-01","2020-03-05",[2084],"Melasma",[2086,2070,2087],"Spironolactone 50Mg","Spironolactone 200Mg",{"trials":2089,"activeCount":98},[],{"trials":2091,"activeCount":98},[],{"trials":2093,"activeCount":98},[2094],{"nctId":2095,"briefTitle":2096,"status":2079,"phases":2097,"primaryCompletion":2098,"completion":2098,"start":2099,"enrollment":98,"conditions":2100,"interventions":2102},"NCT04100083","Spironolactone for Hidradenitis Suppurativa",[89],"2021-06-21","2020-09-21",[2101],"Hidradenitis Suppurativa",[2103,2104,2105],"Spironolactone 50 MG","Spironolactone 100mg","Spironolactone 200 mg",{"trials":2107,"activeCount":98},[],{"intervention":2109,"totalTrials":302,"cells":2110},"Aripiprazole",{"EARLY_PHASE1":2111,"PHASE1":2113,"PHASE2":2115,"PHASE3":2117,"PHASE4":2127,"NA":2139},{"trials":2112,"activeCount":98},[],{"trials":2114,"activeCount":98},[],{"trials":2116,"activeCount":98},[],{"trials":2118,"activeCount":98},[2119],{"nctId":2120,"briefTitle":2121,"status":323,"phases":2122,"primaryCompletion":1833,"completion":1833,"start":2123,"enrollment":2124,"conditions":2125,"interventions":2126},"NCT01292057","Aripiprazole Effects on Alcohol Drinking and Craving",[88],"2011-02",99,[34],[2109],{"trials":2128,"activeCount":98},[2129],{"nctId":2130,"briefTitle":2131,"status":323,"phases":2132,"primaryCompletion":2133,"completion":2133,"start":1604,"enrollment":2134,"conditions":2135,"interventions":2137},"NCT01333072","Biomarkers in Autism of Aripiprazole and Risperidone Treatment (BAART)",[89],"2015-08",80,[2136],"Autistic Disorder",[2109,2138],"Risperidone",{"trials":2140,"activeCount":98},[],{"intervention":2142,"totalTrials":302,"cells":2143},"Valganciclovir",{"EARLY_PHASE1":2144,"PHASE1":2146,"PHASE2":2148,"PHASE3":2150,"PHASE4":2152,"NA":2176},{"trials":2145,"activeCount":98},[],{"trials":2147,"activeCount":98},[],{"trials":2149,"activeCount":98},[],{"trials":2151,"activeCount":98},[],{"trials":2153,"activeCount":98},[2154,2166],{"nctId":2155,"briefTitle":2156,"status":323,"phases":2157,"primaryCompletion":2158,"completion":2159,"start":853,"enrollment":2160,"conditions":2161,"interventions":2164},"NCT06034925","Maribavir vs. Valganciclovir for CMV Prophylaxis in High-Risk Kidney Transplant Recipients",[89],"2025-06-30","2025-08-30",70,[2162,2163],"Transplant Complication","CMV",[2165,2142],"Maribavir",{"nctId":2167,"briefTitle":2168,"status":323,"phases":2169,"primaryCompletion":2170,"completion":1833,"start":2171,"enrollment":1350,"conditions":2172,"interventions":2174},"NCT01509404","Cytogam Administration in Abdominal Organ Transplant Recipients at High Risk for Cytomegalovirus Infection",[89],"2014-12","2011-11",[2173],"Cytomegalovirus Disease",[2142,2175,2142],"CMV hyperimmune globulin",{"trials":2177,"activeCount":98},[],{"intervention":2179,"totalTrials":302,"cells":2180},"Ambrisentan",{"EARLY_PHASE1":2181,"PHASE1":2183,"PHASE2":2185,"PHASE3":2187,"PHASE4":2199,"NA":2210},{"trials":2182,"activeCount":98},[],{"trials":2184,"activeCount":98},[],{"trials":2186,"activeCount":98},[],{"trials":2188,"activeCount":98},[2189],{"nctId":2190,"briefTitle":2191,"status":323,"phases":2192,"primaryCompletion":2193,"completion":2171,"start":2194,"enrollment":1632,"conditions":2195,"interventions":2198},"NCT00851929","Ambrisentan (Letairis) for Sarcoidosis Associated Pulmonary Hypertension",[87,88],"2011-04","2008-11",[2196,2197],"Sarcoidosis","Pulmonary Hypertension",[2179],{"trials":2200,"activeCount":98},[2201],{"nctId":2202,"briefTitle":2203,"status":597,"phases":2204,"primaryCompletion":2205,"completion":2205,"start":2206,"enrollment":573,"conditions":2207,"interventions":2209},"NCT02885012","Crossover Study From Macitentan or Bosentan Over to Ambrisentan",[89],"2017-07-07","2016-06",[2208],"Pulmonary Arterial Hypertension",[2179],{"trials":2211,"activeCount":98},[],{"intervention":2213,"totalTrials":94,"cells":2214},"Paroxetine CR",{"EARLY_PHASE1":2215,"PHASE1":2217,"PHASE2":2219,"PHASE3":2221,"PHASE4":2223,"NA":2233},{"trials":2216,"activeCount":98},[],{"trials":2218,"activeCount":98},[],{"trials":2220,"activeCount":98},[],{"trials":2222,"activeCount":98},[],{"trials":2224,"activeCount":98},[2225],{"nctId":2226,"briefTitle":2227,"status":323,"phases":2228,"completion":2229,"start":1918,"enrollment":2230,"conditions":2231,"interventions":2232},"NCT00330239","Paroxetine Treatment in Outpatients With Comorbid PTSD and Substance Dependence",[89],"2005-05",25,[1060],[2213],{"trials":2234,"activeCount":98},[],{"intervention":2236,"totalTrials":94,"cells":2237},"Canthardin Collodion",{"EARLY_PHASE1":2238,"PHASE1":2240,"PHASE2":2242,"PHASE3":2244,"PHASE4":2246,"NA":2258},{"trials":2239,"activeCount":98},[],{"trials":2241,"activeCount":98},[],{"trials":2243,"activeCount":98},[],{"trials":2245,"activeCount":98},[],{"trials":2247,"activeCount":98},[2248],{"nctId":2249,"briefTitle":2250,"status":323,"phases":2251,"primaryCompletion":39,"completion":39,"start":2252,"enrollment":2253,"conditions":2254,"interventions":2257},"NCT05070754","Cold Atmospheric Plasma Device for Pediatric Molluscum and Verruca",[89],"2021-12-02",17,[2255,2256],"Verruca Vulgaris","Molluscum Contagiosum Skin Infection",[2236],{"trials":2259,"activeCount":98},[],{"intervention":2261,"totalTrials":94,"cells":2262},"Intrathecal Morphine",{"EARLY_PHASE1":2263,"PHASE1":2265,"PHASE2":2267,"PHASE3":2269,"PHASE4":2271,"NA":2287},{"trials":2264,"activeCount":98},[],{"trials":2266,"activeCount":98},[],{"trials":2268,"activeCount":98},[],{"trials":2270,"activeCount":98},[],{"trials":2272,"activeCount":98},[2273],{"nctId":2274,"briefTitle":2275,"status":597,"phases":2276,"primaryCompletion":2277,"completion":2278,"start":2279,"enrollment":2280,"conditions":2281,"interventions":2285},"NCT05506930","ITM vs QL for Pediatric Open Lower Abdominal Procedures",[89],"2024-05-09","2024-05-10","2022-08-17",14,[2282,2283,2284,2261],"Pain Control","Ureteral Reimplantation","Pediatrics",[2261,2286],"Quadratus lumborum block",{"trials":2288,"activeCount":98},[],{"intervention":2286,"totalTrials":94,"cells":2290},{"EARLY_PHASE1":2291,"PHASE1":2293,"PHASE2":2295,"PHASE3":2297,"PHASE4":2299,"NA":2305},{"trials":2292,"activeCount":98},[],{"trials":2294,"activeCount":98},[],{"trials":2296,"activeCount":98},[],{"trials":2298,"activeCount":98},[],{"trials":2300,"activeCount":98},[2301],{"nctId":2274,"briefTitle":2275,"status":597,"phases":2302,"primaryCompletion":2277,"completion":2278,"start":2279,"enrollment":2280,"conditions":2303,"interventions":2304},[89],[2282,2283,2284,2261],[2261,2286],{"trials":2306,"activeCount":98},[],{"intervention":2308,"totalTrials":94,"cells":2309},"Sofosbuvir\u002FLedipasvir x 12 weeks",{"EARLY_PHASE1":2310,"PHASE1":2312,"PHASE2":2314,"PHASE3":2316,"PHASE4":2318,"NA":2332},{"trials":2311,"activeCount":98},[],{"trials":2313,"activeCount":98},[],{"trials":2315,"activeCount":98},[],{"trials":2317,"activeCount":98},[],{"trials":2319,"activeCount":98},[2320],{"nctId":2321,"briefTitle":2322,"status":323,"phases":2323,"primaryCompletion":2324,"completion":2325,"start":2326,"enrollment":2327,"conditions":2328,"interventions":2330},"NCT02631772","LIVE-C-Free: Early and Late Treatment of Hepatitis C With Sofosbuvir\u002FLedipasvir in Liver Transplant Recipients",[89],"2018-05-30","2018-06-30","2016-06-01",32,[2329],"Hepatitis C",[2308,2331],"Sofosbuvir\u002FLedipasvir + Ribavirin x 12 weeks",{"trials":2333,"activeCount":98},[],{"intervention":2331,"totalTrials":94,"cells":2335},{"EARLY_PHASE1":2336,"PHASE1":2338,"PHASE2":2340,"PHASE3":2342,"PHASE4":2344,"NA":2350},{"trials":2337,"activeCount":98},[],{"trials":2339,"activeCount":98},[],{"trials":2341,"activeCount":98},[],{"trials":2343,"activeCount":98},[],{"trials":2345,"activeCount":98},[2346],{"nctId":2321,"briefTitle":2322,"status":323,"phases":2347,"primaryCompletion":2324,"completion":2325,"start":2326,"enrollment":2327,"conditions":2348,"interventions":2349},[89],[2329],[2308,2331],{"trials":2351,"activeCount":98},[],{"intervention":2353,"totalTrials":94,"cells":2354},"Tacrolimus Extended Release",{"EARLY_PHASE1":2355,"PHASE1":2357,"PHASE2":2359,"PHASE3":2361,"PHASE4":2363,"NA":2378},{"trials":2356,"activeCount":98},[],{"trials":2358,"activeCount":98},[],{"trials":2360,"activeCount":98},[],{"trials":2362,"activeCount":98},[],{"trials":2364,"activeCount":98},[2365],{"nctId":2366,"briefTitle":2367,"status":323,"phases":2368,"primaryCompletion":2369,"completion":2370,"start":2371,"enrollment":2230,"conditions":2372,"interventions":2374},"NCT02953873","Dosing Requirements of Astagraf XL® in African American Kidney Transplant Recipients",[89],"2018-09-10","2018-12-14","2017-05-05",[2373],"Immunosuppression",[2353,2375,2376,2377],"Mycophenolate mofetil","Prednisone","Mycophenolate Sodium",{"trials":2379,"activeCount":98},[],{"intervention":2377,"totalTrials":94,"cells":2381},{"EARLY_PHASE1":2382,"PHASE1":2384,"PHASE2":2386,"PHASE3":2388,"PHASE4":2390,"NA":2396},{"trials":2383,"activeCount":98},[],{"trials":2385,"activeCount":98},[],{"trials":2387,"activeCount":98},[],{"trials":2389,"activeCount":98},[],{"trials":2391,"activeCount":98},[2392],{"nctId":2366,"briefTitle":2367,"status":323,"phases":2393,"primaryCompletion":2369,"completion":2370,"start":2371,"enrollment":2230,"conditions":2394,"interventions":2395},[89],[2373],[2353,2375,2376,2377],{"trials":2397,"activeCount":98},[],{"intervention":2138,"totalTrials":94,"cells":2399},{"EARLY_PHASE1":2400,"PHASE1":2402,"PHASE2":2404,"PHASE3":2406,"PHASE4":2408,"NA":2414},{"trials":2401,"activeCount":98},[],{"trials":2403,"activeCount":98},[],{"trials":2405,"activeCount":98},[],{"trials":2407,"activeCount":98},[],{"trials":2409,"activeCount":98},[2410],{"nctId":2130,"briefTitle":2131,"status":323,"phases":2411,"primaryCompletion":2133,"completion":2133,"start":1604,"enrollment":2134,"conditions":2412,"interventions":2413},[89],[2136],[2109,2138],{"trials":2415,"activeCount":98},[],{"intervention":2417,"totalTrials":94,"cells":2418},"Lamotrigine",{"EARLY_PHASE1":2419,"PHASE1":2421,"PHASE2":2423,"PHASE3":2425,"PHASE4":2427,"NA":2439},{"trials":2420,"activeCount":98},[],{"trials":2422,"activeCount":98},[],{"trials":2424,"activeCount":98},[],{"trials":2426,"activeCount":98},[],{"trials":2428,"activeCount":98},[2429],{"nctId":2430,"briefTitle":2431,"status":323,"phases":2432,"primaryCompletion":2433,"completion":2434,"start":2063,"enrollment":16,"conditions":2435,"interventions":2438},"NCT01015586","Treatment of Alcohol Dependence and Comorbid Bipolar Disorder",[89],"2014-05","2014-09",[34,1383,18,2436,2437],"Mania","Psychosis",[2417],{"trials":2440,"activeCount":98},[],{"intervention":2103,"totalTrials":94,"cells":2442},{"EARLY_PHASE1":2443,"PHASE1":2445,"PHASE2":2447,"PHASE3":2449,"PHASE4":2451,"NA":2457},{"trials":2444,"activeCount":98},[],{"trials":2446,"activeCount":98},[],{"trials":2448,"activeCount":98},[],{"trials":2450,"activeCount":98},[],{"trials":2452,"activeCount":98},[2453],{"nctId":2095,"briefTitle":2096,"status":2079,"phases":2454,"primaryCompletion":2098,"completion":2098,"start":2099,"enrollment":98,"conditions":2455,"interventions":2456},[89],[2101],[2103,2104,2105],{"trials":2458,"activeCount":98},[],{"intervention":2105,"totalTrials":94,"cells":2460},{"EARLY_PHASE1":2461,"PHASE1":2463,"PHASE2":2465,"PHASE3":2467,"PHASE4":2469,"NA":2475},{"trials":2462,"activeCount":98},[],{"trials":2464,"activeCount":98},[],{"trials":2466,"activeCount":98},[],{"trials":2468,"activeCount":98},[],{"trials":2470,"activeCount":98},[2471],{"nctId":2095,"briefTitle":2096,"status":2079,"phases":2472,"primaryCompletion":2098,"completion":2098,"start":2099,"enrollment":98,"conditions":2473,"interventions":2474},[89],[2101],[2103,2104,2105],{"trials":2476,"activeCount":98},[],{"intervention":2165,"totalTrials":94,"cells":2478},{"EARLY_PHASE1":2479,"PHASE1":2481,"PHASE2":2483,"PHASE3":2485,"PHASE4":2487,"NA":2493},{"trials":2480,"activeCount":98},[],{"trials":2482,"activeCount":98},[],{"trials":2484,"activeCount":98},[],{"trials":2486,"activeCount":98},[],{"trials":2488,"activeCount":98},[2489],{"nctId":2155,"briefTitle":2156,"status":323,"phases":2490,"primaryCompletion":2158,"completion":2159,"start":853,"enrollment":2160,"conditions":2491,"interventions":2492},[89],[2162,2163],[2165,2142],{"trials":2494,"activeCount":98},[],{"intervention":2496,"totalTrials":94,"cells":2497},"Pioglitazone then Placebo",{"EARLY_PHASE1":2498,"PHASE1":2500,"PHASE2":2502,"PHASE3":2504,"PHASE4":2506,"NA":2518},{"trials":2499,"activeCount":98},[],{"trials":2501,"activeCount":98},[],{"trials":2503,"activeCount":98},[],{"trials":2505,"activeCount":98},[],{"trials":2507,"activeCount":98},[2508],{"nctId":2509,"briefTitle":2510,"status":323,"phases":2511,"primaryCompletion":2512,"completion":2513,"start":2514,"enrollment":9,"conditions":2515,"interventions":2517},"NCT00770367","Pioglitazone and Serum Asymmetric Dimethylarginine (ADMA) in Patients With Diabetes",[89],"2009-12","2010-06","2008-10",[2516],"Diabetes",[2496],{"trials":2519,"activeCount":98},[],{"intervention":1889,"totalTrials":94,"cells":2521},{"EARLY_PHASE1":2522,"PHASE1":2524,"PHASE2":2526,"PHASE3":2528,"PHASE4":2530,"NA":2536},{"trials":2523,"activeCount":98},[],{"trials":2525,"activeCount":98},[],{"trials":2527,"activeCount":98},[],{"trials":2529,"activeCount":98},[],{"trials":2531,"activeCount":98},[2532],{"nctId":1880,"briefTitle":1881,"status":597,"phases":2533,"primaryCompletion":1883,"completion":1884,"start":1885,"enrollment":473,"conditions":2534,"interventions":2535},[89],[143,1887],[1889,1825],{"trials":2537,"activeCount":98},[],{"intervention":2539,"totalTrials":94,"cells":2540},"Envarsus",{"EARLY_PHASE1":2541,"PHASE1":2543,"PHASE2":2545,"PHASE3":2547,"PHASE4":2549,"NA":2562},{"trials":2542,"activeCount":98},[],{"trials":2544,"activeCount":98},[],{"trials":2546,"activeCount":98},[],{"trials":2548,"activeCount":98},[],{"trials":2550,"activeCount":98},[2551],{"nctId":2552,"briefTitle":2553,"status":323,"phases":2554,"primaryCompletion":2555,"completion":2556,"start":497,"enrollment":19,"conditions":2557,"interventions":2560},"NCT03823768","Envarsus Neurotoxicity Burden in Liver Transplant Patients",[89],"2023-04-30","2024-01-30",[2558,2559],"Neurotoxicity","Liver Transplant; Complications",[2539,2561],"Tacrolimus Immediate release",{"trials":2563,"activeCount":98},[],{"intervention":2561,"totalTrials":94,"cells":2565},{"EARLY_PHASE1":2566,"PHASE1":2568,"PHASE2":2570,"PHASE3":2572,"PHASE4":2574,"NA":2580},{"trials":2567,"activeCount":98},[],{"trials":2569,"activeCount":98},[],{"trials":2571,"activeCount":98},[],{"trials":2573,"activeCount":98},[],{"trials":2575,"activeCount":98},[2576],{"nctId":2552,"briefTitle":2553,"status":323,"phases":2577,"primaryCompletion":2555,"completion":2556,"start":497,"enrollment":19,"conditions":2578,"interventions":2579},[89],[2558,2559],[2539,2561],{"trials":2581,"activeCount":98},[],{"intervention":2583,"totalTrials":94,"cells":2584},"Fenofibrate",{"EARLY_PHASE1":2585,"PHASE1":2587,"PHASE2":2589,"PHASE3":2591,"PHASE4":2593,"NA":2604},{"trials":2586,"activeCount":98},[],{"trials":2588,"activeCount":98},[],{"trials":2590,"activeCount":98},[],{"trials":2592,"activeCount":98},[],{"trials":2594,"activeCount":98},[2595],{"nctId":2596,"briefTitle":2597,"status":323,"phases":2598,"primaryCompletion":2599,"completion":2599,"start":2600,"enrollment":601,"conditions":2601,"interventions":2603},"NCT03829514","Fenofibrate in Type 2 Diabetes",[89],"2020-03-04","2019-02-04",[2602],"Diabetes Mellitus, Type II",[2583],{"trials":2605,"activeCount":98},[],{"intervention":2607,"totalTrials":94,"cells":2608},"Acular LS",{"EARLY_PHASE1":2609,"PHASE1":2611,"PHASE2":2613,"PHASE3":2615,"PHASE4":2617,"NA":2629},{"trials":2610,"activeCount":98},[],{"trials":2612,"activeCount":98},[],{"trials":2614,"activeCount":98},[],{"trials":2616,"activeCount":98},[],{"trials":2618,"activeCount":98},[2619],{"nctId":2620,"briefTitle":2621,"status":323,"phases":2622,"completion":2623,"start":2624,"enrollment":1350,"conditions":2625,"interventions":2627},"NCT00366691","Comparison of Acular LS With Lotemax to Prevent Inflammation After Cataract Surgery and Intraocular Lens Implantation",[89],"2007-09","2006-02",[2626],"Cataract Extraction",[2607,2628],"Lotemax",{"trials":2630,"activeCount":98},[],{"intervention":2628,"totalTrials":94,"cells":2632},{"EARLY_PHASE1":2633,"PHASE1":2635,"PHASE2":2637,"PHASE3":2639,"PHASE4":2641,"NA":2647},{"trials":2634,"activeCount":98},[],{"trials":2636,"activeCount":98},[],{"trials":2638,"activeCount":98},[],{"trials":2640,"activeCount":98},[],{"trials":2642,"activeCount":98},[2643],{"nctId":2620,"briefTitle":2621,"status":323,"phases":2644,"completion":2623,"start":2624,"enrollment":1350,"conditions":2645,"interventions":2646},[89],[2626],[2607,2628],{"trials":2648,"activeCount":98},[],{"intervention":2650,"totalTrials":94,"cells":2651},"Suvorexant",{"EARLY_PHASE1":2652,"PHASE1":2654,"PHASE2":2656,"PHASE3":2658,"PHASE4":2660,"NA":2671},{"trials":2653,"activeCount":98},[],{"trials":2655,"activeCount":98},[],{"trials":2657,"activeCount":98},[],{"trials":2659,"activeCount":98},[],{"trials":2661,"activeCount":98},[2662],{"nctId":2663,"briefTitle":2664,"status":597,"phases":2665,"primaryCompletion":2666,"completion":2666,"start":2667,"enrollment":1360,"conditions":2668,"interventions":2670},"NCT06162663","Double-blind Randomized Controlled Trial Comparing Suvorexant 20 mg to Placebo for Treatment of Insomnia in Cancer Survivors",[89],"2026-02-17","2024-09-20",[1562,2669],"Insomnia",[2650],{"trials":2672,"activeCount":98},[],{"intervention":2674,"totalTrials":94,"cells":2675},"Provodine-Iodine Solution",{"EARLY_PHASE1":2676,"PHASE1":2678,"PHASE2":2680,"PHASE3":2682,"PHASE4":2684,"NA":2697},{"trials":2677,"activeCount":98},[],{"trials":2679,"activeCount":98},[],{"trials":2681,"activeCount":98},[],{"trials":2683,"activeCount":98},[],{"trials":2685,"activeCount":98},[2686],{"nctId":2687,"briefTitle":2688,"status":323,"phases":2689,"primaryCompletion":2690,"completion":2690,"start":2691,"enrollment":2692,"conditions":2693,"interventions":2695},"NCT03349515","The Effect of Povidone-iodine Ophthalmic Surgical Prep Solution on Respiration in Children Undergoing Strabismus Surgery With General Anesthesia.",[89],"2018-09-19","2017-11-02",106,[2694],"Strabismus",[2674,2696],"Group B will receive three drops in each eye of ophthalmic balanced salt solution.",{"trials":2698,"activeCount":98},[],{"intervention":2696,"totalTrials":94,"cells":2700},{"EARLY_PHASE1":2701,"PHASE1":2703,"PHASE2":2705,"PHASE3":2707,"PHASE4":2709,"NA":2715},{"trials":2702,"activeCount":98},[],{"trials":2704,"activeCount":98},[],{"trials":2706,"activeCount":98},[],{"trials":2708,"activeCount":98},[],{"trials":2710,"activeCount":98},[2711],{"nctId":2687,"briefTitle":2688,"status":323,"phases":2712,"primaryCompletion":2690,"completion":2690,"start":2691,"enrollment":2692,"conditions":2713,"interventions":2714},[89],[2694],[2674,2696],{"trials":2716,"activeCount":98},[],{"intervention":2175,"totalTrials":94,"cells":2718},{"EARLY_PHASE1":2719,"PHASE1":2721,"PHASE2":2723,"PHASE3":2725,"PHASE4":2727,"NA":2733},{"trials":2720,"activeCount":98},[],{"trials":2722,"activeCount":98},[],{"trials":2724,"activeCount":98},[],{"trials":2726,"activeCount":98},[],{"trials":2728,"activeCount":98},[2729],{"nctId":2167,"briefTitle":2168,"status":323,"phases":2730,"primaryCompletion":2170,"completion":1833,"start":2171,"enrollment":1350,"conditions":2731,"interventions":2732},[89],[2173],[2142,2175,2142],{"trials":2734,"activeCount":98},[],{"intervention":2736,"totalTrials":94,"cells":2737},"Octreotide",{"EARLY_PHASE1":2738,"PHASE1":2740,"PHASE2":2742,"PHASE3":2744,"PHASE4":2746,"NA":2760},{"trials":2739,"activeCount":98},[],{"trials":2741,"activeCount":98},[],{"trials":2743,"activeCount":98},[],{"trials":2745,"activeCount":98},[],{"trials":2747,"activeCount":98},[2748],{"nctId":2749,"briefTitle":2750,"status":597,"phases":2751,"primaryCompletion":2752,"completion":2752,"start":2690,"enrollment":2753,"conditions":2754,"interventions":2759},"NCT03624517","Comparison of 24-hours Versus 72-hours of Octreotide Infusion in Preventing Early Rebleed From Esophageal Varices",[89],"2024-12-01",34,[2755,2756,2757,2758],"Esophageal Varices","Liver Cirrhoses","Bleeding Esophageal Varices","Upper Gastrointestinal Bleeding",[2736],{"trials":2761,"activeCount":98},[],{"intervention":2763,"totalTrials":94,"cells":2764},"Minocycline",{"EARLY_PHASE1":2765,"PHASE1":2767,"PHASE2":2769,"PHASE3":2771,"PHASE4":2773,"NA":2782},{"trials":2766,"activeCount":98},[],{"trials":2768,"activeCount":98},[],{"trials":2770,"activeCount":98},[],{"trials":2772,"activeCount":98},[],{"trials":2774,"activeCount":98},[2775],{"nctId":2776,"briefTitle":2777,"status":2079,"phases":2778,"primaryCompletion":2022,"completion":2022,"start":2022,"enrollment":98,"conditions":2779,"interventions":2781},"NCT02712775","Minocycline Administration During Human Liver Transplantation",[89],[2780],"Liver Disease",[2763],{"trials":2783,"activeCount":98},[],{"intervention":2785,"totalTrials":94,"cells":2786},"Doxycycline",{"EARLY_PHASE1":2787,"PHASE1":2789,"PHASE2":2791,"PHASE3":2793,"PHASE4":2795,"NA":2806},{"trials":2788,"activeCount":98},[],{"trials":2790,"activeCount":98},[],{"trials":2792,"activeCount":98},[],{"trials":2794,"activeCount":98},[],{"trials":2796,"activeCount":98},[2797],{"nctId":2798,"briefTitle":2799,"status":323,"phases":2800,"primaryCompletion":1872,"completion":1872,"start":2001,"enrollment":2801,"conditions":2802,"interventions":2805},"NCT01798225","Relationship of Periodontal Disease Treatment and Type 2 Diabetes Mellitus in the Gullah Population",[89],113,[2803,2804],"Periodontal Disease","Type 2 Diabetes Mellitus",[2785],{"trials":2807,"activeCount":98},[],{"intervention":2809,"totalTrials":94,"cells":2810},"Paroxetine",{"EARLY_PHASE1":2811,"PHASE1":2813,"PHASE2":2815,"PHASE3":2817,"PHASE4":2819,"NA":2830},{"trials":2812,"activeCount":98},[],{"trials":2814,"activeCount":98},[],{"trials":2816,"activeCount":98},[],{"trials":2818,"activeCount":98},[],{"trials":2820,"activeCount":98},[2821],{"nctId":2822,"briefTitle":2823,"status":323,"phases":2824,"primaryCompletion":1421,"completion":1421,"start":2825,"enrollment":1129,"conditions":2826,"interventions":2829},"NCT00246441","Paroxetine for Comorbid Social Anxiety Disorder and Alcoholism",[89],"2002-03",[2056,2827,28,2828,34],"Social Phobia","Alcohol Abuse",[2809],{"trials":2831,"activeCount":98},[],{"intervention":2833,"totalTrials":94,"cells":2834},"Naltrexone 50 Mg",{"EARLY_PHASE1":2835,"PHASE1":2837,"PHASE2":2839,"PHASE3":2841,"PHASE4":2843,"NA":2852},{"trials":2836,"activeCount":98},[],{"trials":2838,"activeCount":98},[],{"trials":2840,"activeCount":98},[],{"trials":2842,"activeCount":98},[],{"trials":2844,"activeCount":98},[2845],{"nctId":2846,"briefTitle":2847,"status":323,"phases":2848,"primaryCompletion":1833,"completion":1833,"start":1917,"enrollment":2849,"conditions":2850,"interventions":2851},"NCT00920829","Genetic and Brain Mechanisms of Naltrexone's Treatment Efficacy for Alcoholism",[89],358,[34],[2833],{"trials":2853,"activeCount":98},[],{"intervention":2855,"totalTrials":94,"cells":2856},"Adductor Canal Block (ACB) Only",{"EARLY_PHASE1":2857,"PHASE1":2859,"PHASE2":2861,"PHASE3":2863,"PHASE4":2865,"NA":2879},{"trials":2858,"activeCount":98},[],{"trials":2860,"activeCount":98},[],{"trials":2862,"activeCount":98},[],{"trials":2864,"activeCount":98},[],{"trials":2866,"activeCount":98},[2867],{"nctId":2868,"briefTitle":2869,"status":323,"phases":2870,"primaryCompletion":2871,"completion":2872,"start":2873,"enrollment":2874,"conditions":2875,"interventions":2877},"NCT05498870","iPACK for Post-op Pain Following ACL Reconstruction",[89],"2023-07-03","2023-08-14","2022-08-25",82,[2876,400],"ACL Injury",[2855,2878],"Adductor Canal Block (ACB) + iPACK Block",{"trials":2880,"activeCount":98},[],{"intervention":2878,"totalTrials":94,"cells":2882},{"EARLY_PHASE1":2883,"PHASE1":2885,"PHASE2":2887,"PHASE3":2889,"PHASE4":2891,"NA":2897},{"trials":2884,"activeCount":98},[],{"trials":2886,"activeCount":98},[],{"trials":2888,"activeCount":98},[],{"trials":2890,"activeCount":98},[],{"trials":2892,"activeCount":98},[2893],{"nctId":2868,"briefTitle":2869,"status":323,"phases":2894,"primaryCompletion":2871,"completion":2872,"start":2873,"enrollment":2874,"conditions":2895,"interventions":2896},[89],[2876,400],[2855,2878],{"trials":2898,"activeCount":98},[],{"intervention":2900,"totalTrials":94,"cells":2901},"Dupilumab",{"EARLY_PHASE1":2902,"PHASE1":2904,"PHASE2":2906,"PHASE3":2908,"PHASE4":2910,"NA":2921},{"trials":2903,"activeCount":98},[],{"trials":2905,"activeCount":98},[],{"trials":2907,"activeCount":98},[],{"trials":2909,"activeCount":98},[],{"trials":2911,"activeCount":98},[2912],{"nctId":2913,"briefTitle":2914,"status":323,"phases":2915,"primaryCompletion":2916,"completion":2916,"start":2917,"enrollment":1513,"conditions":2918,"interventions":2920},"NCT05964465","Mechanisms of Smell Improvement With Dupilumab.",[89],"2025-01-30","2023-08-10",[2919],"Chronic Rhinosinusitis With Nasal Polyps",[2900],{"trials":2922,"activeCount":98},[],{"intervention":2924,"totalTrials":2280,"cells":2925},"N-acetylcysteine",{"EARLY_PHASE1":2926,"PHASE1":2928,"PHASE2":2930,"PHASE3":3040,"PHASE4":3050,"NA":3052},{"trials":2927,"activeCount":98},[],{"trials":2929,"activeCount":98},[],{"trials":2931,"activeCount":98},[2932,2940,2949,2958,2969,2979,2988,2999,3006,3010,3020,3029,3036],{"nctId":2933,"briefTitle":2934,"status":323,"phases":2935,"primaryCompletion":2434,"completion":2434,"start":2936,"enrollment":1726,"conditions":2937,"interventions":2939},"NCT02499029","N-acetylcysteine in the Treatment of PTSD and Addiction",[87],"2013-02",[1060,2938],"Addiction",[2924],{"nctId":2941,"briefTitle":2942,"status":323,"phases":2943,"primaryCompletion":2944,"completion":2944,"start":2945,"enrollment":2946,"conditions":2947,"interventions":2948},"NCT03707951","N-Acetylcysteine for Adolescent Alcohol Use Disorder",[87],"2024-02-26","2019-02-27",126,[28],[2924],{"nctId":2950,"briefTitle":2951,"status":323,"phases":2952,"primaryCompletion":2953,"completion":2953,"start":2954,"enrollment":2327,"conditions":2955,"interventions":2957},"NCT04155632","Neurocircuit Strategy to Decrease Cocaine Cue Reactivity",[87],"2023-03-09","2020-12-18",[2956],"Cocaine-Related Disorders",[2924],{"nctId":2959,"briefTitle":2960,"status":323,"phases":2961,"primaryCompletion":2962,"completion":2963,"start":2964,"enrollment":2053,"conditions":2965,"interventions":2968},"NCT02911285","NAC for Treating Comorbid PTSD and SUD",[87],"2019-08-05","2019-11-04","2016-10",[2966,1131,2967],"Posttraumatic Stress Disorder (PTSD)","Substance Use Disorder (SUD)",[2924],{"nctId":2970,"briefTitle":2971,"status":323,"phases":2972,"primaryCompletion":2973,"completion":2974,"start":2975,"enrollment":2976,"conditions":2977,"interventions":2978},"NCT02737358","N-acetylcysteine for Tobacco Use Disorder",[87],"2019-08-01","2019-10-10","2016-08-30",114,[24,26],[2924],{"nctId":2980,"briefTitle":2981,"status":323,"phases":2982,"primaryCompletion":2983,"completion":2983,"start":2984,"enrollment":2985,"conditions":2986,"interventions":2987},"NCT00218491","Effectiveness of N-Acetylcysteine (NAC) in Treating Cocaine Dependent Individuals - 1",[87],"2010-05","2005-11",111,[1607],[523,523],{"nctId":2989,"briefTitle":2990,"status":323,"phases":2991,"primaryCompletion":2992,"completion":1820,"start":599,"enrollment":2993,"conditions":2994,"interventions":2997},"NCT00724594","Safety of N-acetylcysteine in Maternal Chorioamnionitis (NAC in Chorio)",[86,87],"2014-07",46,[2995,2996],"Chorioamnionitis","Brain Injury",[2924,2998],"Control",{"nctId":3000,"briefTitle":3001,"status":323,"phases":3002,"primaryCompletion":3003,"completion":3003,"start":1821,"enrollment":1605,"conditions":3004,"interventions":3005},"NCT00751257","N-Acetylcysteine and Smoking Reduction",[87],"2007-10",[24],[2924],{"nctId":514,"briefTitle":515,"status":323,"phases":3007,"primaryCompletion":517,"completion":517,"start":518,"enrollment":519,"conditions":3008,"interventions":3009},[87],[521],[472,523],{"nctId":3011,"briefTitle":3012,"status":323,"phases":3013,"primaryCompletion":3014,"completion":3014,"start":3015,"enrollment":3016,"conditions":3017,"interventions":3019},"NCT03238300","Neuroscience-Informed Treatment Development for Adolescent Alcohol Use",[87],"2022-03-01","2017-10-16",57,[3018,2998],"Alcohol Drinking",[523],{"nctId":3021,"briefTitle":3022,"status":323,"phases":3023,"primaryCompletion":3024,"completion":3024,"start":2023,"enrollment":3025,"conditions":3026,"interventions":3028},"NCT01005810","A Trial of N-Acetylcysteine (an Over-the-Counter Medicine) in Adolescents Who Smoke Marijuana",[87],"2011-08",116,[3027],"Cannabis Dependence",[523],{"nctId":3030,"briefTitle":3031,"status":323,"phases":3032,"primaryCompletion":1916,"completion":1916,"start":3033,"enrollment":697,"conditions":3034,"interventions":3035},"NCT00542750","An Open-Label Trial of N-Acetylcysteine in Cannabis Dependent Adolescents",[86,87],"2008-01",[3027],[523],{"nctId":1402,"briefTitle":1403,"status":323,"phases":3037,"primaryCompletion":1405,"completion":1405,"start":1406,"enrollment":1407,"conditions":3038,"interventions":3039},[87],[28,1383],[523,68],{"trials":3041,"activeCount":98},[3042],{"nctId":3043,"briefTitle":3044,"status":323,"phases":3045,"primaryCompletion":3046,"completion":2133,"start":1850,"enrollment":3047,"conditions":3048,"interventions":3049},"NCT01675661","Achieving Cannabis Cessation-Evaluating N-Acetylcysteine Treatment",[88],"2015-07",302,[3027],[523],{"trials":3051,"activeCount":98},[],{"trials":3053,"activeCount":98},[],{"intervention":3055,"totalTrials":302,"cells":3056},"N-acetyl cysteine",{"EARLY_PHASE1":3057,"PHASE1":3059,"PHASE2":3061,"PHASE3":3073,"PHASE4":3084,"NA":3086},{"trials":3058,"activeCount":98},[],{"trials":3060,"activeCount":98},[],{"trials":3062,"activeCount":98},[3063],{"nctId":3064,"briefTitle":3065,"status":323,"phases":3066,"primaryCompletion":3067,"completion":3067,"start":3068,"enrollment":3069,"conditions":3070,"interventions":3071},"NCT05340504","Evaluating the Hypothesized Mechanism of Action of N-acetylcysteine for Bipolar Disorder",[87],"2023-06-21","2022-05-13",12,[1383,1385,1386],[3072],"N-Acetyl cysteine",{"trials":3074,"activeCount":98},[3075],{"nctId":3076,"briefTitle":3077,"status":323,"phases":3078,"primaryCompletion":3079,"completion":2944,"start":3080,"enrollment":3081,"conditions":3082,"interventions":3083},"NCT03055377","N-Acetylcysteine for Youth Cannabis Use Disorder",[87,88],"2024-01-31","2017-08-03",192,[500],[3055],{"trials":3085,"activeCount":98},[],{"trials":3087,"activeCount":98},[],{"intervention":3089,"totalTrials":94,"cells":3090},"Etonogestrel contraceptive implant",{"EARLY_PHASE1":3091,"PHASE1":3093,"PHASE2":3095,"PHASE3":3097,"PHASE4":3107,"NA":3109},{"trials":3092,"activeCount":98},[],{"trials":3094,"activeCount":98},[],{"trials":3096,"activeCount":98},[],{"trials":3098,"activeCount":98},[3099],{"nctId":3100,"briefTitle":3101,"status":323,"phases":3102,"primaryCompletion":3103,"completion":3103,"start":1872,"enrollment":2002,"conditions":3104,"interventions":3106},"NCT03585504","Immediate Versus Delayed Insertion of Implanon in Postpartum Adolescents",[88],"2013-01",[3105],"Contraceptive Usage",[3089],{"trials":3108,"activeCount":98},[],{"trials":3110,"activeCount":98},[],{"intervention":3112,"totalTrials":94,"cells":3113},"Venlafaxine",{"EARLY_PHASE1":3114,"PHASE1":3116,"PHASE2":3118,"PHASE3":3120,"PHASE4":3132,"NA":3134},{"trials":3115,"activeCount":98},[],{"trials":3117,"activeCount":98},[],{"trials":3119,"activeCount":98},[],{"trials":3121,"activeCount":98},[3122],{"nctId":3123,"briefTitle":3124,"status":323,"phases":3125,"primaryCompletion":3126,"completion":3127,"start":3128,"enrollment":1350,"conditions":3129,"interventions":3131},"NCT04218123","Assessing the Efficacy of a Serotonin and Norepinephrine Reuptake Inhibitor for Improving Meniere's Disease Outcomes",[87,88],"2023-09-13","2023-09-14","2020-02-05",[3130],"Meniere Disease",[3112],{"trials":3133,"activeCount":98},[],{"trials":3135,"activeCount":98},[],{"intervention":3137,"totalTrials":94,"cells":3138},"400 IU Vitamin D3",{"EARLY_PHASE1":3139,"PHASE1":3141,"PHASE2":3143,"PHASE3":3145,"PHASE4":3157,"NA":3159},{"trials":3140,"activeCount":98},[],{"trials":3142,"activeCount":98},[],{"trials":3144,"activeCount":98},[],{"trials":3146,"activeCount":98},[3147],{"nctId":3148,"briefTitle":3149,"status":323,"phases":3150,"primaryCompletion":1603,"completion":1603,"start":3151,"enrollment":3152,"conditions":3153,"interventions":3154},"NCT00412074","Establishing the Vitamin D Requirements During Lactation",[88],"2006-08",460,[143],[3137,3155,3156],"2400 IU Vitamin D3","6400 IU Vitamin D3",{"trials":3158,"activeCount":98},[],{"trials":3160,"activeCount":98},[],{"intervention":3155,"totalTrials":94,"cells":3162},{"EARLY_PHASE1":3163,"PHASE1":3165,"PHASE2":3167,"PHASE3":3169,"PHASE4":3175,"NA":3177},{"trials":3164,"activeCount":98},[],{"trials":3166,"activeCount":98},[],{"trials":3168,"activeCount":98},[],{"trials":3170,"activeCount":98},[3171],{"nctId":3148,"briefTitle":3149,"status":323,"phases":3172,"primaryCompletion":1603,"completion":1603,"start":3151,"enrollment":3152,"conditions":3173,"interventions":3174},[88],[143],[3137,3155,3156],{"trials":3176,"activeCount":98},[],{"trials":3178,"activeCount":98},[],{"intervention":3156,"totalTrials":94,"cells":3180},{"EARLY_PHASE1":3181,"PHASE1":3183,"PHASE2":3185,"PHASE3":3187,"PHASE4":3193,"NA":3195},{"trials":3182,"activeCount":98},[],{"trials":3184,"activeCount":98},[],{"trials":3186,"activeCount":98},[],{"trials":3188,"activeCount":98},[3189],{"nctId":3148,"briefTitle":3149,"status":323,"phases":3190,"primaryCompletion":1603,"completion":1603,"start":3151,"enrollment":3152,"conditions":3191,"interventions":3192},[88],[143],[3137,3155,3156],{"trials":3194,"activeCount":98},[],{"trials":3196,"activeCount":98},[],{"intervention":3198,"totalTrials":94,"cells":3199},"Antidepressant Regimen",{"EARLY_PHASE1":3200,"PHASE1":3202,"PHASE2":3204,"PHASE3":3206,"PHASE4":3217,"NA":3219},{"trials":3201,"activeCount":98},[],{"trials":3203,"activeCount":98},[],{"trials":3205,"activeCount":98},[],{"trials":3207,"activeCount":98},[3208],{"nctId":3209,"briefTitle":3210,"status":323,"phases":3211,"primaryCompletion":567,"completion":3212,"start":3213,"enrollment":3214,"conditions":3215,"interventions":3216},"NCT00149838","Magnetic Brain Stimulation for the Treatment of Adult Depression",[87,88],"2009-05","2005-02",190,[18],[3198],{"trials":3218,"activeCount":98},[],{"trials":3220,"activeCount":98},[],{"intervention":3222,"totalTrials":94,"cells":3223},"Ivacaftor",{"EARLY_PHASE1":3224,"PHASE1":3226,"PHASE2":3228,"PHASE3":3230,"PHASE4":3241,"NA":3243},{"trials":3225,"activeCount":98},[],{"trials":3227,"activeCount":98},[],{"trials":3229,"activeCount":98},[],{"trials":3231,"activeCount":98},[3232],{"nctId":3233,"briefTitle":3234,"status":323,"phases":3235,"primaryCompletion":3236,"completion":3236,"start":3237,"enrollment":302,"conditions":3238,"interventions":3240},"NCT02934698","An Efficacy and Safety Study of Ivacaftor in Patients With Cystic Fibrosis and Two Splicing Mutations",[88],"2018-05","2016-11-01",[3239],"Cystic Fibrosis",[3222],{"trials":3242,"activeCount":98},[],{"trials":3244,"activeCount":98},[],{"intervention":1922,"totalTrials":94,"cells":3246},{"EARLY_PHASE1":3247,"PHASE1":3249,"PHASE2":3251,"PHASE3":3253,"PHASE4":3259,"NA":3261},{"trials":3248,"activeCount":98},[],{"trials":3250,"activeCount":98},[],{"trials":3252,"activeCount":98},[],{"trials":3254,"activeCount":98},[3255],{"nctId":1913,"briefTitle":1914,"status":323,"phases":3256,"primaryCompletion":1916,"completion":1917,"start":1918,"enrollment":1919,"conditions":3257,"interventions":3258},[88],[34],[1893,1922],{"trials":3260,"activeCount":98},[],{"trials":3262,"activeCount":98},[],{"intervention":3264,"totalTrials":94,"cells":3265},"Duloxetine",{"EARLY_PHASE1":3266,"PHASE1":3268,"PHASE2":3270,"PHASE3":3272,"PHASE4":3283,"NA":3285},{"trials":3267,"activeCount":98},[],{"trials":3269,"activeCount":98},[],{"trials":3271,"activeCount":98},[],{"trials":3273,"activeCount":98},[3274],{"nctId":3275,"briefTitle":3276,"status":323,"phases":3277,"primaryCompletion":3278,"completion":3278,"start":3279,"enrollment":32,"conditions":3280,"interventions":3282},"NCT00471315","Duloxetine in Patients With Suspected Functional Pancreatic\u002FBiliary Pain (Sphincter of Oddi Dysfunction)",[88],"2012-03","2006-07",[3281],"Sphincter of Oddi Dysfunction",[3264],{"trials":3284,"activeCount":98},[],{"trials":3286,"activeCount":98},[],{"intervention":3288,"totalTrials":94,"cells":3289},"ATM FOG in PD",{"EARLY_PHASE1":3290,"PHASE1":3292,"PHASE2":3294,"PHASE3":3296,"PHASE4":3307,"NA":3309},{"trials":3291,"activeCount":98},[],{"trials":3293,"activeCount":98},[],{"trials":3295,"activeCount":98},[],{"trials":3297,"activeCount":98},[3298],{"nctId":3299,"briefTitle":3300,"status":323,"phases":3301,"primaryCompletion":3302,"completion":3302,"start":3103,"enrollment":601,"conditions":3303,"interventions":3306},"NCT03651856","Atomoxetine for Freezing of Gait in Parkinson's Disease",[88],"2014-02",[3304,3305],"Parkinson's Disease","Freezing of Gait",[3288],{"trials":3308,"activeCount":98},[],{"trials":3310,"activeCount":98},[],{"intervention":3312,"totalTrials":94,"cells":3313},"Vitamin D3 4000 IU in gummy form",{"EARLY_PHASE1":3314,"PHASE1":3316,"PHASE2":3318,"PHASE3":3320,"PHASE4":3332,"NA":3334},{"trials":3315,"activeCount":98},[],{"trials":3317,"activeCount":98},[],{"trials":3319,"activeCount":98},[],{"trials":3321,"activeCount":98},[3322],{"nctId":3323,"briefTitle":3324,"status":323,"phases":3325,"primaryCompletion":3326,"completion":3327,"start":3103,"enrollment":3328,"conditions":3329,"interventions":3331},"NCT01932788","Preventing Health Disparities During Pregnancy Through Vitamin D Supplementation",[88],"2017-04-30","2018-04-30",342,[3330],"Vitamin D3 Deficiency",[3312],{"trials":3333,"activeCount":98},[],{"trials":3335,"activeCount":98},[],{"intervention":3337,"totalTrials":94,"cells":3338},"Mycophenolate",{"EARLY_PHASE1":3339,"PHASE1":3341,"PHASE2":3343,"PHASE3":3345,"PHASE4":3355,"NA":3357},{"trials":3340,"activeCount":98},[],{"trials":3342,"activeCount":98},[],{"trials":3344,"activeCount":98},[],{"trials":3346,"activeCount":98},[3347],{"nctId":3348,"briefTitle":3349,"status":597,"phases":3350,"primaryCompletion":3151,"completion":3151,"start":3351,"enrollment":22,"conditions":3352,"interventions":3354},"NCT00262132","Mycophenolate for Pulmonary Sarcoidosis",[88],"2003-09",[3353],"Pulmonary Sarcoidosis",[3337],{"trials":3356,"activeCount":98},[],{"trials":3358,"activeCount":98},[],{"intervention":3360,"totalTrials":94,"cells":3361},"Pergolide",{"EARLY_PHASE1":3362,"PHASE1":3364,"PHASE2":3366,"PHASE3":3368,"PHASE4":3377,"NA":3379},{"trials":3363,"activeCount":98},[],{"trials":3365,"activeCount":98},[],{"trials":3367,"activeCount":98},[],{"trials":3369,"activeCount":98},[3370],{"nctId":3371,"briefTitle":3372,"status":323,"phases":3373,"start":3374,"enrollment":98,"conditions":3375,"interventions":3376},"NCT00000248","Dose Response Trial of Pergolide for Cocaine Dependence - 1",[88],"1996-02",[2956],[3360],{"trials":3378,"activeCount":98},[],{"trials":3380,"activeCount":98},[],{"intervention":3382,"totalTrials":94,"cells":3383},"Flumazenil and Gabapentin",{"EARLY_PHASE1":3384,"PHASE1":3386,"PHASE2":3388,"PHASE3":3390,"PHASE4":3400,"NA":3402},{"trials":3385,"activeCount":98},[],{"trials":3387,"activeCount":98},[],{"trials":3389,"activeCount":98},[],{"trials":3391,"activeCount":98},[3392],{"nctId":3393,"briefTitle":3394,"status":323,"phases":3395,"primaryCompletion":1421,"completion":3396,"start":3397,"enrollment":1513,"conditions":3398,"interventions":3399},"NCT00262639","Prometa Protocol for Alcohol Dependence",[87,88],"2008-03","2005-12",[34],[3382],{"trials":3401,"activeCount":98},[],{"trials":3403,"activeCount":98},[],{"intervention":660,"totalTrials":1428,"cells":3405},{"EARLY_PHASE1":3406,"PHASE1":3408,"PHASE2":3410,"PHASE3":3439,"PHASE4":3441,"NA":3443},{"trials":3407,"activeCount":98},[],{"trials":3409,"activeCount":98},[],{"trials":3411,"activeCount":98},[3412,3420,3424,3432],{"nctId":3413,"briefTitle":3414,"status":597,"phases":3415,"primaryCompletion":2194,"completion":2194,"start":3416,"enrollment":1632,"conditions":3417,"interventions":3418},"NCT00089128","Gemcitabine and Irinotecan in Treating Patients With Locally Advanced or Metastatic Bladder Cancer",[87],"2001-11",[657],[660,3419],"irinotecan hydrochloride",{"nctId":651,"briefTitle":652,"status":597,"phases":3421,"primaryCompletion":654,"completion":654,"start":655,"enrollment":568,"conditions":3422,"interventions":3423},[87],[657],[630,659,660,661],{"nctId":3425,"briefTitle":3426,"status":323,"phases":3427,"primaryCompletion":791,"completion":791,"start":3428,"enrollment":32,"conditions":3429,"interventions":3430},"NCT00509665","Gemcitabine and Doxorubicin in Treating Patients With Recurrent or Progressive Head and Neck Cancer",[87],"2005-06",[734],[3431,660],"doxorubicin hydrochloride",{"nctId":3433,"briefTitle":3434,"status":597,"phases":3435,"primaryCompletion":1862,"completion":1862,"start":3351,"enrollment":1852,"conditions":3436,"interventions":3438},"NCT00089102","Gemcitabine and Irinotecan in Treating Patients With Locally Advanced Unresectable or Metastatic Kidney Cancer",[87],[3437],"Kidney Cancer",[660,3419],{"trials":3440,"activeCount":98},[],{"trials":3442,"activeCount":98},[],{"trials":3444,"activeCount":98},[],{"intervention":3419,"totalTrials":573,"cells":3446},{"EARLY_PHASE1":3447,"PHASE1":3449,"PHASE2":3451,"PHASE3":3471,"PHASE4":3473,"NA":3475},{"trials":3448,"activeCount":98},[],{"trials":3450,"activeCount":98},[],{"trials":3452,"activeCount":98},[3453,3463,3467],{"nctId":3454,"briefTitle":3455,"status":323,"phases":3456,"primaryCompletion":3457,"completion":3457,"start":3458,"enrollment":3459,"conditions":3460,"interventions":3462},"NCT00003344","Radiation Therapy Plus Irinotecan in Treating Patients With Colon Cancer",[86,87],"2000-01","1998-08",49,[3461],"Colorectal Cancer",[3419],{"nctId":3413,"briefTitle":3414,"status":597,"phases":3464,"primaryCompletion":2194,"completion":2194,"start":3416,"enrollment":1632,"conditions":3465,"interventions":3466},[87],[657],[660,3419],{"nctId":3433,"briefTitle":3434,"status":597,"phases":3468,"primaryCompletion":1862,"completion":1862,"start":3351,"enrollment":1852,"conditions":3469,"interventions":3470},[87],[3437],[660,3419],{"trials":3472,"activeCount":98},[],{"trials":3474,"activeCount":98},[],{"trials":3476,"activeCount":98},[],{"intervention":3478,"totalTrials":573,"cells":3479},"docetaxel",{"EARLY_PHASE1":3480,"PHASE1":3482,"PHASE2":3505,"PHASE3":3519,"PHASE4":3521,"NA":3523},{"trials":3481,"activeCount":98},[],{"trials":3483,"activeCount":98},[3484,3495],{"nctId":3485,"briefTitle":3486,"status":323,"phases":3487,"primaryCompletion":3488,"completion":3489,"start":3490,"enrollment":22,"conditions":3491,"interventions":3492},"NCT00099086","Docetaxel, Radiation Therapy, and Hormone Therapy in Treating Patients With Locally Advanced Prostate Cancer",[86],"2011-01-20","2023-12-13","2007-01-16",[31],[3493,3478,3494],"Bicalutamide","GnRh analog",{"nctId":3496,"briefTitle":3497,"status":597,"phases":3498,"primaryCompletion":3499,"completion":3500,"start":3501,"enrollment":9,"conditions":3502,"interventions":3503},"NCT00096304","Epirubicin and Docetaxel in Treating Patients With Metastatic Prostate Cancer",[86],"2006-09-06","2007-11-30","2004-06-08",[31],[3478,3504],"epirubicin hydrochloride",{"trials":3506,"activeCount":98},[3507],{"nctId":3508,"briefTitle":3509,"status":323,"phases":3510,"primaryCompletion":3511,"completion":3512,"start":3513,"enrollment":612,"conditions":3514,"interventions":3516},"NCT03069937","Phase II Study of Docetaxel Before Degarelix in Patients With Newly Diagnosed Metastatic Prostate Cancer.",[87],"2021-03-03","2024-12-11","2017-03-01",[3515],"Metastatic Prostatic Adenocarcinoma",[3517,3518],"Docetaxel","Degarelix",{"trials":3520,"activeCount":98},[],{"trials":3522,"activeCount":98},[],{"trials":3524,"activeCount":98},[],{"intervention":3526,"totalTrials":573,"cells":3527},"Nivolumab",{"EARLY_PHASE1":3528,"PHASE1":3530,"PHASE2":3532,"PHASE3":3563,"PHASE4":3565,"NA":3567},{"trials":3529,"activeCount":98},[],{"trials":3531,"activeCount":98},[],{"trials":3533,"activeCount":98},[3534,3543,3553],{"nctId":3535,"briefTitle":3536,"status":323,"phases":3537,"primaryCompletion":3538,"completion":3538,"start":3539,"enrollment":2253,"conditions":3540,"interventions":3542},"NCT03021993","Trial of Nivolumab as a Novel Neoadjuvant Pre-Surgical Therapy for Locally Advanced Oral Cavity Cancer",[87],"2021-11-15","2017-05-30",[3541],"Oral Cavity SCC",[3526],{"nctId":3544,"briefTitle":3545,"status":2079,"phases":3546,"primaryCompletion":3547,"completion":3547,"start":3547,"enrollment":98,"conditions":3548,"interventions":3551},"NCT03149159","Investigator-Initiated Trial of Combined Ipilimumab, Nivolumab and Stereotactic Radiation in Patients With Metastatic Clear-Cell RCC (ccRCC) Who Have Failed Treatment With Single-Agent Nivolumab",[87],"2018-04-01",[3549,3550],"Clear Cell Renal Cell Carcinoma","Metastatic Renal Cell Carcinoma",[3526,3552],"Ipilimumab",{"nctId":3554,"briefTitle":3555,"status":323,"phases":3556,"primaryCompletion":3557,"completion":3557,"start":3558,"enrollment":519,"conditions":3559,"interventions":3561},"NCT02523469","ALT-803 Plus Nivolumab in Patients With Pretreated, Advanced or Metastatic Non-Small Cell Lung Cancer",[86,87],"2023-02-24","2016-01-08",[3560],"Non-small Cell Lung Cancer",[3562,3526],"ALT-803",{"trials":3564,"activeCount":98},[],{"trials":3566,"activeCount":98},[],{"trials":3568,"activeCount":98},[],{"intervention":592,"totalTrials":302,"cells":3570},{"EARLY_PHASE1":3571,"PHASE1":3573,"PHASE2":3575,"PHASE3":3585,"PHASE4":3587,"NA":3589},{"trials":3572,"activeCount":98},[],{"trials":3574,"activeCount":98},[],{"trials":3576,"activeCount":98},[3577,3581],{"nctId":582,"briefTitle":583,"status":323,"phases":3578,"primaryCompletion":585,"completion":585,"start":586,"enrollment":587,"conditions":3579,"interventions":3580},[87],[589],[591,592,572,593],{"nctId":595,"briefTitle":596,"status":597,"phases":3582,"primaryCompletion":599,"completion":599,"start":600,"enrollment":601,"conditions":3583,"interventions":3584},[87],[603],[592,572],{"trials":3586,"activeCount":98},[],{"trials":3588,"activeCount":98},[],{"trials":3590,"activeCount":98},[],{"intervention":3592,"totalTrials":302,"cells":3593},"Atomoxetine",{"EARLY_PHASE1":3594,"PHASE1":3596,"PHASE2":3598,"PHASE3":3616,"PHASE4":3618,"NA":3620},{"trials":3595,"activeCount":98},[],{"trials":3597,"activeCount":98},[],{"trials":3599,"activeCount":98},[3600,3608],{"nctId":3601,"briefTitle":3602,"status":323,"phases":3603,"primaryCompletion":1820,"completion":1820,"start":3604,"enrollment":19,"conditions":3605,"interventions":3607},"NCT01738191","Atomoxetine Treatment for Cognitive Impairment in Parkinson's Disease (ATM-Cog)",[87],"2012-11",[3304,3606],"Cognitive Impairment",[3592],{"nctId":3609,"briefTitle":3610,"status":323,"phases":3611,"primaryCompletion":3612,"completion":3612,"start":2984,"enrollment":669,"conditions":3613,"interventions":3615},"NCT00360269","Atomoxetine Treatment for ADHD and Marijuana Dependence",[87],"2008-06",[2004,3614],"Attention Deficit Disorder With Hyperactivity",[3592],{"trials":3617,"activeCount":98},[],{"trials":3619,"activeCount":98},[],{"trials":3621,"activeCount":98},[],{"intervention":3623,"totalTrials":302,"cells":3624},"D-cycloserine",{"EARLY_PHASE1":3625,"PHASE1":3627,"PHASE2":3629,"PHASE3":3649,"PHASE4":3651,"NA":3653},{"trials":3626,"activeCount":98},[],{"trials":3628,"activeCount":98},[],{"trials":3630,"activeCount":98},[3631,3640],{"nctId":3632,"briefTitle":3633,"status":323,"phases":3634,"primaryCompletion":3635,"completion":3635,"start":3636,"enrollment":854,"conditions":3637,"interventions":3639},"NCT00780442","D-Cycloserine and Cue Exposure in Cocaine-Dependent Individuals",[87],"2008-07","2006-09",[3638],"Cocaine Use Disorders",[3623],{"nctId":3641,"briefTitle":3642,"status":323,"phases":3643,"primaryCompletion":1834,"completion":1834,"start":3644,"enrollment":3645,"conditions":3646,"interventions":3647},"NCT00759473","D-Cycloserine Facilitation of Cocaine - Cue Extinction",[87],"2008-09",79,[3638],[3648],"D-Cycloserine",{"trials":3650,"activeCount":98},[],{"trials":3652,"activeCount":98},[],{"trials":3654,"activeCount":98},[],{"intervention":3656,"totalTrials":302,"cells":3657},"Low Dose Mesenchymal Stem Cells",{"EARLY_PHASE1":3658,"PHASE1":3660,"PHASE2":3671,"PHASE3":3683,"PHASE4":3685,"NA":3687},{"trials":3659,"activeCount":98},[],{"trials":3661,"activeCount":98},[3662],{"nctId":3663,"briefTitle":3664,"status":323,"phases":3665,"primaryCompletion":3327,"completion":3666,"start":3667,"enrollment":1460,"conditions":3668,"interventions":3670},"NCT03171194","Pilot Trial of Mesenchymal Stem Cells for Systemic Lupus Erythematosus",[86],"2018-10-25","2017-04-27",[3669],"System; Lupus Erythematosus",[3656],{"trials":3672,"activeCount":98},[3673],{"nctId":3674,"briefTitle":3675,"status":323,"phases":3676,"primaryCompletion":3677,"completion":3678,"start":3679,"enrollment":2002,"conditions":3680,"interventions":3681},"NCT02633163","Phase 2 Trial of Mesenchymal Stem Cells in Systemic Lupus Erythematosus (MiSLE)",[87],"2025-08-05","2026-02-03","2018-11-18",[1823],[3656,3682],"High Dose Mesenchymal Stem Cells",{"trials":3684,"activeCount":98},[],{"trials":3686,"activeCount":98},[],{"trials":3688,"activeCount":98},[],{"intervention":3690,"totalTrials":302,"cells":3691},"Ketamine Hydrochloride",{"EARLY_PHASE1":3692,"PHASE1":3702,"PHASE2":3704,"PHASE3":3715,"PHASE4":3717,"NA":3719},{"trials":3693,"activeCount":98},[3694],{"nctId":3695,"briefTitle":3696,"status":323,"phases":3697,"primaryCompletion":3698,"completion":3698,"start":3699,"enrollment":1810,"conditions":3700,"interventions":3701},"NCT05796791","Ketamine and Motivational Enhancement Therapy for the Treatment of Tobacco Use Disorder",[85],"2024-06-30","2023-05-02",[1779,21,24],[3690],{"trials":3703,"activeCount":98},[],{"trials":3705,"activeCount":98},[3706],{"nctId":3707,"briefTitle":3708,"status":323,"phases":3709,"primaryCompletion":1405,"completion":1405,"start":3710,"enrollment":568,"conditions":3711,"interventions":3714},"NCT04177706","Ketamine for the Treatment of Opioid Use Disorder and Depression",[87],"2020-12-17",[18,3712,3713],"Opioid-use Disorder","Opioid Abuse",[3690],{"trials":3716,"activeCount":98},[],{"trials":3718,"activeCount":98},[],{"trials":3720,"activeCount":98},[],{"intervention":3722,"totalTrials":302,"cells":3723},"Varenicline 0.5 MG",{"EARLY_PHASE1":3724,"PHASE1":3735,"PHASE2":3737,"PHASE3":3751,"PHASE4":3753,"NA":3755},{"trials":3725,"activeCount":98},[3726],{"nctId":3727,"briefTitle":3728,"status":323,"phases":3729,"primaryCompletion":3730,"completion":3730,"start":3731,"enrollment":2124,"conditions":3732,"interventions":3734},"NCT03742154","Hollings Cancer Center Varenicline Sampling Study",[85],"2020-04-06","2018-12-03",[26,21,3733,710],"Smoking, Tobacco",[3722],{"trials":3736,"activeCount":98},[],{"trials":3738,"activeCount":98},[3739],{"nctId":3740,"briefTitle":3741,"status":323,"phases":3742,"primaryCompletion":3743,"completion":3743,"start":3744,"enrollment":3745,"conditions":3746,"interventions":3749},"NCT04525755","STARS (Smoking Treatment And Remote Sampling) Study",[86,87],"2025-04-05","2021-02-08",652,[26,21,3747,3748],"Tobacco Smoking","Cigarette Smoking",[3722,3750],"Nicotine Replacement Therapy",{"trials":3752,"activeCount":98},[],{"trials":3754,"activeCount":98},[],{"trials":3756,"activeCount":98},[],{"intervention":3758,"totalTrials":302,"cells":3759},"Propranolol",{"EARLY_PHASE1":3760,"PHASE1":3762,"PHASE2":3764,"PHASE3":3779,"PHASE4":3781,"NA":3783},{"trials":3761,"activeCount":98},[],{"trials":3763,"activeCount":98},[],{"trials":3765,"activeCount":98},[3766,3772],{"nctId":3767,"briefTitle":3768,"status":323,"phases":3769,"primaryCompletion":1604,"completion":1604,"start":1982,"enrollment":1657,"conditions":3770,"interventions":3771},"NCT00830362","Beta-blockade Effects on Memory for Cocaine Craving",[87],[1607],[3758],{"nctId":3773,"briefTitle":3774,"status":323,"phases":3775,"primaryCompletion":531,"completion":531,"start":1872,"enrollment":3776,"conditions":3777,"interventions":3778},"NCT01055171","Neuromodulation of Trauma Memories in PTSD & Alcohol Dependence",[87],44,[34,1060],[3758],{"trials":3780,"activeCount":98},[],{"trials":3782,"activeCount":98},[],{"trials":3784,"activeCount":98},[],{"intervention":3786,"totalTrials":302,"cells":3787},"Progesterone",{"EARLY_PHASE1":3788,"PHASE1":3798,"PHASE2":3800,"PHASE3":3810,"PHASE4":3812,"NA":3814},{"trials":3789,"activeCount":98},[3790],{"nctId":3791,"briefTitle":3792,"status":323,"phases":3793,"primaryCompletion":3794,"completion":3794,"start":3015,"enrollment":473,"conditions":3795,"interventions":3797},"NCT03430050","Progesterone for Cannabis Withdrawal",[85],"2018-04-04",[500,3796],"Cannabis Withdrawal",[3786],{"trials":3799,"activeCount":98},[],{"trials":3801,"activeCount":98},[3802],{"nctId":3803,"briefTitle":3804,"status":323,"phases":3805,"primaryCompletion":3806,"completion":3806,"start":3807,"enrollment":1106,"conditions":3808,"interventions":3809},"NCT03729869","Impact of Progesterone on Stress Reactivity and Cannabis Use",[87],"2022-11-09","2019-01-18",[545],[3786],{"trials":3811,"activeCount":98},[],{"trials":3813,"activeCount":98},[],{"trials":3815,"activeCount":98},[],{"intervention":3817,"totalTrials":302,"cells":3818},"Metformin",{"EARLY_PHASE1":3819,"PHASE1":3821,"PHASE2":3831,"PHASE3":3843,"PHASE4":3845,"NA":3847},{"trials":3820,"activeCount":98},[],{"trials":3822,"activeCount":98},[3823],{"nctId":3824,"briefTitle":3825,"status":2079,"phases":3826,"primaryCompletion":3827,"completion":3827,"start":3827,"enrollment":98,"conditions":3828,"interventions":3829},"NCT03465345","Study of Metformin Plus Oligomeric Procyanidin Complex for Pharmacologic Manipulation of AGE (Advanced Glycation Endproducts) Levels in Prostate Cancer Patients",[86],"2018-07-11",[31],[3817,3830],"Oligomeric Procyanidin Complex",{"trials":3832,"activeCount":98},[3833],{"nctId":3834,"briefTitle":3835,"status":597,"phases":3836,"primaryCompletion":3837,"completion":3838,"start":3839,"enrollment":3840,"conditions":3841,"interventions":3842},"NCT02946996","Study of Pharmacologic Manipulation of AGE (Advanced Glycation Endproducts) Levels in Prostate Cancer Patients Receiving Androgen Deprivation Therapy",[87],"2023-12-05","2024-08-19","2016-12-28",41,[31],[3817],{"trials":3844,"activeCount":98},[],{"trials":3846,"activeCount":98},[],{"trials":3848,"activeCount":98},[],{"intervention":3850,"totalTrials":302,"cells":3851},"Cannabidiol",{"EARLY_PHASE1":3852,"PHASE1":3854,"PHASE2":3856,"PHASE3":3874,"PHASE4":3876,"NA":3878},{"trials":3853,"activeCount":98},[],{"trials":3855,"activeCount":98},[],{"trials":3857,"activeCount":98},[3858,3866],{"nctId":3859,"briefTitle":3860,"status":2079,"phases":3861,"primaryCompletion":3862,"completion":3862,"start":3863,"enrollment":98,"conditions":3864,"interventions":3865},"NCT03904849","Cannabidiol for Alcohol Use Disorder",[86,87],"2020-04-30","2019-10-01",[28],[3850],{"nctId":3867,"briefTitle":3868,"status":323,"phases":3869,"primaryCompletion":3870,"completion":3870,"start":3871,"enrollment":9,"conditions":3872,"interventions":3873},"NCT05317546","Cannabidiol in Youth Alcohol Use Disorder",[87],"2024-06-25","2022-10-01",[28],[3850],{"trials":3875,"activeCount":98},[],{"trials":3877,"activeCount":98},[],{"trials":3879,"activeCount":98},[],{"intervention":591,"totalTrials":94,"cells":3881},{"EARLY_PHASE1":3882,"PHASE1":3884,"PHASE2":3886,"PHASE3":3892,"PHASE4":3894,"NA":3896},{"trials":3883,"activeCount":98},[],{"trials":3885,"activeCount":98},[],{"trials":3887,"activeCount":98},[3888],{"nctId":582,"briefTitle":583,"status":323,"phases":3889,"primaryCompletion":585,"completion":585,"start":586,"enrollment":587,"conditions":3890,"interventions":3891},[87],[589],[591,592,572,593],{"trials":3893,"activeCount":98},[],{"trials":3895,"activeCount":98},[],{"trials":3897,"activeCount":98},[],{"intervention":3899,"totalTrials":94,"cells":3900},"Prolastin-C",{"EARLY_PHASE1":3901,"PHASE1":3903,"PHASE2":3905,"PHASE3":3916,"PHASE4":3918,"NA":3920},{"trials":3902,"activeCount":98},[],{"trials":3904,"activeCount":98},[],{"trials":3906,"activeCount":98},[3907],{"nctId":3908,"briefTitle":3909,"status":323,"phases":3910,"primaryCompletion":3911,"completion":3912,"start":3913,"enrollment":792,"conditions":3914,"interventions":3915},"NCT02947087","Alpha-1 Antitrypsin (AAT) Enhances Islet Autograft Survival in Patients With Chronic Pancreatitis",[86,87],"2021-11-13","2022-11-13","2017-01-11",[1503],[3899],{"trials":3917,"activeCount":98},[],{"trials":3919,"activeCount":98},[],{"trials":3921,"activeCount":98},[],{"intervention":3923,"totalTrials":94,"cells":3924},"Propranolol, 40 mg",{"EARLY_PHASE1":3925,"PHASE1":3927,"PHASE2":3929,"PHASE3":3941,"PHASE4":3943,"NA":3945},{"trials":3926,"activeCount":98},[],{"trials":3928,"activeCount":98},[],{"trials":3930,"activeCount":98},[3931],{"nctId":3932,"briefTitle":3933,"status":323,"phases":3934,"primaryCompletion":3935,"completion":3935,"start":3936,"enrollment":557,"conditions":3937,"interventions":3939},"NCT01822587","Enhancing Disrupted Reconsolidation: Impact on Cocaine Craving",[87],"2018-11-05","2013-09",[3938],"Cocaine Addiction",[3923,3940],"Propranolol, 80 mg",{"trials":3942,"activeCount":98},[],{"trials":3944,"activeCount":98},[],{"trials":3946,"activeCount":98},[],{"intervention":3940,"totalTrials":94,"cells":3948},{"EARLY_PHASE1":3949,"PHASE1":3951,"PHASE2":3953,"PHASE3":3959,"PHASE4":3961,"NA":3963},{"trials":3950,"activeCount":98},[],{"trials":3952,"activeCount":98},[],{"trials":3954,"activeCount":98},[3955],{"nctId":3932,"briefTitle":3933,"status":323,"phases":3956,"primaryCompletion":3935,"completion":3935,"start":3936,"enrollment":557,"conditions":3957,"interventions":3958},[87],[3938],[3923,3940],{"trials":3960,"activeCount":98},[],{"trials":3962,"activeCount":98},[],{"trials":3964,"activeCount":98},[],{"intervention":3966,"totalTrials":94,"cells":3967},"Pregnenolone",{"EARLY_PHASE1":3968,"PHASE1":3970,"PHASE2":3972,"PHASE3":3981,"PHASE4":3983,"NA":3985},{"trials":3969,"activeCount":98},[],{"trials":3971,"activeCount":98},[],{"trials":3973,"activeCount":98},[3974],{"nctId":3975,"briefTitle":3976,"status":323,"phases":3977,"primaryCompletion":3978,"completion":3978,"start":1640,"enrollment":568,"conditions":3979,"interventions":3980},"NCT02439814","Pregnenolone and Marijuana Dependence",[87],"2016-04",[1634],[3966],{"trials":3982,"activeCount":98},[],{"trials":3984,"activeCount":98},[],{"trials":3986,"activeCount":98},[],{"intervention":3988,"totalTrials":94,"cells":3989},"BIBW 2992",{"EARLY_PHASE1":3990,"PHASE1":3992,"PHASE2":3994,"PHASE3":4003,"PHASE4":4005,"NA":4007},{"trials":3991,"activeCount":98},[],{"trials":3993,"activeCount":98},[],{"trials":3995,"activeCount":98},[3996],{"nctId":3997,"briefTitle":3998,"status":2079,"phases":3999,"primaryCompletion":531,"completion":531,"start":566,"enrollment":98,"conditions":4000,"interventions":4002},"NCT01480141","A Window of Opportunity Trial of Afatinib In Early Stage Non-Small Cell Lung Cancer (NSCLC)",[87],[4001],"Lung Cancer",[3988],{"trials":4004,"activeCount":98},[],{"trials":4006,"activeCount":98},[],{"trials":4008,"activeCount":98},[],{"intervention":4010,"totalTrials":94,"cells":4011},"Cabazitaxel plus bavituximab",{"EARLY_PHASE1":4012,"PHASE1":4014,"PHASE2":4016,"PHASE3":4025,"PHASE4":4027,"NA":4029},{"trials":4013,"activeCount":98},[],{"trials":4015,"activeCount":98},[],{"trials":4017,"activeCount":98},[4018],{"nctId":4019,"briefTitle":4020,"status":597,"phases":4021,"primaryCompletion":1642,"completion":1642,"start":1851,"enrollment":1428,"conditions":4022,"interventions":4024},"NCT01335204","Ph Ib\u002FIIa Study of Cabazitaxel Plus Bavituximab in Castration-resistant Prostate Cancer",[86,87],[31,4023],"Prostatic Neoplasms",[4010],{"trials":4026,"activeCount":98},[],{"trials":4028,"activeCount":98},[],{"trials":4030,"activeCount":98},[],{"intervention":3682,"totalTrials":94,"cells":4032},{"EARLY_PHASE1":4033,"PHASE1":4035,"PHASE2":4037,"PHASE3":4043,"PHASE4":4045,"NA":4047},{"trials":4034,"activeCount":98},[],{"trials":4036,"activeCount":98},[],{"trials":4038,"activeCount":98},[4039],{"nctId":3674,"briefTitle":3675,"status":323,"phases":4040,"primaryCompletion":3677,"completion":3678,"start":3679,"enrollment":2002,"conditions":4041,"interventions":4042},[87],[1823],[3656,3682],{"trials":4044,"activeCount":98},[],{"trials":4046,"activeCount":98},[],{"trials":4048,"activeCount":98},[],{"intervention":648,"totalTrials":94,"cells":4050},{"EARLY_PHASE1":4051,"PHASE1":4053,"PHASE2":4055,"PHASE3":4061,"PHASE4":4063,"NA":4065},{"trials":4052,"activeCount":98},[],{"trials":4054,"activeCount":98},[],{"trials":4056,"activeCount":98},[4057],{"nctId":639,"briefTitle":640,"status":323,"phases":4058,"primaryCompletion":642,"completion":643,"start":644,"enrollment":140,"conditions":4059,"interventions":4060},[87],[646],[630,648,649],{"trials":4062,"activeCount":98},[],{"trials":4064,"activeCount":98},[],{"trials":4066,"activeCount":98},[],{"intervention":649,"totalTrials":94,"cells":4068},{"EARLY_PHASE1":4069,"PHASE1":4071,"PHASE2":4073,"PHASE3":4079,"PHASE4":4081,"NA":4083},{"trials":4070,"activeCount":98},[],{"trials":4072,"activeCount":98},[],{"trials":4074,"activeCount":98},[4075],{"nctId":639,"briefTitle":640,"status":323,"phases":4076,"primaryCompletion":642,"completion":643,"start":644,"enrollment":140,"conditions":4077,"interventions":4078},[87],[646],[630,648,649],{"trials":4080,"activeCount":98},[],{"trials":4082,"activeCount":98},[],{"trials":4084,"activeCount":98},[],{"intervention":4086,"totalTrials":94,"cells":4087},"Opaganib",{"EARLY_PHASE1":4088,"PHASE1":4090,"PHASE2":4092,"PHASE3":4106,"PHASE4":4108,"NA":4110},{"trials":4089,"activeCount":98},[],{"trials":4091,"activeCount":98},[],{"trials":4093,"activeCount":98},[4094],{"nctId":4095,"briefTitle":4096,"status":323,"phases":4097,"primaryCompletion":4098,"completion":4099,"start":4100,"enrollment":4101,"conditions":4102,"interventions":4103},"NCT04207255","Addition of Opaganib to Androgen Antagonists in Patients With mCRPC",[87],"2023-08-31","2024-07-31","2020-03-27",69,[31],[4086,4104,4105,4086],"Abiraterone","Enzalutamide",{"trials":4107,"activeCount":98},[],{"trials":4109,"activeCount":98},[],{"trials":4111,"activeCount":98},[],{"intervention":4104,"totalTrials":94,"cells":4113},{"EARLY_PHASE1":4114,"PHASE1":4116,"PHASE2":4118,"PHASE3":4124,"PHASE4":4126,"NA":4128},{"trials":4115,"activeCount":98},[],{"trials":4117,"activeCount":98},[],{"trials":4119,"activeCount":98},[4120],{"nctId":4095,"briefTitle":4096,"status":323,"phases":4121,"primaryCompletion":4098,"completion":4099,"start":4100,"enrollment":4101,"conditions":4122,"interventions":4123},[87],[31],[4086,4104,4105,4086],{"trials":4125,"activeCount":98},[],{"trials":4127,"activeCount":98},[],{"trials":4129,"activeCount":98},[],{"intervention":4105,"totalTrials":94,"cells":4131},{"EARLY_PHASE1":4132,"PHASE1":4134,"PHASE2":4136,"PHASE3":4142,"PHASE4":4144,"NA":4146},{"trials":4133,"activeCount":98},[],{"trials":4135,"activeCount":98},[],{"trials":4137,"activeCount":98},[4138],{"nctId":4095,"briefTitle":4096,"status":323,"phases":4139,"primaryCompletion":4098,"completion":4099,"start":4100,"enrollment":4101,"conditions":4140,"interventions":4141},[87],[31],[4086,4104,4105,4086],{"trials":4143,"activeCount":98},[],{"trials":4145,"activeCount":98},[],{"trials":4147,"activeCount":98},[],{"intervention":4149,"totalTrials":94,"cells":4150},"aripiprazole (up to 15 mg\u002Fday) for 8 days",{"EARLY_PHASE1":4151,"PHASE1":4153,"PHASE2":4155,"PHASE3":4163,"PHASE4":4165,"NA":4167},{"trials":4152,"activeCount":98},[],{"trials":4154,"activeCount":98},[],{"trials":4156,"activeCount":98},[4157],{"nctId":4158,"briefTitle":4159,"status":323,"phases":4160,"completion":2624,"start":3428,"enrollment":19,"conditions":4161,"interventions":4162},"NCT00183235","Aripiprazole Effects on Alcohol Reactivity and Consumption",[87],[34],[4149],{"trials":4164,"activeCount":98},[],{"trials":4166,"activeCount":98},[],{"trials":4168,"activeCount":98},[],{"intervention":3750,"totalTrials":94,"cells":4170},{"EARLY_PHASE1":4171,"PHASE1":4173,"PHASE2":4175,"PHASE3":4181,"PHASE4":4183,"NA":4185},{"trials":4172,"activeCount":98},[],{"trials":4174,"activeCount":98},[],{"trials":4176,"activeCount":98},[4177],{"nctId":3740,"briefTitle":3741,"status":323,"phases":4178,"primaryCompletion":3743,"completion":3743,"start":3744,"enrollment":3745,"conditions":4179,"interventions":4180},[86,87],[26,21,3747,3748],[3722,3750],{"trials":4182,"activeCount":98},[],{"trials":4184,"activeCount":98},[],{"trials":4186,"activeCount":98},[],{"intervention":4188,"totalTrials":94,"cells":4189},"Velcade",{"EARLY_PHASE1":4190,"PHASE1":4192,"PHASE2":4194,"PHASE3":4206,"PHASE4":4208,"NA":4210},{"trials":4191,"activeCount":98},[],{"trials":4193,"activeCount":98},[],{"trials":4195,"activeCount":98},[4196],{"nctId":4197,"briefTitle":4198,"status":597,"phases":4199,"primaryCompletion":4200,"completion":1851,"start":4201,"enrollment":1397,"conditions":4202,"interventions":4203},"NCT00103376","Bortezomib With or Without Hormone Therapy in Treating Patients With Relapsed Prostate Cancer",[87],"2009-10","2004-10",[31],[4188,4204,4205],"LH-RH Agonist","Androgen Receptor Antagonists",{"trials":4207,"activeCount":98},[],{"trials":4209,"activeCount":98},[],{"trials":4211,"activeCount":98},[],{"intervention":4204,"totalTrials":94,"cells":4213},{"EARLY_PHASE1":4214,"PHASE1":4216,"PHASE2":4218,"PHASE3":4224,"PHASE4":4226,"NA":4228},{"trials":4215,"activeCount":98},[],{"trials":4217,"activeCount":98},[],{"trials":4219,"activeCount":98},[4220],{"nctId":4197,"briefTitle":4198,"status":597,"phases":4221,"primaryCompletion":4200,"completion":1851,"start":4201,"enrollment":1397,"conditions":4222,"interventions":4223},[87],[31],[4188,4204,4205],{"trials":4225,"activeCount":98},[],{"trials":4227,"activeCount":98},[],{"trials":4229,"activeCount":98},[],{"intervention":4205,"totalTrials":94,"cells":4231},{"EARLY_PHASE1":4232,"PHASE1":4234,"PHASE2":4236,"PHASE3":4242,"PHASE4":4244,"NA":4246},{"trials":4233,"activeCount":98},[],{"trials":4235,"activeCount":98},[],{"trials":4237,"activeCount":98},[4238],{"nctId":4197,"briefTitle":4198,"status":597,"phases":4239,"primaryCompletion":4200,"completion":1851,"start":4201,"enrollment":1397,"conditions":4240,"interventions":4241},[87],[31],[4188,4204,4205],{"trials":4243,"activeCount":98},[],{"trials":4245,"activeCount":98},[],{"trials":4247,"activeCount":98},[],{"intervention":3518,"totalTrials":94,"cells":4249},{"EARLY_PHASE1":4250,"PHASE1":4252,"PHASE2":4254,"PHASE3":4260,"PHASE4":4262,"NA":4264},{"trials":4251,"activeCount":98},[],{"trials":4253,"activeCount":98},[],{"trials":4255,"activeCount":98},[4256],{"nctId":3508,"briefTitle":3509,"status":323,"phases":4257,"primaryCompletion":3511,"completion":3512,"start":3513,"enrollment":612,"conditions":4258,"interventions":4259},[87],[3515],[3517,3518],{"trials":4261,"activeCount":98},[],{"trials":4263,"activeCount":98},[],{"trials":4265,"activeCount":98},[],{"intervention":4267,"totalTrials":94,"cells":4268},"levetiracetam",{"EARLY_PHASE1":4269,"PHASE1":4271,"PHASE2":4273,"PHASE3":4282,"PHASE4":4284,"NA":4286},{"trials":4270,"activeCount":98},[],{"trials":4272,"activeCount":98},[],{"trials":4274,"activeCount":98},[4275],{"nctId":4276,"briefTitle":4277,"status":2079,"phases":4278,"primaryCompletion":1421,"start":1421,"enrollment":98,"conditions":4279,"interventions":4281},"NCT00627133","Efficacy of Keppra in Acute Alcohol Related Seizure Control--A Pilot Study",[87],[4280],"Seizure, Alcohol Related",[4267],{"trials":4283,"activeCount":98},[],{"trials":4285,"activeCount":98},[],{"trials":4287,"activeCount":98},[],{"intervention":4289,"totalTrials":94,"cells":4290},"N-Acetylcysteine (NAC) Treatment",{"EARLY_PHASE1":4291,"PHASE1":4293,"PHASE2":4295,"PHASE3":4309,"PHASE4":4311,"NA":4313},{"trials":4292,"activeCount":98},[],{"trials":4294,"activeCount":98},[],{"trials":4296,"activeCount":98},[4297],{"nctId":4298,"briefTitle":4299,"status":323,"phases":4300,"primaryCompletion":4301,"completion":4302,"start":4303,"enrollment":4304,"conditions":4305,"interventions":4307},"NCT02966873","Clinical Trial for Alcohol Use Disorder and Post Traumatic Stress Disorder (PTSD)",[87],"2021-09-16","2022-09-19","2016-10-01",182,[4306,2938,2828],"Post Traumatic Stress Disorder (PTSD)",[4289,4308],"Inactive Placebo Oral",{"trials":4310,"activeCount":98},[],{"trials":4312,"activeCount":98},[],{"trials":4314,"activeCount":98},[],{"intervention":4308,"totalTrials":94,"cells":4316},{"EARLY_PHASE1":4317,"PHASE1":4319,"PHASE2":4321,"PHASE3":4327,"PHASE4":4329,"NA":4331},{"trials":4318,"activeCount":98},[],{"trials":4320,"activeCount":98},[],{"trials":4322,"activeCount":98},[4323],{"nctId":4298,"briefTitle":4299,"status":323,"phases":4324,"primaryCompletion":4301,"completion":4302,"start":4303,"enrollment":4304,"conditions":4325,"interventions":4326},[87],[4306,2938,2828],[4289,4308],{"trials":4328,"activeCount":98},[],{"trials":4330,"activeCount":98},[],{"trials":4332,"activeCount":98},[],{"intervention":4334,"totalTrials":94,"cells":4335},"Bupropion SR",{"EARLY_PHASE1":4336,"PHASE1":4338,"PHASE2":4340,"PHASE3":4351,"PHASE4":4353,"NA":4355},{"trials":4337,"activeCount":98},[],{"trials":4339,"activeCount":98},[],{"trials":4341,"activeCount":98},[4342],{"nctId":4343,"briefTitle":4344,"status":323,"phases":4345,"primaryCompletion":1862,"completion":1862,"start":4346,"enrollment":4347,"conditions":4348,"interventions":4350},"NCT00330187","Combined Pharmaco\u002FBehavior Therapy in Adolescent Smokers",[87],"2004-03",134,[24,4349],"Nicotine Use Disorder",[4334],{"trials":4352,"activeCount":98},[],{"trials":4354,"activeCount":98},[],{"trials":4356,"activeCount":98},[],{"intervention":4358,"totalTrials":94,"cells":4359},"GET73",{"EARLY_PHASE1":4360,"PHASE1":4362,"PHASE2":4364,"PHASE3":4374,"PHASE4":4376,"NA":4378},{"trials":4361,"activeCount":98},[],{"trials":4363,"activeCount":98},[],{"trials":4365,"activeCount":98},[4366],{"nctId":4367,"briefTitle":4368,"status":323,"phases":4369,"primaryCompletion":4370,"completion":4370,"start":4371,"enrollment":3645,"conditions":4372,"interventions":4373},"NCT04831684","Novel mGluR5 Modulator Effects on Alcohol Drinking and MRI Outcomes",[86,87],"2025-12-29","2021-09-15",[28],[4358],{"trials":4375,"activeCount":98},[],{"trials":4377,"activeCount":98},[],{"trials":4379,"activeCount":98},[],{"intervention":4381,"totalTrials":94,"cells":4382},"nicotine patch",{"EARLY_PHASE1":4383,"PHASE1":4385,"PHASE2":4387,"PHASE3":4395,"PHASE4":4397,"NA":4399},{"trials":4384,"activeCount":98},[],{"trials":4386,"activeCount":98},[],{"trials":4388,"activeCount":98},[4389],{"nctId":4390,"briefTitle":4391,"status":323,"phases":4392,"primaryCompletion":790,"completion":790,"start":644,"enrollment":1605,"conditions":4393,"interventions":4394},"NCT00960778","Gender Differences in Response to Nicotine Replacement Therapy and De-Nicotinized Cigarettes",[87],[24],[4381],{"trials":4396,"activeCount":98},[],{"trials":4398,"activeCount":98},[],{"trials":4400,"activeCount":98},[],{"intervention":4402,"totalTrials":94,"cells":4403},"Imatinib Mesylate 400Mg",{"EARLY_PHASE1":4404,"PHASE1":4406,"PHASE2":4408,"PHASE3":4419,"PHASE4":4421,"NA":4423},{"trials":4405,"activeCount":98},[],{"trials":4407,"activeCount":98},[],{"trials":4409,"activeCount":98},[4410],{"nctId":4411,"briefTitle":4412,"status":323,"phases":4413,"primaryCompletion":4414,"completion":4414,"start":4415,"enrollment":32,"conditions":4416,"interventions":4418},"NCT03131999","LAM Pilot Study With Imatinib Mesylate",[86,87],"2019-03-07","2018-01-23",[4417],"Lymphangioleiomyomatosis",[4402],{"trials":4420,"activeCount":98},[],{"trials":4422,"activeCount":98},[],{"trials":4424,"activeCount":98},[],{"intervention":4426,"totalTrials":94,"cells":4427},"naltrexone (up to 50 mg\u002Fday) for 8 days; ondansetron (0.25 mg twice a day) for 8 days",{"EARLY_PHASE1":4428,"PHASE1":4430,"PHASE2":4432,"PHASE3":4440,"PHASE4":4442,"NA":4444},{"trials":4429,"activeCount":98},[],{"trials":4431,"activeCount":98},[],{"trials":4433,"activeCount":98},[4434],{"nctId":4435,"briefTitle":4436,"status":323,"phases":4437,"completion":3397,"start":2229,"enrollment":1939,"conditions":4438,"interventions":4439},"NCT00183222","Effectiveness of Naltrexone and\u002For Ondansetron to Reduce Craving for Alcohol and Drinking",[87],[34],[4426],{"trials":4441,"activeCount":98},[],{"trials":4443,"activeCount":98},[],{"trials":4445,"activeCount":98},[],{"intervention":4447,"totalTrials":94,"cells":4448},"Ketamine-assisted psychotherapy",{"EARLY_PHASE1":4449,"PHASE1":4451,"PHASE2":4453,"PHASE3":4466,"PHASE4":4468,"NA":4470},{"trials":4450,"activeCount":98},[],{"trials":4452,"activeCount":98},[],{"trials":4454,"activeCount":98},[4455],{"nctId":4456,"briefTitle":4457,"status":597,"phases":4458,"primaryCompletion":4459,"completion":4459,"start":4460,"enrollment":1360,"conditions":4461,"interventions":4465},"NCT05193318","KAP for Depression in Abstinent Opioid Users",[87],"2023-03-20","2022-01-13",[4462,4463,4464],"Opioid Use Disorder, Severe, in Sustained Remission","Opioid Use Disorder, Severe, in Early Remission","Major Depressive Disorder",[4447],{"trials":4467,"activeCount":98},[],{"trials":4469,"activeCount":98},[],{"trials":4471,"activeCount":98},[],{"intervention":4473,"totalTrials":94,"cells":4474},"Dose Response Curve Placebo",{"EARLY_PHASE1":4475,"PHASE1":4477,"PHASE2":4479,"PHASE3":4495,"PHASE4":4497,"NA":4499},{"trials":4476,"activeCount":98},[],{"trials":4478,"activeCount":98},[],{"trials":4480,"activeCount":98},[4481],{"nctId":4482,"briefTitle":4483,"status":323,"phases":4484,"primaryCompletion":4485,"completion":4486,"start":4487,"enrollment":1657,"conditions":4488,"interventions":4490},"NCT04562597","A Pilot Trial to Determine the Effective N-acetylcysteine Dose for Opioid Reduction for Spine Surgery.",[86,87],"2022-05-20","2022-05-21","2021-01-20",[4489],"Surgery",[4473,4491,4492,4493,4494],"Dose Response Curve N-acetylcysteine 50 mg\u002Fkg","Dose Response Curve N-acetylcysteine 100 mg\u002Fkg","Dose Response Curve N-acetylcysteine 150 mg\u002Fkg","Opioid Reduction with Optimal N-acetylcysteine Dose",{"trials":4496,"activeCount":98},[],{"trials":4498,"activeCount":98},[],{"trials":4500,"activeCount":98},[],{"intervention":4491,"totalTrials":94,"cells":4502},{"EARLY_PHASE1":4503,"PHASE1":4505,"PHASE2":4507,"PHASE3":4513,"PHASE4":4515,"NA":4517},{"trials":4504,"activeCount":98},[],{"trials":4506,"activeCount":98},[],{"trials":4508,"activeCount":98},[4509],{"nctId":4482,"briefTitle":4483,"status":323,"phases":4510,"primaryCompletion":4485,"completion":4486,"start":4487,"enrollment":1657,"conditions":4511,"interventions":4512},[86,87],[4489],[4473,4491,4492,4493,4494],{"trials":4514,"activeCount":98},[],{"trials":4516,"activeCount":98},[],{"trials":4518,"activeCount":98},[],{"intervention":4492,"totalTrials":94,"cells":4520},{"EARLY_PHASE1":4521,"PHASE1":4523,"PHASE2":4525,"PHASE3":4531,"PHASE4":4533,"NA":4535},{"trials":4522,"activeCount":98},[],{"trials":4524,"activeCount":98},[],{"trials":4526,"activeCount":98},[4527],{"nctId":4482,"briefTitle":4483,"status":323,"phases":4528,"primaryCompletion":4485,"completion":4486,"start":4487,"enrollment":1657,"conditions":4529,"interventions":4530},[86,87],[4489],[4473,4491,4492,4493,4494],{"trials":4532,"activeCount":98},[],{"trials":4534,"activeCount":98},[],{"trials":4536,"activeCount":98},[],{"intervention":4493,"totalTrials":94,"cells":4538},{"EARLY_PHASE1":4539,"PHASE1":4541,"PHASE2":4543,"PHASE3":4549,"PHASE4":4551,"NA":4553},{"trials":4540,"activeCount":98},[],{"trials":4542,"activeCount":98},[],{"trials":4544,"activeCount":98},[4545],{"nctId":4482,"briefTitle":4483,"status":323,"phases":4546,"primaryCompletion":4485,"completion":4486,"start":4487,"enrollment":1657,"conditions":4547,"interventions":4548},[86,87],[4489],[4473,4491,4492,4493,4494],{"trials":4550,"activeCount":98},[],{"trials":4552,"activeCount":98},[],{"trials":4554,"activeCount":98},[],{"intervention":4494,"totalTrials":94,"cells":4556},{"EARLY_PHASE1":4557,"PHASE1":4559,"PHASE2":4561,"PHASE3":4567,"PHASE4":4569,"NA":4571},{"trials":4558,"activeCount":98},[],{"trials":4560,"activeCount":98},[],{"trials":4562,"activeCount":98},[4563],{"nctId":4482,"briefTitle":4483,"status":323,"phases":4564,"primaryCompletion":4485,"completion":4486,"start":4487,"enrollment":1657,"conditions":4565,"interventions":4566},[86,87],[4489],[4473,4491,4492,4493,4494],{"trials":4568,"activeCount":98},[],{"trials":4570,"activeCount":98},[],{"trials":4572,"activeCount":98},[],{"intervention":1973,"totalTrials":94,"cells":4574},{"EARLY_PHASE1":4575,"PHASE1":4577,"PHASE2":4579,"PHASE3":4585,"PHASE4":4587,"NA":4589},{"trials":4576,"activeCount":98},[],{"trials":4578,"activeCount":98},[],{"trials":4580,"activeCount":98},[4581],{"nctId":1965,"briefTitle":1966,"status":323,"phases":4582,"primaryCompletion":1630,"completion":1630,"start":1968,"enrollment":1969,"conditions":4583,"interventions":4584},[87],[1971],[1973,1947],{"trials":4586,"activeCount":98},[],{"trials":4588,"activeCount":98},[],{"trials":4590,"activeCount":98},[],{"intervention":4592,"totalTrials":94,"cells":4593},"Gemcitabine and Pazopanib",{"EARLY_PHASE1":4594,"PHASE1":4596,"PHASE2":4598,"PHASE3":4610,"PHASE4":4612,"NA":4614},{"trials":4595,"activeCount":98},[],{"trials":4597,"activeCount":98},[],{"trials":4599,"activeCount":98},[4600],{"nctId":4601,"briefTitle":4602,"status":323,"phases":4603,"primaryCompletion":4604,"completion":4604,"start":4605,"enrollment":2053,"conditions":4606,"interventions":4608},"NCT01593748","A Phase II Trial Comparing Gemcitabine and Pazopanib Versus Gemcitabine and Docetaxel for Patients With Advanced Soft Tissue Sarcoma",[87],"2019-04-24","2012-09-27",[4607],"Sarcoma",[4592,4609],"Gemcitabine and Docetaxel",{"trials":4611,"activeCount":98},[],{"trials":4613,"activeCount":98},[],{"trials":4615,"activeCount":98},[],{"intervention":4609,"totalTrials":94,"cells":4617},{"EARLY_PHASE1":4618,"PHASE1":4620,"PHASE2":4622,"PHASE3":4628,"PHASE4":4630,"NA":4632},{"trials":4619,"activeCount":98},[],{"trials":4621,"activeCount":98},[],{"trials":4623,"activeCount":98},[4624],{"nctId":4601,"briefTitle":4602,"status":323,"phases":4625,"primaryCompletion":4604,"completion":4604,"start":4605,"enrollment":2053,"conditions":4626,"interventions":4627},[87],[4607],[4592,4609],{"trials":4629,"activeCount":98},[],{"trials":4631,"activeCount":98},[],{"trials":4633,"activeCount":98},[],{"intervention":4635,"totalTrials":94,"cells":4636},"Tolcapone",{"EARLY_PHASE1":4637,"PHASE1":4639,"PHASE2":4641,"PHASE3":4651,"PHASE4":4653,"NA":4655},{"trials":4638,"activeCount":98},[],{"trials":4640,"activeCount":98},[],{"trials":4642,"activeCount":98},[4643],{"nctId":4644,"briefTitle":4645,"status":323,"phases":4646,"primaryCompletion":4647,"completion":4647,"start":4648,"enrollment":2053,"conditions":4649,"interventions":4650},"NCT02949934","Effects of Cortical Dopamine Regulation on Drinking, Craving, and Cognitive Control",[87],"2021-04-13","2016-05-01",[28],[4635],{"trials":4652,"activeCount":98},[],{"trials":4654,"activeCount":98},[],{"trials":4656,"activeCount":98},[],{"intervention":4658,"totalTrials":94,"cells":4659},"ITV DepoCyt + Temozolomide",{"EARLY_PHASE1":4660,"PHASE1":4662,"PHASE2":4664,"PHASE3":4677,"PHASE4":4679,"NA":4681},{"trials":4661,"activeCount":98},[],{"trials":4663,"activeCount":98},[],{"trials":4665,"activeCount":98},[4666],{"nctId":4667,"briefTitle":4668,"status":597,"phases":4669,"primaryCompletion":4670,"completion":2434,"start":2023,"enrollment":3069,"conditions":4671,"interventions":4676},"NCT01044966","A Study of Intraventricular Liposomal Encapsulated Ara-C (DepoCyt) in Patients With Recurrent Glioblastoma",[86,87],"2013-08",[4672,4673,4674,4675],"Glioblastoma Multiforme","Glioma","Astrocytoma","Brain Tumor",[4658],{"trials":4678,"activeCount":98},[],{"trials":4680,"activeCount":98},[],{"trials":4682,"activeCount":98},[],{"intervention":4684,"totalTrials":94,"cells":4685},"PEG-interferon alfa-2b",{"EARLY_PHASE1":4686,"PHASE1":4688,"PHASE2":4690,"PHASE3":4702,"PHASE4":4704,"NA":4706},{"trials":4687,"activeCount":98},[],{"trials":4689,"activeCount":98},[],{"trials":4691,"activeCount":98},[4692],{"nctId":4693,"briefTitle":4694,"status":597,"phases":4695,"primaryCompletion":4696,"completion":4696,"start":4697,"enrollment":601,"conditions":4698,"interventions":4699},"NCT00090870","PEG-Interferon Alfa-2b, Sargramostim, and Thalidomide in Treating Patients With Metastatic Kidney Cancer",[87],"2010-03","2002-04",[3437],[4684,4700,4701],"GM-CSF","thalidomide",{"trials":4703,"activeCount":98},[],{"trials":4705,"activeCount":98},[],{"trials":4707,"activeCount":98},[],{"intervention":4700,"totalTrials":94,"cells":4709},{"EARLY_PHASE1":4710,"PHASE1":4712,"PHASE2":4714,"PHASE3":4720,"PHASE4":4722,"NA":4724},{"trials":4711,"activeCount":98},[],{"trials":4713,"activeCount":98},[],{"trials":4715,"activeCount":98},[4716],{"nctId":4693,"briefTitle":4694,"status":597,"phases":4717,"primaryCompletion":4696,"completion":4696,"start":4697,"enrollment":601,"conditions":4718,"interventions":4719},[87],[3437],[4684,4700,4701],{"trials":4721,"activeCount":98},[],{"trials":4723,"activeCount":98},[],{"trials":4725,"activeCount":98},[],{"intervention":4701,"totalTrials":94,"cells":4727},{"EARLY_PHASE1":4728,"PHASE1":4730,"PHASE2":4732,"PHASE3":4738,"PHASE4":4740,"NA":4742},{"trials":4729,"activeCount":98},[],{"trials":4731,"activeCount":98},[],{"trials":4733,"activeCount":98},[4734],{"nctId":4693,"briefTitle":4694,"status":597,"phases":4735,"primaryCompletion":4696,"completion":4696,"start":4697,"enrollment":601,"conditions":4736,"interventions":4737},[87],[3437],[4684,4700,4701],{"trials":4739,"activeCount":98},[],{"trials":4741,"activeCount":98},[],{"trials":4743,"activeCount":98},[],{"intervention":4745,"totalTrials":94,"cells":4746},"PROSTVAC-V\u002FF",{"EARLY_PHASE1":4747,"PHASE1":4749,"PHASE2":4751,"PHASE3":4761,"PHASE4":4763,"NA":4765},{"trials":4748,"activeCount":98},[],{"trials":4750,"activeCount":98},[],{"trials":4752,"activeCount":98},[4753],{"nctId":4754,"briefTitle":4755,"status":597,"phases":4756,"primaryCompletion":4757,"completion":4757,"start":4758,"enrollment":1605,"conditions":4759,"interventions":4760},"NCT02772562","Adjuvant PROSTVAC-V\u002FF in Subjects at High Risk for Relapse After Radical Prostatectomy",[87],"2024-04-29","2016-07-18",[4023],[4745],{"trials":4762,"activeCount":98},[],{"trials":4764,"activeCount":98},[],{"trials":4766,"activeCount":98},[],{"intervention":2998,"totalTrials":94,"cells":4768},{"EARLY_PHASE1":4769,"PHASE1":4771,"PHASE2":4773,"PHASE3":4779,"PHASE4":4781,"NA":4783},{"trials":4770,"activeCount":98},[],{"trials":4772,"activeCount":98},[],{"trials":4774,"activeCount":98},[4775],{"nctId":2989,"briefTitle":2990,"status":323,"phases":4776,"primaryCompletion":2992,"completion":1820,"start":599,"enrollment":2993,"conditions":4777,"interventions":4778},[86,87],[2995,2996],[2924,2998],{"trials":4780,"activeCount":98},[],{"trials":4782,"activeCount":98},[],{"trials":4784,"activeCount":98},[],{"intervention":4786,"totalTrials":94,"cells":4787},"Ofatumumab",{"EARLY_PHASE1":4788,"PHASE1":4790,"PHASE2":4792,"PHASE3":4803,"PHASE4":4805,"NA":4807},{"trials":4789,"activeCount":98},[],{"trials":4791,"activeCount":98},[],{"trials":4793,"activeCount":98},[4794],{"nctId":4795,"briefTitle":4796,"status":323,"phases":4797,"primaryCompletion":4798,"completion":4799,"start":2983,"enrollment":568,"conditions":4800,"interventions":4801},"NCT01123356","Treatment of Chronic Lymphocytic Leukemia in Patients Previously Exposed to Rituximab",[87],"2013-05","2013-06",[857],[4786,4802],"Lenalidomide",{"trials":4804,"activeCount":98},[],{"trials":4806,"activeCount":98},[],{"trials":4808,"activeCount":98},[],{"intervention":4802,"totalTrials":94,"cells":4810},{"EARLY_PHASE1":4811,"PHASE1":4813,"PHASE2":4815,"PHASE3":4821,"PHASE4":4823,"NA":4825},{"trials":4812,"activeCount":98},[],{"trials":4814,"activeCount":98},[],{"trials":4816,"activeCount":98},[4817],{"nctId":4795,"briefTitle":4796,"status":323,"phases":4818,"primaryCompletion":4798,"completion":4799,"start":2983,"enrollment":568,"conditions":4819,"interventions":4820},[87],[857],[4786,4802],{"trials":4822,"activeCount":98},[],{"trials":4824,"activeCount":98},[],{"trials":4826,"activeCount":98},[],{"intervention":4828,"totalTrials":94,"cells":4829},"Lexiscan",{"EARLY_PHASE1":4830,"PHASE1":4832,"PHASE2":4834,"PHASE3":4846,"PHASE4":4848,"NA":4850},{"trials":4831,"activeCount":98},[],{"trials":4833,"activeCount":98},[],{"trials":4835,"activeCount":98},[4836],{"nctId":4837,"briefTitle":4838,"status":323,"phases":4839,"primaryCompletion":4840,"completion":4840,"start":4841,"enrollment":697,"conditions":4842,"interventions":4845},"NCT03103061","Use of Lexiscan for Myocardial Stress Perfusion Computed Tomography With a 3rd Generation Dual Source CT System",[87],"2018-06-14","2016-02-09",[4843,4844],"Cardiovascular Diseases","Coronary Artery Disease",[4828],{"trials":4847,"activeCount":98},[],{"trials":4849,"activeCount":98},[],{"trials":4851,"activeCount":98},[],{"intervention":4853,"totalTrials":94,"cells":4854},"Yohimbine",{"EARLY_PHASE1":4855,"PHASE1":4857,"PHASE2":4859,"PHASE3":4867,"PHASE4":4869,"NA":4871},{"trials":4856,"activeCount":98},[],{"trials":4858,"activeCount":98},[],{"trials":4860,"activeCount":98},[4861],{"nctId":4862,"briefTitle":4863,"status":323,"phases":4864,"primaryCompletion":531,"completion":531,"start":2623,"enrollment":1622,"conditions":4865,"interventions":4866},"NCT00535002","The Effect of Yohimbine on Cocaine Cue Reactivity",[87],[1971],[4853],{"trials":4868,"activeCount":98},[],{"trials":4870,"activeCount":98},[],{"trials":4872,"activeCount":98},[],{"intervention":4874,"totalTrials":94,"cells":4875},"ABC294640",{"EARLY_PHASE1":4876,"PHASE1":4878,"PHASE2":4880,"PHASE3":4891,"PHASE4":4893,"NA":4895},{"trials":4877,"activeCount":98},[],{"trials":4879,"activeCount":98},[],{"trials":4881,"activeCount":98},[4882],{"nctId":4883,"briefTitle":4884,"status":2079,"phases":4885,"primaryCompletion":4886,"completion":2556,"start":4887,"enrollment":98,"conditions":4888,"interventions":4890},"NCT02939807","A Phase II Study of ABC294640 as Monotherapy in Patients With Advanced Hepatocellular Carcinoma",[87],"2023-09-30","2019-09-30",[4889],"Carcinoma, Hepatocellular",[4874],{"trials":4892,"activeCount":98},[],{"trials":4894,"activeCount":98},[],{"trials":4896,"activeCount":98},[],{"intervention":4898,"totalTrials":94,"cells":4899},"Chitosan",{"EARLY_PHASE1":4900,"PHASE1":4902,"PHASE2":4904,"PHASE3":4915,"PHASE4":4917,"NA":4919},{"trials":4901,"activeCount":98},[],{"trials":4903,"activeCount":98},[],{"trials":4905,"activeCount":98},[4906],{"nctId":4907,"briefTitle":4908,"status":597,"phases":4909,"primaryCompletion":4910,"completion":4911,"start":4912,"enrollment":3069,"conditions":4913,"interventions":4914},"NCT03712371","Study of Chitosan for Pharmacologic Manipulation of AGE Levels in Prostate Cancer Patients",[86,87],"2020-07-02","2021-09-07","2019-01-16",[31],[4898],{"trials":4916,"activeCount":98},[],{"trials":4918,"activeCount":98},[],{"trials":4920,"activeCount":98},[],{"intervention":3431,"totalTrials":94,"cells":4922},{"EARLY_PHASE1":4923,"PHASE1":4925,"PHASE2":4927,"PHASE3":4933,"PHASE4":4935,"NA":4937},{"trials":4924,"activeCount":98},[],{"trials":4926,"activeCount":98},[],{"trials":4928,"activeCount":98},[4929],{"nctId":3425,"briefTitle":3426,"status":323,"phases":4930,"primaryCompletion":791,"completion":791,"start":3428,"enrollment":32,"conditions":4931,"interventions":4932},[87],[734],[3431,660],{"trials":4934,"activeCount":98},[],{"trials":4936,"activeCount":98},[],{"trials":4938,"activeCount":98},[],{"intervention":1909,"totalTrials":94,"cells":4940},{"EARLY_PHASE1":4941,"PHASE1":4943,"PHASE2":4945,"PHASE3":4951,"PHASE4":4953,"NA":4955},{"trials":4942,"activeCount":98},[],{"trials":4944,"activeCount":98},[],{"trials":4946,"activeCount":98},[4947],{"nctId":1902,"briefTitle":1903,"status":323,"phases":4948,"primaryCompletion":791,"completion":791,"start":1905,"enrollment":1906,"conditions":4949,"interventions":4950},[87],[34],[1893,1909],{"trials":4952,"activeCount":98},[],{"trials":4954,"activeCount":98},[],{"trials":4956,"activeCount":98},[],{"intervention":4958,"totalTrials":94,"cells":4959},"Unframed messaging materials",{"EARLY_PHASE1":4960,"PHASE1":4962,"PHASE2":4964,"PHASE3":4977,"PHASE4":4979,"NA":4981},{"trials":4961,"activeCount":98},[],{"trials":4963,"activeCount":98},[],{"trials":4965,"activeCount":98},[4966],{"nctId":4967,"briefTitle":4968,"status":323,"phases":4969,"primaryCompletion":4970,"completion":4971,"start":4972,"enrollment":4973,"conditions":4974,"interventions":4976},"NCT03069924","Gain-framed Messages and NRT for Lung Cancer Screening Patients",[87],"2023-11-10","2024-08-10","2017-07-01",367,[4975,21],"Lung Cancer Screening",[4958],{"trials":4978,"activeCount":98},[],{"trials":4980,"activeCount":98},[],{"trials":4982,"activeCount":98},[],{"intervention":4984,"totalTrials":94,"cells":4985},"Ketamine",{"EARLY_PHASE1":4986,"PHASE1":4988,"PHASE2":4990,"PHASE3":4999,"PHASE4":5001,"NA":5003},{"trials":4987,"activeCount":98},[],{"trials":4989,"activeCount":98},[],{"trials":4991,"activeCount":98},[4992],{"nctId":4993,"briefTitle":4994,"status":597,"phases":4995,"primaryCompletion":4996,"completion":4996,"start":3103,"enrollment":1810,"conditions":4997,"interventions":4998},"NCT01755169","Ketamine in Chronic Kid's (KiCK) Pain",[87],"2015-05",[1266],[4984],{"trials":5000,"activeCount":98},[],{"trials":5002,"activeCount":98},[],{"trials":5004,"activeCount":98},[],{"intervention":5006,"totalTrials":94,"cells":5007},"Regular Nicotine patch and lozenge dose",{"EARLY_PHASE1":5008,"PHASE1":5010,"PHASE2":5012,"PHASE3":5023,"PHASE4":5025,"NA":5027},{"trials":5009,"activeCount":98},[],{"trials":5011,"activeCount":98},[],{"trials":5013,"activeCount":98},[5014],{"nctId":5015,"briefTitle":5016,"status":323,"phases":5017,"primaryCompletion":5018,"completion":5018,"start":3837,"enrollment":2993,"conditions":5019,"interventions":5021},"NCT06087328","CAN-DOSE Study: Cessation With Augmented Nicotine for Dual Use Of Smoking and E-cigarettes",[87],"2024-11-05",[21,5020,3748],"Electronic Cigarette Use",[5006,5022],"Augmented Nicotine patch and lozenge dose",{"trials":5024,"activeCount":98},[],{"trials":5026,"activeCount":98},[],{"trials":5028,"activeCount":98},[],{"intervention":5022,"totalTrials":94,"cells":5030},{"EARLY_PHASE1":5031,"PHASE1":5033,"PHASE2":5035,"PHASE3":5041,"PHASE4":5043,"NA":5045},{"trials":5032,"activeCount":98},[],{"trials":5034,"activeCount":98},[],{"trials":5036,"activeCount":98},[5037],{"nctId":5015,"briefTitle":5016,"status":323,"phases":5038,"primaryCompletion":5018,"completion":5018,"start":3837,"enrollment":2993,"conditions":5039,"interventions":5040},[87],[21,5020,3748],[5006,5022],{"trials":5042,"activeCount":98},[],{"trials":5044,"activeCount":98},[],{"trials":5046,"activeCount":98},[],{"intervention":5048,"totalTrials":94,"cells":5049},"Neem Mouthrinse",{"EARLY_PHASE1":5050,"PHASE1":5052,"PHASE2":5054,"PHASE3":5065,"PHASE4":5067,"NA":5069},{"trials":5051,"activeCount":98},[],{"trials":5053,"activeCount":98},[],{"trials":5055,"activeCount":98},[5056],{"nctId":5057,"briefTitle":5058,"status":323,"phases":5059,"primaryCompletion":5060,"completion":1640,"start":5061,"enrollment":1657,"conditions":5062,"interventions":5064},"NCT01898091","Herbal Mouthrinse for Oral Mucositis Study",[87],"2015-04","2013-07",[5063],"Oral Mucositis",[5048],{"trials":5066,"activeCount":98},[],{"trials":5068,"activeCount":98},[],{"trials":5070,"activeCount":98},[],{"intervention":5072,"totalTrials":94,"cells":5073},"Sotorasib and Tarloxotinib",{"EARLY_PHASE1":5074,"PHASE1":5076,"PHASE2":5078,"PHASE3":5089,"PHASE4":5091,"NA":5093},{"trials":5075,"activeCount":98},[],{"trials":5077,"activeCount":98},[],{"trials":5079,"activeCount":98},[5080],{"nctId":5081,"briefTitle":5082,"status":597,"phases":5083,"primaryCompletion":5084,"completion":138,"start":5085,"enrollment":1360,"conditions":5086,"interventions":5088},"NCT05313009","Tarlox and Sotorasib in Patients With KRAS G12C Mutations",[86,87],"2023-07-07","2022-03-07",[5087],"Non-Small Cell Lung Cancer",[5072,5072],{"trials":5090,"activeCount":98},[],{"trials":5092,"activeCount":98},[],{"trials":5094,"activeCount":98},[],{"intervention":5096,"totalTrials":94,"cells":5097},"Alginates",{"EARLY_PHASE1":5098,"PHASE1":5100,"PHASE2":5102,"PHASE3":5113,"PHASE4":5115,"NA":5117},{"trials":5099,"activeCount":98},[],{"trials":5101,"activeCount":98},[],{"trials":5103,"activeCount":98},[5104],{"nctId":5105,"briefTitle":5106,"status":323,"phases":5107,"primaryCompletion":5108,"completion":5108,"start":5109,"enrollment":697,"conditions":5110,"interventions":5112},"NCT03193216","The Impact of Adjuvant Liquid Alginate on Endoscopic Ablation Therapy of Complicated Barrett's Esophagus",[87],"2022-01-01","2017-08-25",[5111],"Barretts Esophagus With Dysplasia",[5096],{"trials":5114,"activeCount":98},[],{"trials":5116,"activeCount":98},[],{"trials":5118,"activeCount":98},[],{"intervention":5120,"totalTrials":94,"cells":5121},"gNO",{"EARLY_PHASE1":5122,"PHASE1":5124,"PHASE2":5126,"PHASE3":5137,"PHASE4":5139,"NA":5141},{"trials":5123,"activeCount":98},[],{"trials":5125,"activeCount":98},[],{"trials":5127,"activeCount":98},[5128],{"nctId":5129,"briefTitle":5130,"status":323,"phases":5131,"primaryCompletion":5132,"completion":5132,"start":5133,"enrollment":601,"conditions":5134,"interventions":5136},"NCT03748992","A Proof of Concept Study of Inhaled Nitric Oxide for Adults With Pulmonary Non-Tuberculous Mycobacterial Infection",[87],"2020-03-26","2019-01-28",[5135],"Nontuberculous Mycobacterium Infection",[5120],{"trials":5138,"activeCount":98},[],{"trials":5140,"activeCount":98},[],{"trials":5142,"activeCount":98},[],{"intervention":5144,"totalTrials":94,"cells":5145},"Carbamazepine",{"EARLY_PHASE1":5146,"PHASE1":5148,"PHASE2":5150,"PHASE3":5161,"PHASE4":5163,"NA":5165},{"trials":5147,"activeCount":98},[],{"trials":5149,"activeCount":98},[],{"trials":5151,"activeCount":98},[5152],{"nctId":5153,"briefTitle":5154,"status":323,"phases":5155,"primaryCompletion":5156,"completion":5156,"start":5157,"enrollment":98,"conditions":5158,"interventions":5160},"NCT00000242","Carbamazepine Treatment of Cocaine Dependence - 1",[87],"1997-01-25","1992-10-01",[2956,5159],"Substance-Related Disorders",[5144],{"trials":5162,"activeCount":98},[],{"trials":5164,"activeCount":98},[],{"trials":5166,"activeCount":98},[],{"intervention":3552,"totalTrials":94,"cells":5168},{"EARLY_PHASE1":5169,"PHASE1":5171,"PHASE2":5173,"PHASE3":5179,"PHASE4":5181,"NA":5183},{"trials":5170,"activeCount":98},[],{"trials":5172,"activeCount":98},[],{"trials":5174,"activeCount":98},[5175],{"nctId":3544,"briefTitle":3545,"status":2079,"phases":5176,"primaryCompletion":3547,"completion":3547,"start":3547,"enrollment":98,"conditions":5177,"interventions":5178},[87],[3549,3550],[3526,3552],{"trials":5180,"activeCount":98},[],{"trials":5182,"activeCount":98},[],{"trials":5184,"activeCount":98},[],{"intervention":5186,"totalTrials":94,"cells":5187},"arsenic trioxide",{"EARLY_PHASE1":5188,"PHASE1":5190,"PHASE2":5192,"PHASE3":5205,"PHASE4":5207,"NA":5209},{"trials":5189,"activeCount":98},[],{"trials":5191,"activeCount":98},[],{"trials":5193,"activeCount":98},[5194],{"nctId":5195,"briefTitle":5196,"status":597,"phases":5197,"primaryCompletion":5198,"completion":5198,"start":5199,"enrollment":94,"conditions":5200,"interventions":5203},"NCT00118196","Azacitidine and Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia",[87],"2006-08-11","2005-04",[5201,5202],"Leukemia","Myelodysplastic Syndromes",[5186,5204],"azacitidine",{"trials":5206,"activeCount":98},[],{"trials":5208,"activeCount":98},[],{"trials":5210,"activeCount":98},[],{"intervention":5204,"totalTrials":94,"cells":5212},{"EARLY_PHASE1":5213,"PHASE1":5215,"PHASE2":5217,"PHASE3":5223,"PHASE4":5225,"NA":5227},{"trials":5214,"activeCount":98},[],{"trials":5216,"activeCount":98},[],{"trials":5218,"activeCount":98},[5219],{"nctId":5195,"briefTitle":5196,"status":597,"phases":5220,"primaryCompletion":5198,"completion":5198,"start":5199,"enrollment":94,"conditions":5221,"interventions":5222},[87],[5201,5202],[5186,5204],{"trials":5224,"activeCount":98},[],{"trials":5226,"activeCount":98},[],{"trials":5228,"activeCount":98},[],{"intervention":5230,"totalTrials":94,"cells":5231},"ginkgo biloba",{"EARLY_PHASE1":5232,"PHASE1":5234,"PHASE2":5236,"PHASE3":5247,"PHASE4":5249,"NA":5251},{"trials":5233,"activeCount":98},[],{"trials":5235,"activeCount":98},[],{"trials":5237,"activeCount":98},[5238],{"nctId":5239,"briefTitle":5240,"status":597,"phases":5241,"primaryCompletion":600,"completion":5242,"start":5243,"enrollment":1657,"conditions":5244,"interventions":5246},"NCT00070954","Ginkgo Biloba to Improve Short-Term Memory Losses Associated With Electroconvulsive Therapy (ECT)",[86,87],"2005-03","2003-02",[5245],"Memory, Short-Term",[5230],{"trials":5248,"activeCount":98},[],{"trials":5250,"activeCount":98},[],{"trials":5252,"activeCount":98},[],{"intervention":5254,"totalTrials":94,"cells":5255},"Placebos",{"EARLY_PHASE1":5256,"PHASE1":5258,"PHASE2":5260,"PHASE3":5270,"PHASE4":5272,"NA":5274},{"trials":5257,"activeCount":98},[],{"trials":5259,"activeCount":98},[],{"trials":5261,"activeCount":98},[5262],{"nctId":5263,"briefTitle":5264,"status":323,"phases":5265,"primaryCompletion":5266,"completion":5266,"start":5267,"enrollment":2253,"conditions":5268,"interventions":5269},"NCT03238924","Prolonged Exposure and Oxytocin",[87],"2016-12-31","2015-01-01",[1060],[1625,5254],{"trials":5271,"activeCount":98},[],{"trials":5273,"activeCount":98},[],{"trials":5275,"activeCount":98},[],{"intervention":5277,"totalTrials":94,"cells":5278},"Vilazodone",{"EARLY_PHASE1":5279,"PHASE1":5281,"PHASE2":5283,"PHASE3":5292,"PHASE4":5294,"NA":5296},{"trials":5280,"activeCount":98},[],{"trials":5282,"activeCount":98},[],{"trials":5284,"activeCount":98},[5285],{"nctId":5286,"briefTitle":5287,"status":323,"phases":5288,"primaryCompletion":2133,"completion":5289,"start":531,"enrollment":1155,"conditions":5290,"interventions":5291},"NCT01574183","Vilazodone Treatment for Marijuana Dependence",[87],"2016-02",[1634],[5277],{"trials":5293,"activeCount":98},[],{"trials":5295,"activeCount":98},[],{"trials":5297,"activeCount":98},[],{"intervention":5299,"totalTrials":94,"cells":5300},"minocycline (200 mg daily) and NAC (1200 mg daily) followed by placebo",{"EARLY_PHASE1":5301,"PHASE1":5303,"PHASE2":5305,"PHASE3":5316,"PHASE4":5318,"NA":5320},{"trials":5302,"activeCount":98},[],{"trials":5304,"activeCount":98},[],{"trials":5306,"activeCount":98},[5307],{"nctId":5308,"briefTitle":5309,"status":323,"phases":5310,"primaryCompletion":5311,"completion":5311,"start":5312,"enrollment":2280,"conditions":5313,"interventions":5315},"NCT04594733","The Effect of Minocycline and N-acetylcysteine for the Treatment of Fibromyalgia",[86,87],"2022-08-31","2021-12-06",[5314],"Fibromyalgia",[5299],{"trials":5317,"activeCount":98},[],{"trials":5319,"activeCount":98},[],{"trials":5321,"activeCount":98},[],{"intervention":5323,"totalTrials":94,"cells":5324},"Regimen A",{"EARLY_PHASE1":5325,"PHASE1":5327,"PHASE2":5329,"PHASE3":5341,"PHASE4":5343,"NA":5345},{"trials":5326,"activeCount":98},[],{"trials":5328,"activeCount":98},[],{"trials":5330,"activeCount":98},[5331],{"nctId":5332,"briefTitle":5333,"status":597,"phases":5334,"primaryCompletion":2434,"completion":1833,"start":2513,"enrollment":5335,"conditions":5336,"interventions":5338},"NCT01139164","Allogeneic Hematopoietic Stem Cell Transplantation With Reduced Intensity Pre-transplant Conditioning for the Treatment of High-risk Hematological Malignancies (V3)",[87],78,[5337],"Hematological Malignancies",[5323,5339,5340],"Regimen B","Regimen C",{"trials":5342,"activeCount":98},[],{"trials":5344,"activeCount":98},[],{"trials":5346,"activeCount":98},[],{"intervention":5339,"totalTrials":94,"cells":5348},{"EARLY_PHASE1":5349,"PHASE1":5351,"PHASE2":5353,"PHASE3":5359,"PHASE4":5361,"NA":5363},{"trials":5350,"activeCount":98},[],{"trials":5352,"activeCount":98},[],{"trials":5354,"activeCount":98},[5355],{"nctId":5332,"briefTitle":5333,"status":597,"phases":5356,"primaryCompletion":2434,"completion":1833,"start":2513,"enrollment":5335,"conditions":5357,"interventions":5358},[87],[5337],[5323,5339,5340],{"trials":5360,"activeCount":98},[],{"trials":5362,"activeCount":98},[],{"trials":5364,"activeCount":98},[],{"intervention":5340,"totalTrials":94,"cells":5366},{"EARLY_PHASE1":5367,"PHASE1":5369,"PHASE2":5371,"PHASE3":5377,"PHASE4":5379,"NA":5381},{"trials":5368,"activeCount":98},[],{"trials":5370,"activeCount":98},[],{"trials":5372,"activeCount":98},[5373],{"nctId":5332,"briefTitle":5333,"status":597,"phases":5374,"primaryCompletion":2434,"completion":1833,"start":2513,"enrollment":5335,"conditions":5375,"interventions":5376},[87],[5337],[5323,5339,5340],{"trials":5378,"activeCount":98},[],{"trials":5380,"activeCount":98},[],{"trials":5382,"activeCount":98},[],{"intervention":5384,"totalTrials":94,"cells":5385},"Neo-adjuvant Chemotherapy",{"EARLY_PHASE1":5386,"PHASE1":5388,"PHASE2":5390,"PHASE3":5400,"PHASE4":5402,"NA":5404},{"trials":5387,"activeCount":98},[],{"trials":5389,"activeCount":98},[],{"trials":5391,"activeCount":98},[5392],{"nctId":5393,"briefTitle":5394,"status":597,"phases":5395,"primaryCompletion":5396,"start":1630,"enrollment":573,"conditions":5397,"interventions":5399},"NCT01677988","Neoadjuvant Folfirinox Followed by Capecitabine and Limited Field Radiation for Localized Pancreatic Head Adenocarcinoma",[87],"2015-10",[5398],"Adenocarcinoma of Head of Pancreas",[5384],{"trials":5401,"activeCount":98},[],{"trials":5403,"activeCount":98},[],{"trials":5405,"activeCount":98},[],{"intervention":3562,"totalTrials":94,"cells":5407},{"EARLY_PHASE1":5408,"PHASE1":5410,"PHASE2":5412,"PHASE3":5418,"PHASE4":5420,"NA":5422},{"trials":5409,"activeCount":98},[],{"trials":5411,"activeCount":98},[],{"trials":5413,"activeCount":98},[5414],{"nctId":3554,"briefTitle":3555,"status":323,"phases":5415,"primaryCompletion":3557,"completion":3557,"start":3558,"enrollment":519,"conditions":5416,"interventions":5417},[86,87],[3560],[3562,3526],{"trials":5419,"activeCount":98},[],{"trials":5421,"activeCount":98},[],{"trials":5423,"activeCount":98},[],{"intervention":5425,"totalTrials":94,"cells":5426},"Dexamethasone",{"EARLY_PHASE1":5427,"PHASE1":5429,"PHASE2":5431,"PHASE3":5445,"PHASE4":5447,"NA":5449},{"trials":5428,"activeCount":98},[],{"trials":5430,"activeCount":98},[],{"trials":5432,"activeCount":98},[5433],{"nctId":5434,"briefTitle":5435,"status":323,"phases":5436,"primaryCompletion":5437,"completion":5438,"start":5439,"enrollment":5440,"conditions":5441,"interventions":5444},"NCT03995628","Steroids and Pain Control After Tonsillectomy",[87],"2025-09-15","2025-12-31","2018-12-18",163,[5442,5443],"Tonsillitis","Obstructive Sleep Apnea of Child",[5425],{"trials":5446,"activeCount":98},[],{"trials":5448,"activeCount":98},[],{"trials":5450,"activeCount":98},[],{"intervention":5452,"totalTrials":94,"cells":5453},"Lofexidine",{"EARLY_PHASE1":5454,"PHASE1":5456,"PHASE2":5458,"PHASE3":5468,"PHASE4":5470,"NA":5472},{"trials":5455,"activeCount":98},[],{"trials":5457,"activeCount":98},[],{"trials":5459,"activeCount":98},[5460],{"nctId":5461,"briefTitle":5462,"status":323,"phases":5463,"primaryCompletion":2556,"completion":2556,"start":5464,"enrollment":1622,"conditions":5465,"interventions":5467},"NCT03718065","Impact of Lofexidine on Stress, Craving and Opioid Use",[87],"2019-06-26",[3712,5466],"Opiate Dependence",[5452],{"trials":5469,"activeCount":98},[],{"trials":5471,"activeCount":98},[],{"trials":5473,"activeCount":98},[],{"intervention":5475,"totalTrials":94,"cells":5476},"Grape Seed Extract",{"EARLY_PHASE1":5477,"PHASE1":5479,"PHASE2":5489,"PHASE3":5491,"PHASE4":5493,"NA":5495},{"trials":5478,"activeCount":98},[],{"trials":5480,"activeCount":98},[5481],{"nctId":5482,"briefTitle":5483,"status":323,"phases":5484,"primaryCompletion":642,"completion":642,"start":1642,"enrollment":708,"conditions":5485,"interventions":5487},"NCT01820299","Phase I Assay-guided Trial of Anti-inflammatory Phytochemicals in Patients With Advanced Cancer",[86],[5486],"Solid Cancers",[5475,5488],"Vitamin D",{"trials":5490,"activeCount":98},[],{"trials":5492,"activeCount":98},[],{"trials":5494,"activeCount":98},[],{"trials":5496,"activeCount":98},[],{"intervention":2086,"totalTrials":94,"cells":5498},{"EARLY_PHASE1":5499,"PHASE1":5501,"PHASE2":5507,"PHASE3":5509,"PHASE4":5511,"NA":5513},{"trials":5500,"activeCount":98},[],{"trials":5502,"activeCount":98},[5503],{"nctId":2077,"briefTitle":2078,"status":2079,"phases":5504,"primaryCompletion":2081,"completion":2081,"start":2082,"enrollment":98,"conditions":5505,"interventions":5506},[86],[2084],[2086,2070,2087],{"trials":5508,"activeCount":98},[],{"trials":5510,"activeCount":98},[],{"trials":5512,"activeCount":98},[],{"trials":5514,"activeCount":98},[],{"intervention":2087,"totalTrials":94,"cells":5516},{"EARLY_PHASE1":5517,"PHASE1":5519,"PHASE2":5525,"PHASE3":5527,"PHASE4":5529,"NA":5531},{"trials":5518,"activeCount":98},[],{"trials":5520,"activeCount":98},[5521],{"nctId":2077,"briefTitle":2078,"status":2079,"phases":5522,"primaryCompletion":2081,"completion":2081,"start":2082,"enrollment":98,"conditions":5523,"interventions":5524},[86],[2084],[2086,2070,2087],{"trials":5526,"activeCount":98},[],{"trials":5528,"activeCount":98},[],{"trials":5530,"activeCount":98},[],{"trials":5532,"activeCount":98},[],{"intervention":5534,"totalTrials":94,"cells":5535},"OPC",{"EARLY_PHASE1":5536,"PHASE1":5538,"PHASE2":5549,"PHASE3":5551,"PHASE4":5553,"NA":5555},{"trials":5537,"activeCount":98},[],{"trials":5539,"activeCount":98},[5540],{"nctId":5541,"briefTitle":5542,"status":597,"phases":5543,"primaryCompletion":5544,"completion":5545,"start":5546,"enrollment":1852,"conditions":5547,"interventions":5548},"NCT03092635","AGE Levels in ER+ Metastatic Breast Cancer Patients Receiving Endocrine Therapy",[86],"2021-11-10","2022-04-22","2017-06-06",[1562],[5534],{"trials":5550,"activeCount":98},[],{"trials":5552,"activeCount":98},[],{"trials":5554,"activeCount":98},[],{"trials":5556,"activeCount":98},[],{"intervention":5558,"totalTrials":94,"cells":5559},"Curcumin",{"EARLY_PHASE1":5560,"PHASE1":5562,"PHASE2":5573,"PHASE3":5575,"PHASE4":5577,"NA":5579},{"trials":5561,"activeCount":98},[],{"trials":5563,"activeCount":98},[5564],{"nctId":5565,"briefTitle":5566,"status":323,"phases":5567,"primaryCompletion":5568,"completion":5569,"start":5570,"enrollment":708,"conditions":5571,"interventions":5572},"NCT03980509","A \"Window Trial\" on Curcumin for Invasive Breast Cancer Primary Tumors",[86],"2022-03-24","2023-03-24","2020-01-29",[1562],[5558],{"trials":5574,"activeCount":98},[],{"trials":5576,"activeCount":98},[],{"trials":5578,"activeCount":98},[],{"trials":5580,"activeCount":98},[],{"intervention":5582,"totalTrials":94,"cells":5583},"Cranberry juice and",{"EARLY_PHASE1":5584,"PHASE1":5586,"PHASE2":5596,"PHASE3":5598,"PHASE4":5600,"NA":5602},{"trials":5585,"activeCount":98},[],{"trials":5587,"activeCount":98},[5588],{"nctId":5589,"briefTitle":5590,"status":323,"phases":5591,"primaryCompletion":2001,"completion":2001,"start":4201,"enrollment":1632,"conditions":5592,"interventions":5595},"NCT00200759","Drug Interactions and Bioavailability of Cranberry",[86],[5593,5594],"Healthy","Drug Interactions",[5582],{"trials":5597,"activeCount":98},[],{"trials":5599,"activeCount":98},[],{"trials":5601,"activeCount":98},[],{"trials":5603,"activeCount":98},[],{"intervention":5605,"totalTrials":94,"cells":5606},"Lycopene and Docetaxel",{"EARLY_PHASE1":5607,"PHASE1":5609,"PHASE2":5620,"PHASE3":5622,"PHASE4":5624,"NA":5626},{"trials":5608,"activeCount":98},[],{"trials":5610,"activeCount":98},[5611],{"nctId":5612,"briefTitle":5613,"status":323,"phases":5614,"primaryCompletion":1640,"completion":5615,"start":5616,"enrollment":697,"conditions":5617,"interventions":5619},"NCT01949519","Docetaxel and Lycopene in Metastatic Prostate Cancer",[86],"2017-07-12","2013-11",[5618],"Adenocarcinoma of the Prostate",[5605],{"trials":5621,"activeCount":98},[],{"trials":5623,"activeCount":98},[],{"trials":5625,"activeCount":98},[],{"trials":5627,"activeCount":98},[],{"intervention":5629,"totalTrials":94,"cells":5630},"Valproic Acid",{"EARLY_PHASE1":5631,"PHASE1":5633,"PHASE2":5645,"PHASE3":5647,"PHASE4":5649,"NA":5651},{"trials":5632,"activeCount":98},[],{"trials":5634,"activeCount":98},[5635],{"nctId":5636,"briefTitle":5637,"status":2079,"phases":5638,"primaryCompletion":485,"completion":485,"start":4798,"enrollment":98,"conditions":5639,"interventions":5644},"NCT01861990","Valproic Acid in Childhood Progressive Brain Tumors",[86],[5640,4673,5641,5642,5643],"Pediatric Brain Tumor","Anaplastic Astrocytoma","Medulloblastoma","Glioblastoma",[5629],{"trials":5646,"activeCount":98},[],{"trials":5648,"activeCount":98},[],{"trials":5650,"activeCount":98},[],{"trials":5652,"activeCount":98},[],{"intervention":5654,"totalTrials":94,"cells":5655},"Boswellia",{"EARLY_PHASE1":5656,"PHASE1":5658,"PHASE2":5667,"PHASE3":5669,"PHASE4":5671,"NA":5673},{"trials":5657,"activeCount":98},[],{"trials":5659,"activeCount":98},[5660],{"nctId":5661,"briefTitle":5662,"status":323,"phases":5663,"primaryCompletion":4757,"completion":4757,"start":5664,"enrollment":2993,"conditions":5665,"interventions":5666},"NCT03149081","A \"Window Trial\" on Boswellia for Breast Cancer Primary Tumors",[86],"2017-08-31",[1562],[5654],{"trials":5668,"activeCount":98},[],{"trials":5670,"activeCount":98},[],{"trials":5672,"activeCount":98},[],{"trials":5674,"activeCount":98},[],{"intervention":5676,"totalTrials":94,"cells":5677},"Allogeneic Mesenchymal Stromal Cells",{"EARLY_PHASE1":5678,"PHASE1":5680,"PHASE2":5690,"PHASE3":5692,"PHASE4":5694,"NA":5696},{"trials":5679,"activeCount":98},[],{"trials":5681,"activeCount":98},[5682],{"nctId":5683,"briefTitle":5684,"status":2079,"phases":5685,"primaryCompletion":1012,"completion":1012,"start":1012,"enrollment":98,"conditions":5686,"interventions":5689},"NCT05286255","Mesenchymal Stromal Cells for COVID-19 and Viral Pneumonias",[86],[5687,5688],"COVID-19 Pneumonia","Viral Pneumonia",[5676],{"trials":5691,"activeCount":98},[],{"trials":5693,"activeCount":98},[],{"trials":5695,"activeCount":98},[],{"trials":5697,"activeCount":98},[],{"intervention":5699,"totalTrials":94,"cells":5700},"bortezomib",{"EARLY_PHASE1":5701,"PHASE1":5703,"PHASE2":5714,"PHASE3":5716,"PHASE4":5718,"NA":5720},{"trials":5702,"activeCount":98},[],{"trials":5704,"activeCount":98},[5705],{"nctId":5706,"briefTitle":5707,"status":323,"phases":5708,"primaryCompletion":5709,"completion":5709,"start":5242,"enrollment":9,"conditions":5710,"interventions":5712},"NCT00290680","Bortezomib and Celecoxib in Treating Patients With Advanced Solid Tumors",[86],"2009-01",[5711],"Unspecified Adult Solid Tumor, Protocol Specific",[5699,5713],"celecoxib",{"trials":5715,"activeCount":98},[],{"trials":5717,"activeCount":98},[],{"trials":5719,"activeCount":98},[],{"trials":5721,"activeCount":98},[],{"intervention":5713,"totalTrials":94,"cells":5723},{"EARLY_PHASE1":5724,"PHASE1":5726,"PHASE2":5732,"PHASE3":5734,"PHASE4":5736,"NA":5738},{"trials":5725,"activeCount":98},[],{"trials":5727,"activeCount":98},[5728],{"nctId":5706,"briefTitle":5707,"status":323,"phases":5729,"primaryCompletion":5709,"completion":5709,"start":5242,"enrollment":9,"conditions":5730,"interventions":5731},[86],[5711],[5699,5713],{"trials":5733,"activeCount":98},[],{"trials":5735,"activeCount":98},[],{"trials":5737,"activeCount":98},[],{"trials":5739,"activeCount":98},[],{"intervention":5741,"totalTrials":94,"cells":5742},"Lovastatin 2%, 2% Cholesterol Cream",{"EARLY_PHASE1":5743,"PHASE1":5745,"PHASE2":5758,"PHASE3":5760,"PHASE4":5762,"NA":5764},{"trials":5744,"activeCount":98},[],{"trials":5746,"activeCount":98},[5747],{"nctId":5748,"briefTitle":5749,"status":323,"phases":5750,"primaryCompletion":5751,"completion":5751,"start":5752,"enrollment":5753,"conditions":5754,"interventions":5756},"NCT04359823","DSAP Treatment Comparison: 2% Lovastatin\u002F 2% Cholesterol vs 2% Lovastatin Alone",[86],"2021-04-23","2020-08-24",31,[5755],"Actinic Porokeratosis",[5741,5757],"Lovastatin 2% Cream",{"trials":5759,"activeCount":98},[],{"trials":5761,"activeCount":98},[],{"trials":5763,"activeCount":98},[],{"trials":5765,"activeCount":98},[],{"intervention":5757,"totalTrials":94,"cells":5767},{"EARLY_PHASE1":5768,"PHASE1":5770,"PHASE2":5776,"PHASE3":5778,"PHASE4":5780,"NA":5782},{"trials":5769,"activeCount":98},[],{"trials":5771,"activeCount":98},[5772],{"nctId":5748,"briefTitle":5749,"status":323,"phases":5773,"primaryCompletion":5751,"completion":5751,"start":5752,"enrollment":5753,"conditions":5774,"interventions":5775},[86],[5755],[5741,5757],{"trials":5777,"activeCount":98},[],{"trials":5779,"activeCount":98},[],{"trials":5781,"activeCount":98},[],{"trials":5783,"activeCount":98},[],{"intervention":5785,"totalTrials":94,"cells":5786},"Poly-ICLC",{"EARLY_PHASE1":5787,"PHASE1":5789,"PHASE2":5799,"PHASE3":5801,"PHASE4":5803,"NA":5805},{"trials":5788,"activeCount":98},[],{"trials":5790,"activeCount":98},[5791],{"nctId":5792,"briefTitle":5793,"status":323,"phases":5794,"primaryCompletion":2434,"completion":642,"start":531,"enrollment":3069,"conditions":5795,"interventions":5797},"NCT01677962","A Study of Vaccination With Poly-ICLC and Dendritic Cells in Patients With Pancreatic Adenocarcinoma",[86],[5796],"Pancreatic Adenocarcinoma Non-resectable",[5785,5798],"dendritic cell",{"trials":5800,"activeCount":98},[],{"trials":5802,"activeCount":98},[],{"trials":5804,"activeCount":98},[],{"trials":5806,"activeCount":98},[],{"intervention":5798,"totalTrials":94,"cells":5808},{"EARLY_PHASE1":5809,"PHASE1":5811,"PHASE2":5817,"PHASE3":5819,"PHASE4":5821,"NA":5823},{"trials":5810,"activeCount":98},[],{"trials":5812,"activeCount":98},[5813],{"nctId":5792,"briefTitle":5793,"status":323,"phases":5814,"primaryCompletion":2434,"completion":642,"start":531,"enrollment":3069,"conditions":5815,"interventions":5816},[86],[5796],[5785,5798],{"trials":5818,"activeCount":98},[],{"trials":5820,"activeCount":98},[],{"trials":5822,"activeCount":98},[],{"trials":5824,"activeCount":98},[],{"intervention":3830,"totalTrials":94,"cells":5826},{"EARLY_PHASE1":5827,"PHASE1":5829,"PHASE2":5835,"PHASE3":5837,"PHASE4":5839,"NA":5841},{"trials":5828,"activeCount":98},[],{"trials":5830,"activeCount":98},[5831],{"nctId":3824,"briefTitle":3825,"status":2079,"phases":5832,"primaryCompletion":3827,"completion":3827,"start":3827,"enrollment":98,"conditions":5833,"interventions":5834},[86],[31],[3817,3830],{"trials":5836,"activeCount":98},[],{"trials":5838,"activeCount":98},[],{"trials":5840,"activeCount":98},[],{"trials":5842,"activeCount":98},[],{"intervention":5844,"totalTrials":94,"cells":5845},"Dextromethorphan Hydrobromide",{"EARLY_PHASE1":5846,"PHASE1":5848,"PHASE2":5858,"PHASE3":5860,"PHASE4":5862,"NA":5864},{"trials":5847,"activeCount":98},[],{"trials":5849,"activeCount":98},[5850],{"nctId":5851,"briefTitle":5852,"status":323,"phases":5853,"primaryCompletion":5854,"completion":5854,"start":5855,"enrollment":1428,"conditions":5856,"interventions":5857},"NCT02860962","A Trial of Dextromethorphan for Treatment of Major Depressive Disorder",[86],"2017-06","2016-08",[4464],[5844],{"trials":5859,"activeCount":98},[],{"trials":5861,"activeCount":98},[],{"trials":5863,"activeCount":98},[],{"trials":5865,"activeCount":98},[],{"intervention":736,"totalTrials":94,"cells":5867},{"EARLY_PHASE1":5868,"PHASE1":5870,"PHASE2":5876,"PHASE3":5878,"PHASE4":5880,"NA":5882},{"trials":5869,"activeCount":98},[],{"trials":5871,"activeCount":98},[5872],{"nctId":727,"briefTitle":728,"status":323,"phases":5873,"primaryCompletion":730,"completion":731,"start":732,"enrollment":22,"conditions":5874,"interventions":5875},[86],[734],[720,736,737],{"trials":5877,"activeCount":98},[],{"trials":5879,"activeCount":98},[],{"trials":5881,"activeCount":98},[],{"trials":5883,"activeCount":98},[],{"intervention":737,"totalTrials":94,"cells":5885},{"EARLY_PHASE1":5886,"PHASE1":5888,"PHASE2":5894,"PHASE3":5896,"PHASE4":5898,"NA":5900},{"trials":5887,"activeCount":98},[],{"trials":5889,"activeCount":98},[5890],{"nctId":727,"briefTitle":728,"status":323,"phases":5891,"primaryCompletion":730,"completion":731,"start":732,"enrollment":22,"conditions":5892,"interventions":5893},[86],[734],[720,736,737],{"trials":5895,"activeCount":98},[],{"trials":5897,"activeCount":98},[],{"trials":5899,"activeCount":98},[],{"trials":5901,"activeCount":98},[],{"intervention":3493,"totalTrials":94,"cells":5903},{"EARLY_PHASE1":5904,"PHASE1":5906,"PHASE2":5912,"PHASE3":5914,"PHASE4":5916,"NA":5918},{"trials":5905,"activeCount":98},[],{"trials":5907,"activeCount":98},[5908],{"nctId":3485,"briefTitle":3486,"status":323,"phases":5909,"primaryCompletion":3488,"completion":3489,"start":3490,"enrollment":22,"conditions":5910,"interventions":5911},[86],[31],[3493,3478,3494],{"trials":5913,"activeCount":98},[],{"trials":5915,"activeCount":98},[],{"trials":5917,"activeCount":98},[],{"trials":5919,"activeCount":98},[],{"intervention":3494,"totalTrials":94,"cells":5921},{"EARLY_PHASE1":5922,"PHASE1":5924,"PHASE2":5930,"PHASE3":5932,"PHASE4":5934,"NA":5936},{"trials":5923,"activeCount":98},[],{"trials":5925,"activeCount":98},[5926],{"nctId":3485,"briefTitle":3486,"status":323,"phases":5927,"primaryCompletion":3488,"completion":3489,"start":3490,"enrollment":22,"conditions":5928,"interventions":5929},[86],[31],[3493,3478,3494],{"trials":5931,"activeCount":98},[],{"trials":5933,"activeCount":98},[],{"trials":5935,"activeCount":98},[],{"trials":5937,"activeCount":98},[],{"intervention":5939,"totalTrials":94,"cells":5940},"Ropivicaine",{"EARLY_PHASE1":5941,"PHASE1":5943,"PHASE2":5951,"PHASE3":5953,"PHASE4":5955,"NA":5957},{"trials":5942,"activeCount":98},[],{"trials":5944,"activeCount":98},[5945],{"nctId":5946,"briefTitle":5947,"status":323,"phases":5948,"primaryCompletion":1373,"completion":1373,"start":2992,"enrollment":601,"conditions":5949,"interventions":5950},"NCT02297191","Ultrasound Guided Local Anesthetic Block: Thoracolumbar Interfascial Plane",[86],[5593],[5939],{"trials":5952,"activeCount":98},[],{"trials":5954,"activeCount":98},[],{"trials":5956,"activeCount":98},[],{"trials":5958,"activeCount":98},[],{"intervention":797,"totalTrials":94,"cells":5960},{"EARLY_PHASE1":5961,"PHASE1":5963,"PHASE2":5969,"PHASE3":5971,"PHASE4":5973,"NA":5975},{"trials":5962,"activeCount":98},[],{"trials":5964,"activeCount":98},[5965],{"nctId":787,"briefTitle":788,"status":597,"phases":5966,"primaryCompletion":790,"completion":790,"start":791,"enrollment":792,"conditions":5967,"interventions":5968},[86],[794,795],[797,750,797,622],{"trials":5970,"activeCount":98},[],{"trials":5972,"activeCount":98},[],{"trials":5974,"activeCount":98},[],{"trials":5976,"activeCount":98},[],{"intervention":5978,"totalTrials":94,"cells":5979},"dabigatran etexilate",{"EARLY_PHASE1":5980,"PHASE1":5982,"PHASE2":5995,"PHASE3":5997,"PHASE4":5999,"NA":6001},{"trials":5981,"activeCount":98},[],{"trials":5983,"activeCount":98},[5984],{"nctId":5985,"briefTitle":5986,"status":323,"phases":5987,"primaryCompletion":5988,"completion":5989,"start":5289,"enrollment":5990,"conditions":5991,"interventions":5994},"NCT02426229","Safety & Suitability of Dabigatran to Inhibit Thrombin in Scleroderma",[86],"2018-06","2018-06-21",15,[5992,5993],"Scleroderma","Interstitial Lung Disease",[5978],{"trials":5996,"activeCount":98},[],{"trials":5998,"activeCount":98},[],{"trials":6000,"activeCount":98},[],{"trials":6002,"activeCount":98},[],{"intervention":6004,"totalTrials":94,"cells":6005},"Panobinostat (LBH589), Sorafenib",{"EARLY_PHASE1":6006,"PHASE1":6008,"PHASE2":6022,"PHASE3":6024,"PHASE4":6026,"NA":6028},{"trials":6007,"activeCount":98},[],{"trials":6009,"activeCount":98},[6010],{"nctId":6011,"briefTitle":6012,"status":323,"phases":6013,"primaryCompletion":6014,"completion":6015,"start":6016,"enrollment":669,"conditions":6017,"interventions":6021},"NCT01005797","Study of Panobinostat in Combination With Sorafenib in Kidney, Soft Tissue or Lung Cancers",[86],"2014-03","2017-01","2009-11",[6018,6019,6020],"Renal Cancer","Non Small Cell Lung Cancer (NSCLC)","Soft Tissue Sarcoma",[6004],{"trials":6023,"activeCount":98},[],{"trials":6025,"activeCount":98},[],{"trials":6027,"activeCount":98},[],{"trials":6029,"activeCount":98},[],{"intervention":6031,"totalTrials":94,"cells":6032},"topotecan hydrochloride",{"EARLY_PHASE1":6033,"PHASE1":6035,"PHASE2":6045,"PHASE3":6047,"PHASE4":6049,"NA":6051},{"trials":6034,"activeCount":98},[],{"trials":6036,"activeCount":98},[6037],{"nctId":6038,"briefTitle":6039,"status":323,"phases":6040,"primaryCompletion":1872,"completion":1872,"start":6041,"enrollment":32,"conditions":6042,"interventions":6043},"NCT00287963","Topotecan and Vinorelbine in Treating Patients With Recurrent Lung Cancer",[86],"2004-02",[4001],[6031,6044],"vinorelbine tartrate",{"trials":6046,"activeCount":98},[],{"trials":6048,"activeCount":98},[],{"trials":6050,"activeCount":98},[],{"trials":6052,"activeCount":98},[],{"intervention":6044,"totalTrials":94,"cells":6054},{"EARLY_PHASE1":6055,"PHASE1":6057,"PHASE2":6063,"PHASE3":6065,"PHASE4":6067,"NA":6069},{"trials":6056,"activeCount":98},[],{"trials":6058,"activeCount":98},[6059],{"nctId":6038,"briefTitle":6039,"status":323,"phases":6060,"primaryCompletion":1872,"completion":1872,"start":6041,"enrollment":32,"conditions":6061,"interventions":6062},[86],[4001],[6031,6044],{"trials":6064,"activeCount":98},[],{"trials":6066,"activeCount":98},[],{"trials":6068,"activeCount":98},[],{"trials":6070,"activeCount":98},[],{"intervention":6072,"totalTrials":94,"cells":6073},"Oral azacitidine",{"EARLY_PHASE1":6074,"PHASE1":6076,"PHASE2":6087,"PHASE3":6089,"PHASE4":6091,"NA":6093},{"trials":6075,"activeCount":98},[],{"trials":6077,"activeCount":98},[6078],{"nctId":6079,"briefTitle":6080,"status":323,"phases":6081,"primaryCompletion":4098,"completion":2556,"start":6082,"enrollment":1852,"conditions":6083,"interventions":6085},"NCT03450343","Oral Azacitidine Plus Salvage Chemotherapy in Relapsed\u002FRefractory Diffuse Large B Cell Lymphoma",[86],"2019-04-04",[6084],"Large B-Cell Diffuse Lymphoma",[6072,6086],"R-ICE",{"trials":6088,"activeCount":98},[],{"trials":6090,"activeCount":98},[],{"trials":6092,"activeCount":98},[],{"trials":6094,"activeCount":98},[],{"intervention":6086,"totalTrials":94,"cells":6096},{"EARLY_PHASE1":6097,"PHASE1":6099,"PHASE2":6105,"PHASE3":6107,"PHASE4":6109,"NA":6111},{"trials":6098,"activeCount":98},[],{"trials":6100,"activeCount":98},[6101],{"nctId":6079,"briefTitle":6080,"status":323,"phases":6102,"primaryCompletion":4098,"completion":2556,"start":6082,"enrollment":1852,"conditions":6103,"interventions":6104},[86],[6084],[6072,6086],{"trials":6106,"activeCount":98},[],{"trials":6108,"activeCount":98},[],{"trials":6110,"activeCount":98},[],{"trials":6112,"activeCount":98},[],{"intervention":6114,"totalTrials":94,"cells":6115},"autologous mesenchymal stromal cell",{"EARLY_PHASE1":6116,"PHASE1":6118,"PHASE2":6127,"PHASE3":6129,"PHASE4":6131,"NA":6133},{"trials":6117,"activeCount":98},[],{"trials":6119,"activeCount":98},[6120],{"nctId":6121,"briefTitle":6122,"status":323,"phases":6123,"primaryCompletion":2326,"completion":6124,"start":2170,"enrollment":573,"conditions":6125,"interventions":6126},"NCT02384018","Mesenchymal Stem Cell and Islet Co-transplantation",[86],"2017-11-21",[1503,2516],[6114],{"trials":6128,"activeCount":98},[],{"trials":6130,"activeCount":98},[],{"trials":6132,"activeCount":98},[],{"trials":6134,"activeCount":98},[],{"intervention":3504,"totalTrials":94,"cells":6136},{"EARLY_PHASE1":6137,"PHASE1":6139,"PHASE2":6145,"PHASE3":6147,"PHASE4":6149,"NA":6151},{"trials":6138,"activeCount":98},[],{"trials":6140,"activeCount":98},[6141],{"nctId":3496,"briefTitle":3497,"status":597,"phases":6142,"primaryCompletion":3499,"completion":3500,"start":3501,"enrollment":9,"conditions":6143,"interventions":6144},[86],[31],[3478,3504],{"trials":6146,"activeCount":98},[],{"trials":6148,"activeCount":98},[],{"trials":6150,"activeCount":98},[],{"trials":6152,"activeCount":98},[],{"intervention":6154,"totalTrials":94,"cells":6155},"Study Juice",{"EARLY_PHASE1":6156,"PHASE1":6158,"PHASE2":6169,"PHASE3":6171,"PHASE4":6173,"NA":6175},{"trials":6157,"activeCount":98},[],{"trials":6159,"activeCount":98},[6160],{"nctId":6161,"briefTitle":6162,"status":597,"phases":6163,"primaryCompletion":2975,"completion":2975,"start":6164,"enrollment":6165,"conditions":6166,"interventions":6168},"NCT01901887","The Better Resiliency Among Veterans With Omega-3's (BRAVO) Study",[86],"2014-03-01",125,[6167],"Suicide",[6154],{"trials":6170,"activeCount":98},[],{"trials":6172,"activeCount":98},[],{"trials":6174,"activeCount":98},[],{"trials":6176,"activeCount":98},[],{"intervention":6178,"totalTrials":94,"cells":6179},"Poly ICLC",{"EARLY_PHASE1":6180,"PHASE1":6182,"PHASE2":6191,"PHASE3":6193,"PHASE4":6195,"NA":6197},{"trials":6181,"activeCount":98},[],{"trials":6183,"activeCount":98},[6184],{"nctId":6185,"briefTitle":6186,"status":597,"phases":6187,"primaryCompletion":5061,"completion":5616,"start":1603,"enrollment":94,"conditions":6188,"interventions":6190},"NCT01783431","Study of Vaccination With Poly-ICLC and Peptide-pulsed Dendritic Cells",[86],[6189],"Melanoma",[6178],{"trials":6192,"activeCount":98},[],{"trials":6194,"activeCount":98},[],{"trials":6196,"activeCount":98},[],{"trials":6198,"activeCount":98},[],{"intervention":6200,"totalTrials":94,"cells":6201},"N-acetylcysteine, NAC, and calcitriol",{"EARLY_PHASE1":6202,"PHASE1":6213,"PHASE2":6215,"PHASE3":6217,"PHASE4":6219,"NA":6221},{"trials":6203,"activeCount":98},[6204],{"nctId":6205,"briefTitle":6206,"status":323,"phases":6207,"primaryCompletion":6208,"completion":6209,"start":5267,"enrollment":19,"conditions":6210,"interventions":6212},"NCT04643821","NVD in Hypothermic HIE Neonates",[85],"2017-04-01","2020-03-01",[6211],"HIE - Perinatal Hypoxic - Ischemic Encephalopathy",[6200],{"trials":6214,"activeCount":98},[],{"trials":6216,"activeCount":98},[],{"trials":6218,"activeCount":98},[],{"trials":6220,"activeCount":98},[],{"trials":6222,"activeCount":98},[],{"intervention":6224,"totalTrials":94,"cells":6225},"Custom EMG triggered Soterix taVNS stimulation with CIMT therapy in lab",{"EARLY_PHASE1":6226,"PHASE1":6238,"PHASE2":6240,"PHASE3":6242,"PHASE4":6244,"NA":6246},{"trials":6227,"activeCount":98},[6228],{"nctId":6229,"briefTitle":6230,"status":323,"phases":6231,"primaryCompletion":6232,"completion":6232,"start":6233,"enrollment":1428,"conditions":6234,"interventions":6236},"NCT05857527","Extending taVNS Paired With Infant CIMT Into a Home-Based Setting",[85],"2024-03-30","2023-04-17",[6235],"Cerebral Palsy",[6224,6237],"Custom EMG triggered Soterix taVNS stimulation with CIMT therapy in home",{"trials":6239,"activeCount":98},[],{"trials":6241,"activeCount":98},[],{"trials":6243,"activeCount":98},[],{"trials":6245,"activeCount":98},[],{"trials":6247,"activeCount":98},[],{"intervention":6237,"totalTrials":94,"cells":6249},{"EARLY_PHASE1":6250,"PHASE1":6256,"PHASE2":6258,"PHASE3":6260,"PHASE4":6262,"NA":6264},{"trials":6251,"activeCount":98},[6252],{"nctId":6229,"briefTitle":6230,"status":323,"phases":6253,"primaryCompletion":6232,"completion":6232,"start":6233,"enrollment":1428,"conditions":6254,"interventions":6255},[85],[6235],[6224,6237],{"trials":6257,"activeCount":98},[],{"trials":6259,"activeCount":98},[],{"trials":6261,"activeCount":98},[],{"trials":6263,"activeCount":98},[],{"trials":6265,"activeCount":98},[],{"intervention":6267,"totalTrials":94,"cells":6268},"ProQuad",{"EARLY_PHASE1":6269,"PHASE1":6281,"PHASE2":6283,"PHASE3":6285,"PHASE4":6287,"NA":6289},{"trials":6270,"activeCount":98},[6271],{"nctId":6272,"briefTitle":6273,"status":323,"phases":6274,"primaryCompletion":6275,"completion":6275,"start":1833,"enrollment":1360,"conditions":6276,"interventions":6280},"NCT02687763","Safety and Efficacy of ProQuad® in Children 6-24 Month Being Evaluated for Solid Organ Transplant",[85],"2016-11-03",[6277,6278,6279],"RENAL INSUFFICIENCY, CHRONIC","LIVER FAILURE, ACUTE","HEART DISEASE",[6267],{"trials":6282,"activeCount":98},[],{"trials":6284,"activeCount":98},[],{"trials":6286,"activeCount":98},[],{"trials":6288,"activeCount":98},[],{"trials":6290,"activeCount":98},[],{"intervention":6292,"totalTrials":94,"cells":6293},"Pneumococcal polysaccharide vaccine 23 valent",{"EARLY_PHASE1":6294,"PHASE1":6307,"PHASE2":6309,"PHASE3":6311,"PHASE4":6313,"NA":6315},{"trials":6295,"activeCount":98},[6296],{"nctId":6297,"briefTitle":6298,"status":323,"phases":6299,"primaryCompletion":6300,"completion":6300,"start":6301,"enrollment":1939,"conditions":6302,"interventions":6305},"NCT03039491","Immune Response to Pneumococcal Vaccination in Aging HIV Positive Adults",[85],"2020-03-30","2015-09-01",[6303,6304],"HIV Lipodystrophy","Aging",[6292,6306],"13 valent conjugated pneumococcal vaccine",{"trials":6308,"activeCount":98},[],{"trials":6310,"activeCount":98},[],{"trials":6312,"activeCount":98},[],{"trials":6314,"activeCount":98},[],{"trials":6316,"activeCount":98},[],{"intervention":6306,"totalTrials":94,"cells":6318},{"EARLY_PHASE1":6319,"PHASE1":6325,"PHASE2":6327,"PHASE3":6329,"PHASE4":6331,"NA":6333},{"trials":6320,"activeCount":98},[6321],{"nctId":6297,"briefTitle":6298,"status":323,"phases":6322,"primaryCompletion":6300,"completion":6300,"start":6301,"enrollment":1939,"conditions":6323,"interventions":6324},[85],[6303,6304],[6292,6306],{"trials":6326,"activeCount":98},[],{"trials":6328,"activeCount":98},[],{"trials":6330,"activeCount":98},[],{"trials":6332,"activeCount":98},[],{"trials":6334,"activeCount":98},[],{"intervention":6336,"totalTrials":94,"cells":6337},"N acetyl cysteine + vagus nerve stimulation",{"EARLY_PHASE1":6338,"PHASE1":6353,"PHASE2":6355,"PHASE3":6357,"PHASE4":6359,"NA":6361},{"trials":6339,"activeCount":98},[6340],{"nctId":6341,"briefTitle":6342,"status":323,"phases":6343,"primaryCompletion":6344,"completion":6345,"start":6346,"enrollment":601,"conditions":6347,"interventions":6352},"NCT04632069","NAC +taVNS in IDM Who Are Poor Oral Feeders",[85],"2024-03-01","2024-07-01","2021-08-12",[6348,6349,6350,6351],"Infant of Diabetic Mother","Oxidative Stress","Vagus Nerve Stimulation","Feeding Disorders",[6336],{"trials":6354,"activeCount":98},[],{"trials":6356,"activeCount":98},[],{"trials":6358,"activeCount":98},[],{"trials":6360,"activeCount":98},[],{"trials":6362,"activeCount":98},[],{"intervention":6364,"totalTrials":94,"cells":6365},"Bimatoprost",{"EARLY_PHASE1":6366,"PHASE1":6376,"PHASE2":6378,"PHASE3":6380,"PHASE4":6382,"NA":6384},{"trials":6367,"activeCount":98},[6368],{"nctId":6369,"briefTitle":6370,"status":323,"phases":6371,"primaryCompletion":6372,"completion":6372,"start":6373,"enrollment":1428,"conditions":6374,"interventions":6375},"NCT04738149","Effect of Microneedling, Bimatoprost and Excimer in Vitiligo Treatment",[85],"2022-05-15","2021-11-02",[834],[6364],{"trials":6377,"activeCount":98},[],{"trials":6379,"activeCount":98},[],{"trials":6381,"activeCount":98},[],{"trials":6383,"activeCount":98},[],{"trials":6385,"activeCount":98},[],{"intervention":6387,"totalTrials":94,"cells":6388},"Imiquimod 5% Cream",{"EARLY_PHASE1":6389,"PHASE1":6399,"PHASE2":6401,"PHASE3":6403,"PHASE4":6405,"NA":6407},{"trials":6390,"activeCount":98},[6391],{"nctId":6392,"briefTitle":6393,"status":323,"phases":6394,"primaryCompletion":325,"completion":4099,"start":6395,"enrollment":1632,"conditions":6396,"interventions":6398},"NCT04883645","Neoadjuvant Imiquimod Immunotherapy for Oral Cancer",[85],"2022-04-28",[6397],"Oral Squamous Cell Carcinoma",[6387],{"trials":6400,"activeCount":98},[],{"trials":6402,"activeCount":98},[],{"trials":6404,"activeCount":98},[],{"trials":6406,"activeCount":98},[],{"trials":6408,"activeCount":98},[],{"intervention":6410,"totalTrials":94,"cells":6411},"Genetic Expression",{"EARLY_PHASE1":6412,"PHASE1":6422,"PHASE2":6424,"PHASE3":6426,"PHASE4":6428,"NA":6430},{"trials":6413,"activeCount":98},[6414],{"nctId":6415,"briefTitle":6416,"status":597,"phases":6417,"primaryCompletion":5396,"start":1630,"enrollment":302,"conditions":6418,"interventions":6420},"NCT01783054","Pilot, Neoadjuvant Gemcitabine and Abraxane Chemotherapy Followed by Surgery, Adenocarcinoma of the Pancreas",[85],[6419],"Adenocarcinoma Pancreas",[6410,6421],"Chemotherapy",{"trials":6423,"activeCount":98},[],{"trials":6425,"activeCount":98},[],{"trials":6427,"activeCount":98},[],{"trials":6429,"activeCount":98},[],{"trials":6431,"activeCount":98},[],{"intervention":6421,"totalTrials":94,"cells":6433},{"EARLY_PHASE1":6434,"PHASE1":6440,"PHASE2":6442,"PHASE3":6444,"PHASE4":6446,"NA":6448},{"trials":6435,"activeCount":98},[6436],{"nctId":6415,"briefTitle":6416,"status":597,"phases":6437,"primaryCompletion":5396,"start":1630,"enrollment":302,"conditions":6438,"interventions":6439},[85],[6419],[6410,6421],{"trials":6441,"activeCount":98},[],{"trials":6443,"activeCount":98},[],{"trials":6445,"activeCount":98},[],{"trials":6447,"activeCount":98},[],{"trials":6449,"activeCount":98},[],{"intervention":6451,"totalTrials":94,"cells":6452},"receiving 0.1 mg IT morphine",{"EARLY_PHASE1":6453,"PHASE1":6466,"PHASE2":6468,"PHASE3":6470,"PHASE4":6472,"NA":6474},{"trials":6454,"activeCount":98},[6455],{"nctId":6456,"briefTitle":6457,"status":323,"phases":6458,"primaryCompletion":6459,"completion":6459,"start":6460,"enrollment":6461,"conditions":6462,"interventions":6464},"NCT03427463","Comparison of 0.1 and 0.05mg Intrathecal Morphine for Post-cesarean Analgesia.",[85],"2023-08-03","2018-01-16",229,[6463],"Cesarean Section",[6451,6465],"recieving 0.05 mg IT morphine",{"trials":6467,"activeCount":98},[],{"trials":6469,"activeCount":98},[],{"trials":6471,"activeCount":98},[],{"trials":6473,"activeCount":98},[],{"trials":6475,"activeCount":98},[],{"intervention":6465,"totalTrials":94,"cells":6477},{"EARLY_PHASE1":6478,"PHASE1":6484,"PHASE2":6486,"PHASE3":6488,"PHASE4":6490,"NA":6492},{"trials":6479,"activeCount":98},[6480],{"nctId":6456,"briefTitle":6457,"status":323,"phases":6481,"primaryCompletion":6459,"completion":6459,"start":6460,"enrollment":6461,"conditions":6482,"interventions":6483},[85],[6463],[6451,6465],{"trials":6485,"activeCount":98},[],{"trials":6487,"activeCount":98},[],{"trials":6489,"activeCount":98},[],{"trials":6491,"activeCount":98},[],{"trials":6493,"activeCount":98},[],{"intervention":6495,"totalTrials":94,"cells":6496},"High Volume-Low Concentration without Clonidine",{"EARLY_PHASE1":6497,"PHASE1":6510,"PHASE2":6512,"PHASE3":6514,"PHASE4":6516,"NA":6518},{"trials":6498,"activeCount":98},[6499],{"nctId":6500,"briefTitle":6501,"status":323,"phases":6502,"primaryCompletion":2279,"completion":6503,"start":6504,"enrollment":6505,"conditions":6506,"interventions":6508},"NCT04263064","High Volume Caudal Study",[85],"2022-08-19","2020-03-06",129,[6507],"Male Circumcision",[6495,6509],"High Volume-Low Concentration with clonidine",{"trials":6511,"activeCount":98},[],{"trials":6513,"activeCount":98},[],{"trials":6515,"activeCount":98},[],{"trials":6517,"activeCount":98},[],{"trials":6519,"activeCount":98},[],{"intervention":6509,"totalTrials":94,"cells":6521},{"EARLY_PHASE1":6522,"PHASE1":6528,"PHASE2":6530,"PHASE3":6532,"PHASE4":6534,"NA":6536},{"trials":6523,"activeCount":98},[6524],{"nctId":6500,"briefTitle":6501,"status":323,"phases":6525,"primaryCompletion":2279,"completion":6503,"start":6504,"enrollment":6505,"conditions":6526,"interventions":6527},[85],[6507],[6495,6509],{"trials":6529,"activeCount":98},[],{"trials":6531,"activeCount":98},[],{"trials":6533,"activeCount":98},[],{"trials":6535,"activeCount":98},[],{"trials":6537,"activeCount":98},[],{"intervention":1625,"totalTrials":6539,"cells":6540},11,{"EARLY_PHASE1":6541,"PHASE1":6543,"PHASE2":6554,"PHASE3":6607,"PHASE4":6609,"NA":6611},{"trials":6542,"activeCount":98},[],{"trials":6544,"activeCount":98},[6545],{"nctId":6546,"briefTitle":6547,"status":323,"phases":6548,"primaryCompletion":6015,"completion":6549,"start":3302,"enrollment":6550,"conditions":6551,"interventions":6553},"NCT02058251","Oxytocin Suppresses Substance Use Disorders Associated With Chronic Stress",[86],"2017-04",73,[6552],"Alcohol Use Disorders",[1625],{"trials":6555,"activeCount":98},[6556,6564,6575,6583,6590,6594,6598],{"nctId":6557,"briefTitle":6558,"status":323,"phases":6559,"primaryCompletion":6560,"completion":6560,"start":4972,"enrollment":542,"conditions":6561,"interventions":6563},"NCT03046836","Oxytocin, Alcohol Craving, and Intimate Partner Aggression",[87],"2021-04-11",[6562],"Alcohol Use",[1625],{"nctId":6565,"briefTitle":6566,"status":323,"phases":6567,"primaryCompletion":6568,"completion":6568,"start":2021,"enrollment":6569,"conditions":6570,"interventions":6574},"NCT02941692","Oxytocin for Couples Conflict Resolution",[87],"2017-03",66,[6571,6572,6573],"Substance Misuse","Interpersonal Conflict","Neuroendocrine Reactivity",[1625],{"nctId":6576,"briefTitle":6577,"status":323,"phases":6578,"primaryCompletion":3079,"completion":3079,"start":6579,"enrollment":3081,"conditions":6580,"interventions":6582},"NCT03846505","Oxytocin to Enhance Alcohol Behavioral Couple Therapy (ABCT)",[87],"2019-05-16",[28,6581],"Couples",[1625],{"nctId":6584,"briefTitle":6585,"status":323,"phases":6586,"primaryCompletion":6587,"completion":6587,"start":2022,"enrollment":6539,"conditions":6588,"interventions":6589},"NCT03610633","Oxytocin and Stress Response in Alcohol Use Disorder",[87],"2018-09",[28],[1625],{"nctId":1600,"briefTitle":1601,"status":323,"phases":6591,"primaryCompletion":1603,"completion":1603,"start":1604,"enrollment":1605,"conditions":6592,"interventions":6593},[87],[1607],[1609,1610],{"nctId":5263,"briefTitle":5264,"status":323,"phases":6595,"primaryCompletion":5266,"completion":5266,"start":5267,"enrollment":2253,"conditions":6596,"interventions":6597},[87],[1060],[1625,5254],{"nctId":6599,"briefTitle":6600,"status":323,"phases":6601,"primaryCompletion":6602,"completion":6602,"start":3046,"enrollment":6603,"conditions":6604,"interventions":6606},"NCT02682784","Neural Substrates of Emotion: Impact of Cocaine Dependence",[87],"2020-07-27",138,[6605],"Cocaine Use Disorder",[1625],{"trials":6608,"activeCount":98},[],{"trials":6610,"activeCount":98},[],{"trials":6612,"activeCount":98},[6613,6617,6621],{"nctId":1618,"briefTitle":1619,"status":323,"phases":6614,"primaryCompletion":1621,"completion":1621,"start":1603,"enrollment":1622,"conditions":6615,"interventions":6616},[90],[1607],[1625,1573],{"nctId":1627,"briefTitle":1628,"status":323,"phases":6618,"primaryCompletion":1630,"completion":1630,"start":1631,"enrollment":1632,"conditions":6619,"interventions":6620},[90],[1634],[1625,1573],{"nctId":1637,"briefTitle":1638,"status":323,"phases":6622,"primaryCompletion":1640,"completion":1641,"start":1642,"enrollment":1632,"conditions":6623,"interventions":6624},[90],[1634],[1625,1573],{"intervention":6626,"totalTrials":1428,"cells":6627},"Methylprednisolone",{"EARLY_PHASE1":6628,"PHASE1":6642,"PHASE2":6644,"PHASE3":6646,"PHASE4":6648,"NA":6650},{"trials":6629,"activeCount":98},[6630],{"nctId":6631,"briefTitle":6632,"status":597,"phases":6633,"primaryCompletion":6634,"completion":5396,"start":6635,"enrollment":328,"conditions":6636,"interventions":6640},"NCT02212210","Maternal Epidural Steroids and Hyperthemia",[85],"2014-04","2012-02",[6637,6638,6639],"Fever","Labor Pain","Complication of Anesthesia During Pregnancy, Unspecified",[6626,6641],"Normal saline",{"trials":6643,"activeCount":98},[],{"trials":6645,"activeCount":98},[],{"trials":6647,"activeCount":98},[],{"trials":6649,"activeCount":98},[],{"trials":6651,"activeCount":98},[6652,6662,6674],{"nctId":6653,"briefTitle":6654,"status":323,"phases":6655,"primaryCompletion":6656,"completion":6657,"start":790,"enrollment":3214,"conditions":6658,"interventions":6661},"NCT01579513","Corticosteroid Therapy in Neonates Undergoing Cardiopulmonary Bypass",[90],"2018-05-25","2018-12-19",[6659,6660],"Congenital Heart Disease","Disorder of Fetus or Newborn",[6626],{"nctId":6663,"briefTitle":6664,"status":323,"phases":6665,"primaryCompletion":6666,"completion":6667,"start":6668,"enrollment":6669,"conditions":6670,"interventions":6672},"NCT04528797","Thyroid and Adrenocortical Hormone Replacement in Organ Donors",[90],"2012-08-09","2013-09-30","2010-09-02",199,[6671],"Brain Death",[6673,6626],"Levothyroxine",{"nctId":6675,"briefTitle":6676,"status":323,"phases":6677,"primaryCompletion":6678,"completion":6678,"start":6679,"enrollment":6680,"conditions":6681,"interventions":6682},"NCT00934843","Preoperative Corticosteroid Therapy in Neonates Undergoing Cardiopulmonary Bypass",[90],"2011-09","2007-03",77,[6659,6660],[6683,6683],"methylprednisolone",{"intervention":6685,"totalTrials":573,"cells":6686},"Alendronate",{"EARLY_PHASE1":6687,"PHASE1":6689,"PHASE2":6691,"PHASE3":6709,"PHASE4":6711,"NA":6713},{"trials":6688,"activeCount":98},[],{"trials":6690,"activeCount":98},[],{"trials":6692,"activeCount":98},[6693,6702],{"nctId":6694,"briefTitle":6695,"status":323,"phases":6696,"primaryCompletion":3396,"completion":6697,"start":6698,"enrollment":708,"conditions":6699,"interventions":6701},"NCT00259857","Safety and Efficacy of Alendronate (Fosamax) in Children With Osteoporosis",[87],"2009-08","2003-10",[6700],"Osteoporosis",[6685],{"nctId":6703,"briefTitle":6704,"status":323,"phases":6705,"primaryCompletion":6698,"completion":2194,"start":6706,"enrollment":601,"conditions":6707,"interventions":6708},"NCT00010439","Phase II Study of Alendronate Sodium in Children With High-Turnover Idiopathic Juvenile Osteoporosis",[87],"2000-09",[6700],[6685],{"trials":6710,"activeCount":98},[],{"trials":6712,"activeCount":98},[],{"trials":6714,"activeCount":98},[6715],{"nctId":6716,"briefTitle":6717,"status":323,"phases":6718,"primaryCompletion":2023,"completion":6719,"start":1862,"enrollment":6539,"conditions":6720,"interventions":6724},"NCT00920075","Alendronate in Juvenile Osteoporosis",[],"2010-10",[6721,6722,6723],"Juvenile Osteoporosis","Low Bone Density","Fractures",[6685],{"intervention":5488,"totalTrials":302,"cells":6726},{"EARLY_PHASE1":6727,"PHASE1":6729,"PHASE2":6735,"PHASE3":6737,"PHASE4":6739,"NA":6741},{"trials":6728,"activeCount":98},[],{"trials":6730,"activeCount":98},[6731],{"nctId":5482,"briefTitle":5483,"status":323,"phases":6732,"primaryCompletion":642,"completion":642,"start":1642,"enrollment":708,"conditions":6733,"interventions":6734},[86],[5486],[5475,5488],{"trials":6736,"activeCount":98},[],{"trials":6738,"activeCount":98},[],{"trials":6740,"activeCount":98},[],{"trials":6742,"activeCount":98},[6743],{"nctId":6744,"briefTitle":6745,"status":2079,"phases":6746,"primaryCompletion":6747,"completion":6747,"start":6747,"enrollment":98,"conditions":6748,"interventions":6749},"NCT01185808","Vitamin D Supplementation in Chronic Rhinosinusitis With Nasal Polyps",[90],"2013-10",[296],[5488],{"intervention":2375,"totalTrials":302,"cells":6751},{"EARLY_PHASE1":6752,"PHASE1":6754,"PHASE2":6756,"PHASE3":6758,"PHASE4":6760,"NA":6766},{"trials":6753,"activeCount":98},[],{"trials":6755,"activeCount":98},[],{"trials":6757,"activeCount":98},[],{"trials":6759,"activeCount":98},[],{"trials":6761,"activeCount":98},[6762],{"nctId":2366,"briefTitle":2367,"status":323,"phases":6763,"primaryCompletion":2369,"completion":2370,"start":2371,"enrollment":2230,"conditions":6764,"interventions":6765},[89],[2373],[2353,2375,2376,2377],{"trials":6767,"activeCount":98},[6768],{"nctId":6769,"briefTitle":6770,"status":323,"phases":6771,"primaryCompletion":6772,"completion":6772,"start":6773,"enrollment":1350,"conditions":6774,"interventions":6775},"NCT02954198","Once-daily Regimen With Envarsus® to Optimize Immunosuppression Management and Outcomes in Kidney Transplant Recipients",[90],"2018-12-27","2016-12-01",[2373],[6776,2376,2375,6777],"Tacrolimus","Everolimus",{"intervention":2376,"totalTrials":302,"cells":6779},{"EARLY_PHASE1":6780,"PHASE1":6782,"PHASE2":6784,"PHASE3":6786,"PHASE4":6788,"NA":6794},{"trials":6781,"activeCount":98},[],{"trials":6783,"activeCount":98},[],{"trials":6785,"activeCount":98},[],{"trials":6787,"activeCount":98},[],{"trials":6789,"activeCount":98},[6790],{"nctId":2366,"briefTitle":2367,"status":323,"phases":6791,"primaryCompletion":2369,"completion":2370,"start":2371,"enrollment":2230,"conditions":6792,"interventions":6793},[89],[2373],[2353,2375,2376,2377],{"trials":6795,"activeCount":98},[6796],{"nctId":6769,"briefTitle":6770,"status":323,"phases":6797,"primaryCompletion":6772,"completion":6772,"start":6773,"enrollment":1350,"conditions":6798,"interventions":6799},[90],[2373],[6776,2376,2375,6777],{"intervention":6777,"totalTrials":302,"cells":6801},{"EARLY_PHASE1":6802,"PHASE1":6804,"PHASE2":6806,"PHASE3":6808,"PHASE4":6810,"NA":6821},{"trials":6803,"activeCount":98},[],{"trials":6805,"activeCount":98},[],{"trials":6807,"activeCount":98},[],{"trials":6809,"activeCount":98},[],{"trials":6811,"activeCount":98},[6812],{"nctId":6813,"briefTitle":6814,"status":323,"phases":6815,"primaryCompletion":6816,"completion":6816,"start":3302,"enrollment":1513,"conditions":6817,"interventions":6820},"NCT02096107","Novartis Everolimus Transition",[89],"2017-05",[6818,6819],"Graft Dysfunction","Interstitial Fibrosis",[6777],{"trials":6822,"activeCount":98},[6823],{"nctId":6769,"briefTitle":6770,"status":323,"phases":6824,"primaryCompletion":6772,"completion":6772,"start":6773,"enrollment":1350,"conditions":6825,"interventions":6826},[90],[2373],[6776,2376,2375,6777],{"intervention":6641,"totalTrials":302,"cells":6828},{"EARLY_PHASE1":6829,"PHASE1":6835,"PHASE2":6837,"PHASE3":6839,"PHASE4":6841,"NA":6843},{"trials":6830,"activeCount":98},[6831],{"nctId":6631,"briefTitle":6632,"status":597,"phases":6832,"primaryCompletion":6634,"completion":5396,"start":6635,"enrollment":328,"conditions":6833,"interventions":6834},[85],[6637,6638,6639],[6626,6641],{"trials":6836,"activeCount":98},[],{"trials":6838,"activeCount":98},[],{"trials":6840,"activeCount":98},[],{"trials":6842,"activeCount":98},[],{"trials":6844,"activeCount":98},[6845],{"nctId":6846,"briefTitle":6847,"status":597,"phases":6848,"primaryCompletion":6849,"completion":6849,"start":6850,"enrollment":9,"conditions":6851,"interventions":6852},"NCT02564016","Efficacy of Labor Epidurals for Postpartum Tubal Ligation",[90],"2016-09","2014-10",[1866],[6853],"Normal Saline",{"intervention":6855,"totalTrials":94,"cells":6856},"NeutraSal",{"EARLY_PHASE1":6857,"PHASE1":6859,"PHASE2":6861,"PHASE3":6863,"PHASE4":6865,"NA":6867},{"trials":6858,"activeCount":98},[],{"trials":6860,"activeCount":98},[],{"trials":6862,"activeCount":98},[],{"trials":6864,"activeCount":98},[],{"trials":6866,"activeCount":98},[],{"trials":6868,"activeCount":98},[6869],{"nctId":6870,"briefTitle":6871,"status":323,"phases":6872,"primaryCompletion":6873,"completion":6874,"start":5616,"enrollment":2327,"conditions":6875,"interventions":6877},"NCT02107300","NeutraSal Treatment for Xerostomia in OSAS Patients Using CPAP Therapy",[90],"2015-04-10","2017-07-03",[6876],"Xerostomia",[6855],{"intervention":6879,"totalTrials":94,"cells":6880},"Ultravist 370Mg I\u002FMl Solution for",{"EARLY_PHASE1":6881,"PHASE1":6883,"PHASE2":6885,"PHASE3":6887,"PHASE4":6889,"NA":6891},{"trials":6882,"activeCount":98},[],{"trials":6884,"activeCount":98},[],{"trials":6886,"activeCount":98},[],{"trials":6888,"activeCount":98},[],{"trials":6890,"activeCount":98},[],{"trials":6892,"activeCount":98},[6893],{"nctId":6894,"briefTitle":6895,"status":323,"phases":6896,"primaryCompletion":6897,"completion":6897,"start":6898,"enrollment":1080,"conditions":6899,"interventions":6900},"NCT03179592","VOLtage-based Contrast Media AdaptatioN in Coronary Computed Tomography Angiography",[],"2019-02-11","2017-03-22",[4844,4843],[6879],{"intervention":6902,"totalTrials":94,"cells":6903},"Acetaminophen Intravenous",{"EARLY_PHASE1":6904,"PHASE1":6906,"PHASE2":6908,"PHASE3":6910,"PHASE4":6912,"NA":6914},{"trials":6905,"activeCount":98},[],{"trials":6907,"activeCount":98},[],{"trials":6909,"activeCount":98},[],{"trials":6911,"activeCount":98},[],{"trials":6913,"activeCount":98},[],{"trials":6915,"activeCount":98},[6916],{"nctId":6917,"briefTitle":6918,"status":323,"phases":6919,"primaryCompletion":6920,"completion":6920,"start":6921,"enrollment":1106,"conditions":6922,"interventions":6924},"NCT02487303","Intravenous Versus Oral Acetaminophen for Postoperative Pain Control After Cesarean Delivery",[90],"2017-07-27","2015-03-17",[6923],"Pain, Postoperative",[6902,6925],"Acetaminophen",{"intervention":6925,"totalTrials":94,"cells":6927},{"EARLY_PHASE1":6928,"PHASE1":6930,"PHASE2":6932,"PHASE3":6934,"PHASE4":6936,"NA":6938},{"trials":6929,"activeCount":98},[],{"trials":6931,"activeCount":98},[],{"trials":6933,"activeCount":98},[],{"trials":6935,"activeCount":98},[],{"trials":6937,"activeCount":98},[],{"trials":6939,"activeCount":98},[6940],{"nctId":6917,"briefTitle":6918,"status":323,"phases":6941,"primaryCompletion":6920,"completion":6920,"start":6921,"enrollment":1106,"conditions":6942,"interventions":6943},[90],[6923],[6902,6925],{"intervention":6945,"totalTrials":94,"cells":6946},"Acthrel",{"EARLY_PHASE1":6947,"PHASE1":6949,"PHASE2":6951,"PHASE3":6953,"PHASE4":6955,"NA":6957},{"trials":6948,"activeCount":98},[],{"trials":6950,"activeCount":98},[],{"trials":6952,"activeCount":98},[],{"trials":6954,"activeCount":98},[],{"trials":6956,"activeCount":98},[],{"trials":6958,"activeCount":98},[6959],{"nctId":6960,"briefTitle":6961,"status":323,"phases":6962,"primaryCompletion":6963,"completion":6963,"start":1982,"enrollment":29,"conditions":6964,"interventions":6965},"NCT00756925","Gender and Neural Substrates of Stress and Craving",[],"2010-08",[1607],[6945],{"intervention":6967,"totalTrials":94,"cells":6968},"Contingency Management",{"EARLY_PHASE1":6969,"PHASE1":6971,"PHASE2":6973,"PHASE3":6975,"PHASE4":6977,"NA":6979},{"trials":6970,"activeCount":98},[],{"trials":6972,"activeCount":98},[],{"trials":6974,"activeCount":98},[],{"trials":6976,"activeCount":98},[],{"trials":6978,"activeCount":98},[],{"trials":6980,"activeCount":98},[6981],{"nctId":6982,"briefTitle":6983,"status":323,"phases":6984,"primaryCompletion":6985,"completion":668,"start":6986,"enrollment":6987,"conditions":6988,"interventions":6989},"NCT04605458","Contingency Management to Promote Smoking Abstinence in Cancer Patients",[90],"2025-07-10","2020-11-25",282,[21],[6967,6990],"Standard Care",{"intervention":6990,"totalTrials":94,"cells":6992},{"EARLY_PHASE1":6993,"PHASE1":6995,"PHASE2":6997,"PHASE3":6999,"PHASE4":7001,"NA":7003},{"trials":6994,"activeCount":98},[],{"trials":6996,"activeCount":98},[],{"trials":6998,"activeCount":98},[],{"trials":7000,"activeCount":98},[],{"trials":7002,"activeCount":98},[],{"trials":7004,"activeCount":98},[7005],{"nctId":6982,"briefTitle":6983,"status":323,"phases":7006,"primaryCompletion":6985,"completion":668,"start":6986,"enrollment":6987,"conditions":7007,"interventions":7008},[90],[21],[6967,6990],{"intervention":6673,"totalTrials":94,"cells":7010},{"EARLY_PHASE1":7011,"PHASE1":7013,"PHASE2":7015,"PHASE3":7017,"PHASE4":7019,"NA":7021},{"trials":7012,"activeCount":98},[],{"trials":7014,"activeCount":98},[],{"trials":7016,"activeCount":98},[],{"trials":7018,"activeCount":98},[],{"trials":7020,"activeCount":98},[],{"trials":7022,"activeCount":98},[7023],{"nctId":6663,"briefTitle":6664,"status":323,"phases":7024,"primaryCompletion":6666,"completion":6667,"start":6668,"enrollment":6669,"conditions":7025,"interventions":7026},[90],[6671],[6673,6626],{"intervention":7028,"totalTrials":94,"cells":7029},"Potentially Reduced Exposure Product (PREP): a smokeless, spit-free tobacco product",{"EARLY_PHASE1":7030,"PHASE1":7032,"PHASE2":7034,"PHASE3":7036,"PHASE4":7038,"NA":7040},{"trials":7031,"activeCount":98},[],{"trials":7033,"activeCount":98},[],{"trials":7035,"activeCount":98},[],{"trials":7037,"activeCount":98},[],{"trials":7039,"activeCount":98},[],{"trials":7041,"activeCount":98},[7042],{"nctId":7043,"briefTitle":7044,"status":323,"phases":7045,"primaryCompletion":2022,"completion":2022,"start":2171,"enrollment":7046,"conditions":7047,"interventions":7048},"NCT01509586","A Test of Short and Long Term Naturalistic Outcomes of Smokers Who Sample Smokeless Tobacco",[90],1236,[26,21],[7028],{"intervention":7050,"totalTrials":94,"cells":7051},"DM\u002FHTN medications as needed",{"EARLY_PHASE1":7052,"PHASE1":7054,"PHASE2":7056,"PHASE3":7058,"PHASE4":7060,"NA":7062},{"trials":7053,"activeCount":98},[],{"trials":7055,"activeCount":98},[],{"trials":7057,"activeCount":98},[],{"trials":7059,"activeCount":98},[],{"trials":7061,"activeCount":98},[],{"trials":7063,"activeCount":98},[7064],{"nctId":7065,"briefTitle":7066,"status":323,"phases":7067,"primaryCompletion":7068,"completion":7068,"start":7069,"enrollment":7070,"conditions":7071,"interventions":7075},"NCT03098654","Impact of Integrated HIV\u002FNCD Screening on HIV Testing Uptake and Engagement in HIV Care in Kisarawe, Tanzania",[90],"2022-08-05","2018-02-05",214,[7072,7073,7074],"Human Immunodeficiency Virus","Diabetes Mellitus, Type 2","Hypertension",[7050],{"intervention":7077,"totalTrials":94,"cells":7078},"Vasopressin",{"EARLY_PHASE1":7079,"PHASE1":7081,"PHASE2":7083,"PHASE3":7085,"PHASE4":7087,"NA":7089},{"trials":7080,"activeCount":98},[],{"trials":7082,"activeCount":98},[],{"trials":7084,"activeCount":98},[],{"trials":7086,"activeCount":98},[],{"trials":7088,"activeCount":98},[],{"trials":7090,"activeCount":98},[7091],{"nctId":7092,"briefTitle":7093,"status":323,"phases":7094,"primaryCompletion":3024,"completion":3024,"start":486,"enrollment":32,"conditions":7095,"interventions":7097},"NCT00886262","Study to Evaluate if the Drug Vasopressin Protects the Kidneys for Patients Undergoing Liver Transplant",[90],[7096],"Liver Failure",[7077,7098],"Normal saline placebo",{"intervention":7098,"totalTrials":94,"cells":7100},{"EARLY_PHASE1":7101,"PHASE1":7103,"PHASE2":7105,"PHASE3":7107,"PHASE4":7109,"NA":7111},{"trials":7102,"activeCount":98},[],{"trials":7104,"activeCount":98},[],{"trials":7106,"activeCount":98},[],{"trials":7108,"activeCount":98},[],{"trials":7110,"activeCount":98},[],{"trials":7112,"activeCount":98},[7113],{"nctId":7092,"briefTitle":7093,"status":323,"phases":7114,"primaryCompletion":3024,"completion":3024,"start":486,"enrollment":32,"conditions":7115,"interventions":7116},[90],[7096],[7077,7098],{"intervention":7118,"totalTrials":94,"cells":7119},"insulin",{"EARLY_PHASE1":7120,"PHASE1":7122,"PHASE2":7124,"PHASE3":7126,"PHASE4":7128,"NA":7130},{"trials":7121,"activeCount":98},[],{"trials":7123,"activeCount":98},[],{"trials":7125,"activeCount":98},[],{"trials":7127,"activeCount":98},[],{"trials":7129,"activeCount":98},[],{"trials":7131,"activeCount":98},[7132],{"nctId":7133,"briefTitle":7134,"status":323,"phases":7135,"primaryCompletion":6719,"completion":6719,"start":486,"enrollment":7136,"conditions":7137,"interventions":7140},"NCT00609986","IV Insulin Protocol in Diabetes and Renal Transplantation",[90],104,[7138,2516,7139],"Kidney Transplantation","Hyperglycemia",[7118,7141],"NPH Insulin or glargine insulin and aspartame insulin",{"intervention":7141,"totalTrials":94,"cells":7143},{"EARLY_PHASE1":7144,"PHASE1":7146,"PHASE2":7148,"PHASE3":7150,"PHASE4":7152,"NA":7154},{"trials":7145,"activeCount":98},[],{"trials":7147,"activeCount":98},[],{"trials":7149,"activeCount":98},[],{"trials":7151,"activeCount":98},[],{"trials":7153,"activeCount":98},[],{"trials":7155,"activeCount":98},[7156],{"nctId":7133,"briefTitle":7134,"status":323,"phases":7157,"primaryCompletion":6719,"completion":6719,"start":486,"enrollment":7136,"conditions":7158,"interventions":7159},[90],[7138,2516,7139],[7118,7141],{"intervention":7161,"totalTrials":94,"cells":7162},"Ketorolac Dose",{"EARLY_PHASE1":7163,"PHASE1":7165,"PHASE2":7167,"PHASE3":7169,"PHASE4":7171,"NA":7173},{"trials":7164,"activeCount":98},[],{"trials":7166,"activeCount":98},[],{"trials":7168,"activeCount":98},[],{"trials":7170,"activeCount":98},[],{"trials":7172,"activeCount":98},[],{"trials":7174,"activeCount":98},[7175],{"nctId":7176,"briefTitle":7177,"status":323,"phases":7178,"primaryCompletion":7179,"completion":7179,"start":3278,"enrollment":1622,"conditions":7180,"interventions":7182},"NCT02181426","Dose Response of Ketorolac in Knee Arthroscopy",[90],"2016-12-15",[7181],"Meniscectomy",[7161],{"intervention":7184,"totalTrials":94,"cells":7185},"clinical hypertension specialist-no specific med. Any anti-hypertension meds.",{"EARLY_PHASE1":7186,"PHASE1":7188,"PHASE2":7190,"PHASE3":7192,"PHASE4":7194,"NA":7196},{"trials":7187,"activeCount":98},[],{"trials":7189,"activeCount":98},[],{"trials":7191,"activeCount":98},[],{"trials":7193,"activeCount":98},[],{"trials":7195,"activeCount":98},[],{"trials":7197,"activeCount":98},[7198],{"nctId":7199,"briefTitle":7200,"status":323,"phases":7201,"primaryCompletion":5242,"completion":7202,"start":3351,"enrollment":612,"conditions":7203,"interventions":7204},"NCT00684489","Renin-Guided Therapeutics in the Management of Untreated, Uncontrolled, or Complicated Hypertension",[90],"2005-09",[7074],[7184,7205],"renin guided therapeutics-no specific med. Any anti-hypertensive med.",{"intervention":7205,"totalTrials":94,"cells":7207},{"EARLY_PHASE1":7208,"PHASE1":7210,"PHASE2":7212,"PHASE3":7214,"PHASE4":7216,"NA":7218},{"trials":7209,"activeCount":98},[],{"trials":7211,"activeCount":98},[],{"trials":7213,"activeCount":98},[],{"trials":7215,"activeCount":98},[],{"trials":7217,"activeCount":98},[],{"trials":7219,"activeCount":98},[7220],{"nctId":7199,"briefTitle":7200,"status":323,"phases":7221,"primaryCompletion":5242,"completion":7202,"start":3351,"enrollment":612,"conditions":7222,"interventions":7223},[90],[7074],[7184,7205],{"intervention":7225,"totalTrials":94,"cells":7226},"Metronidazole",{"EARLY_PHASE1":7227,"PHASE1":7229,"PHASE2":7231,"PHASE3":7233,"PHASE4":7235,"NA":7237},{"trials":7228,"activeCount":98},[],{"trials":7230,"activeCount":98},[],{"trials":7232,"activeCount":98},[],{"trials":7234,"activeCount":98},[],{"trials":7236,"activeCount":98},[],{"trials":7238,"activeCount":98},[7239],{"nctId":7240,"briefTitle":7241,"status":323,"phases":7242,"primaryCompletion":7243,"completion":7243,"start":2624,"enrollment":7244,"conditions":7245,"interventions":7247},"NCT00720291","Inflammation and Treatment of Bacterial Vaginosis Near Term",[90],"2010-11-23",59,[7246],"Bacterial Vaginosis",[7225],{"intervention":6776,"totalTrials":94,"cells":7249},{"EARLY_PHASE1":7250,"PHASE1":7252,"PHASE2":7254,"PHASE3":7256,"PHASE4":7258,"NA":7260},{"trials":7251,"activeCount":98},[],{"trials":7253,"activeCount":98},[],{"trials":7255,"activeCount":98},[],{"trials":7257,"activeCount":98},[],{"trials":7259,"activeCount":98},[],{"trials":7261,"activeCount":98},[7262],{"nctId":6769,"briefTitle":6770,"status":323,"phases":7263,"primaryCompletion":6772,"completion":6772,"start":6773,"enrollment":1350,"conditions":7264,"interventions":7265},[90],[2373],[6776,2376,2375,6777],{"intervention":7267,"totalTrials":94,"cells":7268},"EVICEL",{"EARLY_PHASE1":7269,"PHASE1":7271,"PHASE2":7273,"PHASE3":7275,"PHASE4":7277,"NA":7279},{"trials":7270,"activeCount":98},[],{"trials":7272,"activeCount":98},[],{"trials":7274,"activeCount":98},[],{"trials":7276,"activeCount":98},[],{"trials":7278,"activeCount":98},[],{"trials":7280,"activeCount":98},[7281],{"nctId":7282,"briefTitle":7283,"status":323,"phases":7284,"primaryCompletion":2992,"completion":2992,"start":2513,"enrollment":7285,"conditions":7286,"interventions":7289},"NCT01226914","A Trial Comparing Wound Drainage and Post-operative Complications With and Without the Use of EVICEL™ Fibrin Sealant in Thyroidectomy",[90],55,[7287,7288],"Thyroid Neoplasm","Goiter",[7267],{"intervention":7291,"totalTrials":94,"cells":7292},"Operant Conditioning",{"EARLY_PHASE1":7293,"PHASE1":7295,"PHASE2":7297,"PHASE3":7299,"PHASE4":7301,"NA":7303},{"trials":7294,"activeCount":98},[],{"trials":7296,"activeCount":98},[],{"trials":7298,"activeCount":98},[],{"trials":7300,"activeCount":98},[],{"trials":7302,"activeCount":98},[],{"trials":7304,"activeCount":98},[7305],{"nctId":7306,"briefTitle":7307,"status":323,"phases":7308,"primaryCompletion":7309,"completion":7309,"start":7310,"enrollment":568,"conditions":7311,"interventions":7316},"NCT04286191","Physiological Changes Induced Through MEP Conditioning in People With SCI",[90],"2025-11-30","2021-02-22",[7312,7313,7314,7315],"Spinal Cord Injuries","Neurological Injury","Paralysis","Spasticity, Muscle",[7291,7317],"Control Group",{"intervention":7317,"totalTrials":94,"cells":7319},{"EARLY_PHASE1":7320,"PHASE1":7322,"PHASE2":7324,"PHASE3":7326,"PHASE4":7328,"NA":7330},{"trials":7321,"activeCount":98},[],{"trials":7323,"activeCount":98},[],{"trials":7325,"activeCount":98},[],{"trials":7327,"activeCount":98},[],{"trials":7329,"activeCount":98},[],{"trials":7331,"activeCount":98},[7332],{"nctId":7306,"briefTitle":7307,"status":323,"phases":7333,"primaryCompletion":7309,"completion":7309,"start":7310,"enrollment":568,"conditions":7334,"interventions":7335},[90],[7312,7313,7314,7315],[7291,7317],{"intervention":7337,"totalTrials":94,"cells":7338},"Gadopiclenol",{"EARLY_PHASE1":7339,"PHASE1":7341,"PHASE2":7343,"PHASE3":7345,"PHASE4":7347,"NA":7349},{"trials":7340,"activeCount":98},[],{"trials":7342,"activeCount":98},[],{"trials":7344,"activeCount":98},[],{"trials":7346,"activeCount":98},[],{"trials":7348,"activeCount":98},[],{"trials":7350,"activeCount":98},[7351],{"nctId":7352,"briefTitle":7353,"status":2079,"phases":7354,"primaryCompletion":7355,"completion":7355,"start":7355,"enrollment":98,"conditions":7356,"interventions":7358},"NCT06127810","MRI Gadopiclenol Enhanced Imaging of CNS Tumors",[],"2024-12-30",[7357],"Image",[7337],{"intervention":7360,"totalTrials":94,"cells":7361},"Buprenorphine Initiation - Phase I",{"EARLY_PHASE1":7362,"PHASE1":7364,"PHASE2":7366,"PHASE3":7368,"PHASE4":7370,"NA":7372},{"trials":7363,"activeCount":98},[],{"trials":7365,"activeCount":98},[],{"trials":7367,"activeCount":98},[],{"trials":7369,"activeCount":98},[],{"trials":7371,"activeCount":98},[],{"trials":7373,"activeCount":98},[7374],{"nctId":7375,"briefTitle":7376,"status":323,"phases":7377,"primaryCompletion":7378,"completion":7379,"start":642,"enrollment":2327,"conditions":7380,"interventions":7382},"NCT02737826","Discontinuation From Chronic Opioid Therapy For Pain Using a Buprenorphine Taper",[90],"2019-12-09","2021-01-13",[1266,7381],"Opioid Pain Medication",[7360,7383,7384],"Gabapentin + Buprenorphine - Phase II","Buprenorphine taper - Phase II",{"intervention":7383,"totalTrials":94,"cells":7386},{"EARLY_PHASE1":7387,"PHASE1":7389,"PHASE2":7391,"PHASE3":7393,"PHASE4":7395,"NA":7397},{"trials":7388,"activeCount":98},[],{"trials":7390,"activeCount":98},[],{"trials":7392,"activeCount":98},[],{"trials":7394,"activeCount":98},[],{"trials":7396,"activeCount":98},[],{"trials":7398,"activeCount":98},[7399],{"nctId":7375,"briefTitle":7376,"status":323,"phases":7400,"primaryCompletion":7378,"completion":7379,"start":642,"enrollment":2327,"conditions":7401,"interventions":7402},[90],[1266,7381],[7360,7383,7384],{"intervention":7384,"totalTrials":94,"cells":7404},{"EARLY_PHASE1":7405,"PHASE1":7407,"PHASE2":7409,"PHASE3":7411,"PHASE4":7413,"NA":7415},{"trials":7406,"activeCount":98},[],{"trials":7408,"activeCount":98},[],{"trials":7410,"activeCount":98},[],{"trials":7412,"activeCount":98},[],{"trials":7414,"activeCount":98},[],{"trials":7416,"activeCount":98},[7417],{"nctId":7375,"briefTitle":7376,"status":323,"phases":7418,"primaryCompletion":7378,"completion":7379,"start":642,"enrollment":2327,"conditions":7419,"interventions":7420},[90],[1266,7381],[7360,7383,7384],{"intervention":7422,"totalTrials":94,"cells":7423},"Gadavist 15Ml Solution for",{"EARLY_PHASE1":7424,"PHASE1":7426,"PHASE2":7428,"PHASE3":7430,"PHASE4":7432,"NA":7434},{"trials":7425,"activeCount":98},[],{"trials":7427,"activeCount":98},[],{"trials":7429,"activeCount":98},[],{"trials":7431,"activeCount":98},[],{"trials":7433,"activeCount":98},[],{"trials":7435,"activeCount":98},[7436],{"nctId":7437,"briefTitle":7438,"status":323,"phases":7439,"primaryCompletion":7440,"completion":7440,"start":7441,"enrollment":2053,"conditions":7442,"interventions":7445},"NCT03937921","Dotarem Evaluation for Myocardial Perfusion CMR",[],"2024-10-31","2019-07-03",[7443,7444],"Myocardial Perfusion Imaging","Magnetic Resonance Imaging",[7422],{"intervention":7447,"totalTrials":94,"cells":7448},"Istradefylline 40 mg",{"EARLY_PHASE1":7449,"PHASE1":7451,"PHASE2":7453,"PHASE3":7455,"PHASE4":7457,"NA":7459},{"trials":7450,"activeCount":98},[],{"trials":7452,"activeCount":98},[],{"trials":7454,"activeCount":98},[],{"trials":7456,"activeCount":98},[],{"trials":7458,"activeCount":98},[],{"trials":7460,"activeCount":98},[7461],{"nctId":7462,"briefTitle":7463,"status":597,"phases":7464,"primaryCompletion":496,"completion":496,"start":7465,"enrollment":473,"conditions":7466,"interventions":7469},"NCT05182151","Effect of Istradefylline Treatment on Behavioral Measures of Apathy in Parkinson's Disease.",[],"2022-07-29",[7467,7468],"Apathy","Parkinson Disease",[7447],{"intervention":7471,"totalTrials":94,"cells":7472},"Bupivacaine Only",{"EARLY_PHASE1":7473,"PHASE1":7475,"PHASE2":7477,"PHASE3":7479,"PHASE4":7481,"NA":7483},{"trials":7474,"activeCount":98},[],{"trials":7476,"activeCount":98},[],{"trials":7478,"activeCount":98},[],{"trials":7480,"activeCount":98},[],{"trials":7482,"activeCount":98},[],{"trials":7484,"activeCount":98},[7485],{"nctId":7486,"briefTitle":7487,"status":323,"phases":7488,"primaryCompletion":7489,"completion":7489,"start":7490,"enrollment":19,"conditions":7491,"interventions":7494},"NCT02619409","Evaluation of the Duration of Bupivacaine Spinal Block in Orthopedic Procedures With and Without Epinephrine Wash",[90],"2016-10-20","2016-02-11",[7492,7493],"Arthropathy of Hip","Arthropathy of Knee",[7471,7495,7496,7497,7498],"EPI25","EPI50 group","EPI75 group","EPI100 group",{"intervention":7495,"totalTrials":94,"cells":7500},{"EARLY_PHASE1":7501,"PHASE1":7503,"PHASE2":7505,"PHASE3":7507,"PHASE4":7509,"NA":7511},{"trials":7502,"activeCount":98},[],{"trials":7504,"activeCount":98},[],{"trials":7506,"activeCount":98},[],{"trials":7508,"activeCount":98},[],{"trials":7510,"activeCount":98},[],{"trials":7512,"activeCount":98},[7513],{"nctId":7486,"briefTitle":7487,"status":323,"phases":7514,"primaryCompletion":7489,"completion":7489,"start":7490,"enrollment":19,"conditions":7515,"interventions":7516},[90],[7492,7493],[7471,7495,7496,7497,7498],{"intervention":7496,"totalTrials":94,"cells":7518},{"EARLY_PHASE1":7519,"PHASE1":7521,"PHASE2":7523,"PHASE3":7525,"PHASE4":7527,"NA":7529},{"trials":7520,"activeCount":98},[],{"trials":7522,"activeCount":98},[],{"trials":7524,"activeCount":98},[],{"trials":7526,"activeCount":98},[],{"trials":7528,"activeCount":98},[],{"trials":7530,"activeCount":98},[7531],{"nctId":7486,"briefTitle":7487,"status":323,"phases":7532,"primaryCompletion":7489,"completion":7489,"start":7490,"enrollment":19,"conditions":7533,"interventions":7534},[90],[7492,7493],[7471,7495,7496,7497,7498],{"intervention":7497,"totalTrials":94,"cells":7536},{"EARLY_PHASE1":7537,"PHASE1":7539,"PHASE2":7541,"PHASE3":7543,"PHASE4":7545,"NA":7547},{"trials":7538,"activeCount":98},[],{"trials":7540,"activeCount":98},[],{"trials":7542,"activeCount":98},[],{"trials":7544,"activeCount":98},[],{"trials":7546,"activeCount":98},[],{"trials":7548,"activeCount":98},[7549],{"nctId":7486,"briefTitle":7487,"status":323,"phases":7550,"primaryCompletion":7489,"completion":7489,"start":7490,"enrollment":19,"conditions":7551,"interventions":7552},[90],[7492,7493],[7471,7495,7496,7497,7498],{"intervention":7498,"totalTrials":94,"cells":7554},{"EARLY_PHASE1":7555,"PHASE1":7557,"PHASE2":7559,"PHASE3":7561,"PHASE4":7563,"NA":7565},{"trials":7556,"activeCount":98},[],{"trials":7558,"activeCount":98},[],{"trials":7560,"activeCount":98},[],{"trials":7562,"activeCount":98},[],{"trials":7564,"activeCount":98},[],{"trials":7566,"activeCount":98},[7567],{"nctId":7486,"briefTitle":7487,"status":323,"phases":7568,"primaryCompletion":7489,"completion":7489,"start":7490,"enrollment":19,"conditions":7569,"interventions":7570},[90],[7492,7493],[7471,7495,7496,7497,7498],{"intervention":7572,"totalTrials":94,"cells":7573},"Low-volume, low-concentration contrast (iodixanol - Visipaque 270) CT scan",{"EARLY_PHASE1":7574,"PHASE1":7576,"PHASE2":7578,"PHASE3":7580,"PHASE4":7582,"NA":7584},{"trials":7575,"activeCount":98},[],{"trials":7577,"activeCount":98},[],{"trials":7579,"activeCount":98},[],{"trials":7581,"activeCount":98},[],{"trials":7583,"activeCount":98},[],{"trials":7585,"activeCount":98},[7586],{"nctId":7587,"briefTitle":7588,"status":323,"phases":7589,"primaryCompletion":7590,"completion":7590,"start":2936,"enrollment":1350,"conditions":7591,"interventions":7593},"NCT01843426","Aortic Stenosis Pre-Transcatheter Aortic Valve Replacement (TAVR) Procedure CT Scan",[90],"2017-09-25",[7592],"Aortic Valve Stenosis",[7572],{"intervention":7595,"totalTrials":94,"cells":7596},"Femoral nerve catheter and sciatic nerve block",{"EARLY_PHASE1":7597,"PHASE1":7599,"PHASE2":7601,"PHASE3":7603,"PHASE4":7605,"NA":7607},{"trials":7598,"activeCount":98},[],{"trials":7600,"activeCount":98},[],{"trials":7602,"activeCount":98},[],{"trials":7604,"activeCount":98},[],{"trials":7606,"activeCount":98},[],{"trials":7608,"activeCount":98},[7609],{"nctId":7610,"briefTitle":7611,"status":323,"phases":7612,"primaryCompletion":7613,"completion":7613,"start":5396,"enrollment":7614,"conditions":7615,"interventions":7617},"NCT02773537","Motor-Sparing Peripheral Nerve Blockade Facilitates Mobility Post Total Knee Arthroplasty: A Randomized Controlled Trial",[90],"2016-11",75,[7616],"Arthroplasty, Replacement, Knee",[7595,7618,7619],"Adductor canal catheter and selective tibial block","Adductor canal catheter only",{"intervention":7618,"totalTrials":94,"cells":7621},{"EARLY_PHASE1":7622,"PHASE1":7624,"PHASE2":7626,"PHASE3":7628,"PHASE4":7630,"NA":7632},{"trials":7623,"activeCount":98},[],{"trials":7625,"activeCount":98},[],{"trials":7627,"activeCount":98},[],{"trials":7629,"activeCount":98},[],{"trials":7631,"activeCount":98},[],{"trials":7633,"activeCount":98},[7634],{"nctId":7610,"briefTitle":7611,"status":323,"phases":7635,"primaryCompletion":7613,"completion":7613,"start":5396,"enrollment":7614,"conditions":7636,"interventions":7637},[90],[7616],[7595,7618,7619],{"intervention":7619,"totalTrials":94,"cells":7639},{"EARLY_PHASE1":7640,"PHASE1":7642,"PHASE2":7644,"PHASE3":7646,"PHASE4":7648,"NA":7650},{"trials":7641,"activeCount":98},[],{"trials":7643,"activeCount":98},[],{"trials":7645,"activeCount":98},[],{"trials":7647,"activeCount":98},[],{"trials":7649,"activeCount":98},[],{"trials":7651,"activeCount":98},[7652],{"nctId":7610,"briefTitle":7611,"status":323,"phases":7653,"primaryCompletion":7613,"completion":7613,"start":5396,"enrollment":7614,"conditions":7654,"interventions":7655},[90],[7616],[7595,7618,7619],{"intervention":7657,"totalTrials":94,"cells":7658},"Cefazolin",{"EARLY_PHASE1":7659,"PHASE1":7661,"PHASE2":7663,"PHASE3":7665,"PHASE4":7667,"NA":7669},{"trials":7660,"activeCount":98},[],{"trials":7662,"activeCount":98},[],{"trials":7664,"activeCount":98},[],{"trials":7666,"activeCount":98},[],{"trials":7668,"activeCount":98},[],{"trials":7670,"activeCount":98},[7671],{"nctId":7672,"briefTitle":7673,"status":323,"phases":7674,"completion":586,"start":1918,"enrollment":7675,"conditions":7676,"interventions":7679},"NCT00330278","Timing of Prophylactic Antibiotics for Cesarean Sections",[90],350,[7677,7678],"Endometritis","Wound Infection",[7657],{"intervention":7681,"totalTrials":94,"cells":7682},"Genetic Sequencing",{"EARLY_PHASE1":7683,"PHASE1":7685,"PHASE2":7687,"PHASE3":7689,"PHASE4":7691,"NA":7693},{"trials":7684,"activeCount":98},[],{"trials":7686,"activeCount":98},[],{"trials":7688,"activeCount":98},[],{"trials":7690,"activeCount":98},[],{"trials":7692,"activeCount":98},[],{"trials":7694,"activeCount":98},[7695],{"nctId":7696,"briefTitle":7697,"status":323,"phases":7698,"primaryCompletion":6549,"completion":6549,"start":7699,"enrollment":7700,"conditions":7701,"interventions":7705},"NCT02810327","Alpha-1 Carrier Genomics Study",[],"2015-02",117,[7702,7703,7704,26],"Alpha-1 Antitrypsin Deficiency","Emphysema","COPD",[7681],{"intervention":7707,"totalTrials":94,"cells":7708},"Cyclosporin A Restasis®",{"EARLY_PHASE1":7709,"PHASE1":7711,"PHASE2":7713,"PHASE3":7715,"PHASE4":7717,"NA":7719},{"trials":7710,"activeCount":98},[],{"trials":7712,"activeCount":98},[],{"trials":7714,"activeCount":98},[],{"trials":7716,"activeCount":98},[],{"trials":7718,"activeCount":98},[],{"trials":7720,"activeCount":98},[7721],{"nctId":7722,"briefTitle":7723,"status":323,"phases":7724,"primaryCompletion":2514,"completion":2514,"start":3003,"enrollment":22,"conditions":7725,"interventions":7727},"NCT00565669","Evaluation of Blink Tears and Systane Concomitant With Restasis for the Treatment of Dry Eye Symptoms",[90],[7726],"Dry Eye Syndrome",[7707,7728,7729],"Blink tears","Systane",{"intervention":7728,"totalTrials":94,"cells":7731},{"EARLY_PHASE1":7732,"PHASE1":7734,"PHASE2":7736,"PHASE3":7738,"PHASE4":7740,"NA":7742},{"trials":7733,"activeCount":98},[],{"trials":7735,"activeCount":98},[],{"trials":7737,"activeCount":98},[],{"trials":7739,"activeCount":98},[],{"trials":7741,"activeCount":98},[],{"trials":7743,"activeCount":98},[7744],{"nctId":7722,"briefTitle":7723,"status":323,"phases":7745,"primaryCompletion":2514,"completion":2514,"start":3003,"enrollment":22,"conditions":7746,"interventions":7747},[90],[7726],[7707,7728,7729],{"intervention":7729,"totalTrials":94,"cells":7749},{"EARLY_PHASE1":7750,"PHASE1":7752,"PHASE2":7754,"PHASE3":7756,"PHASE4":7758,"NA":7760},{"trials":7751,"activeCount":98},[],{"trials":7753,"activeCount":98},[],{"trials":7755,"activeCount":98},[],{"trials":7757,"activeCount":98},[],{"trials":7759,"activeCount":98},[],{"trials":7761,"activeCount":98},[7762],{"nctId":7722,"briefTitle":7723,"status":323,"phases":7763,"primaryCompletion":2514,"completion":2514,"start":3003,"enrollment":22,"conditions":7764,"interventions":7765},[90],[7726],[7707,7728,7729],{"intervention":7767,"totalTrials":94,"cells":7768},"Renin treatment-guided Therapeutics",{"EARLY_PHASE1":7769,"PHASE1":7771,"PHASE2":7773,"PHASE3":7775,"PHASE4":7777,"NA":7779},{"trials":7770,"activeCount":98},[],{"trials":7772,"activeCount":98},[],{"trials":7774,"activeCount":98},[],{"trials":7776,"activeCount":98},[],{"trials":7778,"activeCount":98},[],{"trials":7780,"activeCount":98},[7781],{"nctId":7782,"briefTitle":7783,"status":323,"phases":7784,"primaryCompletion":7785,"completion":7785,"start":1851,"enrollment":2160,"conditions":7786,"interventions":7787},"NCT02167464","Controlling Blood Pressure in Treatment Resistant Hypertension: A Pilot Study",[90],"2015-01",[7074],[7767,7788],"Aldosterone Antagonist",{"intervention":7788,"totalTrials":94,"cells":7790},{"EARLY_PHASE1":7791,"PHASE1":7793,"PHASE2":7795,"PHASE3":7797,"PHASE4":7799,"NA":7801},{"trials":7792,"activeCount":98},[],{"trials":7794,"activeCount":98},[],{"trials":7796,"activeCount":98},[],{"trials":7798,"activeCount":98},[],{"trials":7800,"activeCount":98},[],{"trials":7802,"activeCount":98},[7803],{"nctId":7782,"briefTitle":7783,"status":323,"phases":7804,"primaryCompletion":7785,"completion":7785,"start":1851,"enrollment":2160,"conditions":7805,"interventions":7806},[90],[7074],[7767,7788],{"intervention":7808,"totalTrials":94,"cells":7809},"Goal2Quit + NRT Sampling",{"EARLY_PHASE1":7810,"PHASE1":7812,"PHASE2":7814,"PHASE3":7816,"PHASE4":7818,"NA":7820},{"trials":7811,"activeCount":98},[],{"trials":7813,"activeCount":98},[],{"trials":7815,"activeCount":98},[],{"trials":7817,"activeCount":98},[],{"trials":7819,"activeCount":98},[],{"trials":7821,"activeCount":98},[7822],{"nctId":7823,"briefTitle":7808,"status":323,"phases":7824,"primaryCompletion":7825,"completion":7825,"start":7826,"enrollment":7827,"conditions":7828,"interventions":7829},"NCT03837379",[90],"2022-05-18","2020-06-22",164,[3748,21,18],[7808],{"intervention":7831,"totalTrials":94,"cells":7832},"rapamune, mycophenolate mofetil and steroid",{"EARLY_PHASE1":7833,"PHASE1":7835,"PHASE2":7837,"PHASE3":7839,"PHASE4":7841,"NA":7843},{"trials":7834,"activeCount":98},[],{"trials":7836,"activeCount":98},[],{"trials":7838,"activeCount":98},[],{"trials":7840,"activeCount":98},[],{"trials":7842,"activeCount":98},[],{"trials":7844,"activeCount":98},[7845],{"nctId":7846,"briefTitle":7847,"status":323,"phases":7848,"primaryCompletion":5061,"completion":2992,"start":6697,"enrollment":1350,"conditions":7849,"interventions":7851},"NCT01005706","Sirolimus Conversions in African-American Renal Transplant Recipients",[90],[7850],"Absence; Kidney",[7831,7852],"tacrolimus, sirolimus and steroid",{"intervention":7852,"totalTrials":94,"cells":7854},{"EARLY_PHASE1":7855,"PHASE1":7857,"PHASE2":7859,"PHASE3":7861,"PHASE4":7863,"NA":7865},{"trials":7856,"activeCount":98},[],{"trials":7858,"activeCount":98},[],{"trials":7860,"activeCount":98},[],{"trials":7862,"activeCount":98},[],{"trials":7864,"activeCount":98},[],{"trials":7866,"activeCount":98},[7867],{"nctId":7846,"briefTitle":7847,"status":323,"phases":7868,"primaryCompletion":5061,"completion":2992,"start":6697,"enrollment":1350,"conditions":7869,"interventions":7870},[90],[7850],[7831,7852],{"intervention":7872,"totalTrials":94,"cells":7873},"Daytrana",{"EARLY_PHASE1":7874,"PHASE1":7876,"PHASE2":7878,"PHASE3":7880,"PHASE4":7882,"NA":7884},{"trials":7875,"activeCount":98},[],{"trials":7877,"activeCount":98},[],{"trials":7879,"activeCount":98},[],{"trials":7881,"activeCount":98},[],{"trials":7883,"activeCount":98},[],{"trials":7885,"activeCount":98},[7886],{"nctId":7887,"briefTitle":7888,"status":323,"phases":7889,"primaryCompletion":2514,"completion":1982,"start":2064,"enrollment":2280,"conditions":7890,"interventions":7892},"NCT00780208","Evaluating the Methylphenidate Patch to Treat Former Stimulant Users With ADHD",[90],[7891],"Adult Attention Deficit Hyperactivity Disorder (ADHD)",[7872],{"intervention":7894,"totalTrials":94,"cells":7895},"Rabbit Antithymocyte globulin",{"EARLY_PHASE1":7896,"PHASE1":7898,"PHASE2":7900,"PHASE3":7902,"PHASE4":7904,"NA":7906},{"trials":7897,"activeCount":98},[],{"trials":7899,"activeCount":98},[],{"trials":7901,"activeCount":98},[],{"trials":7903,"activeCount":98},[],{"trials":7905,"activeCount":98},[],{"trials":7907,"activeCount":98},[7908],{"nctId":7909,"briefTitle":7910,"status":323,"phases":7911,"primaryCompletion":1630,"completion":2992,"start":644,"enrollment":542,"conditions":7912,"interventions":7914},"NCT00859131","Safety and Efficacy Study of Thymoglobulin Versus IL2 Receptor Antagonists",[90],[7913],"End Stage Renal Disease",[7894,7915],"Daclizumab",{"intervention":7915,"totalTrials":94,"cells":7917},{"EARLY_PHASE1":7918,"PHASE1":7920,"PHASE2":7922,"PHASE3":7924,"PHASE4":7926,"NA":7928},{"trials":7919,"activeCount":98},[],{"trials":7921,"activeCount":98},[],{"trials":7923,"activeCount":98},[],{"trials":7925,"activeCount":98},[],{"trials":7927,"activeCount":98},[],{"trials":7929,"activeCount":98},[7930],{"nctId":7909,"briefTitle":7910,"status":323,"phases":7931,"primaryCompletion":1630,"completion":2992,"start":644,"enrollment":542,"conditions":7932,"interventions":7933},[90],[7913],[7894,7915],{"intervention":333,"totalTrials":94,"cells":7935},{"EARLY_PHASE1":7936,"PHASE1":7938,"PHASE2":7940,"PHASE3":7942,"PHASE4":7944,"NA":7946},{"trials":7937,"activeCount":98},[],{"trials":7939,"activeCount":98},[],{"trials":7941,"activeCount":98},[],{"trials":7943,"activeCount":98},[],{"trials":7945,"activeCount":98},[],{"trials":7947,"activeCount":98},[7948],{"nctId":321,"briefTitle":322,"status":323,"phases":7949,"primaryCompletion":325,"completion":326,"start":327,"enrollment":328,"conditions":7950,"interventions":7951},[90],[330],[332,333],{"intervention":7953,"totalTrials":94,"cells":7954},"NeilMed® Sinus Rinse™ System with Isotonic Saline",{"EARLY_PHASE1":7955,"PHASE1":7957,"PHASE2":7959,"PHASE3":7961,"PHASE4":7963,"NA":7965},{"trials":7956,"activeCount":98},[],{"trials":7958,"activeCount":98},[],{"trials":7960,"activeCount":98},[],{"trials":7962,"activeCount":98},[],{"trials":7964,"activeCount":98},[],{"trials":7966,"activeCount":98},[7967],{"nctId":7968,"briefTitle":7969,"status":323,"phases":7970,"primaryCompletion":4799,"completion":4799,"start":2512,"enrollment":1350,"conditions":7971,"interventions":7973},"NCT01030146","Management of Allergic Rhinitis Patients With Nasal Steroids and NeilMed® Sinus Rinse™ System With Isotonic Saline",[90],[7972],"Rhinitis",[7953],{"intervention":7975,"totalTrials":94,"cells":7976},"Vatiquinone",{"EARLY_PHASE1":7977,"PHASE1":7979,"PHASE2":7981,"PHASE3":7983,"PHASE4":7985,"NA":7987},{"trials":7978,"activeCount":98},[],{"trials":7980,"activeCount":98},[],{"trials":7982,"activeCount":98},[],{"trials":7984,"activeCount":98},[],{"trials":7986,"activeCount":98},[],{"trials":7988,"activeCount":98},[7989],{"nctId":7990,"briefTitle":7991,"status":7992,"phases":7993,"conditions":7994,"interventions":7996},"NCT07159139","Vatiquinone Expanded Access Protocol","NO_LONGER_AVAILABLE",[],[7995],"Mitochondrial Disease",[7975]]